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Thesis summary 
 
Tissue Transglutaminase  (TG2)  is  a  cross-linking  enzyme  that  links  
proteins  by  the formation of covalent bonds and confers resistance to proteolytic 
degradation. TG2 acts as a cell adhesion protein by binding to matrix fibronectin, 
cell surface heparan sulphates and integrins. TG2 has been implicated in a variety 
of diseases such as neurodegenerative disease, fibrosis and cancer. However, 
little is known about the mechanisms involved in its secretion, intracellular or 
extracellular activation or how these are regulated. The activity of TG2 is tightly 
controlled by GTP binding and calcium is required for its activation. TG2 assumes 
two strikingly different conformations, a catalytically inactive compact one in the 
presence of GTP and an active extended one in the presence of Ca2+. This 
conformation change affects the functions of TG2 including its transamidating 
activity, its affinities and juxtaposition of binding sites for fibronectin, heparan 
sulphates and integrins. To study this, a FRET (Förster Resonance energy 
Transfer) sensor was constructed using the fluorescent proteins CFP and YFP 
fused to the N and C terminus of TG2, respectively. The FRET sensor has 
demonstrated different fluorescent characteristics depending on the conformation 
of TG2 and was used to monitor the conformational change that is induced by 
calcium or GTP binding.   
 
 
 
 
 
 
 
 
 
 3 
 
Dedication 
 
 
To my wonderful mother, Mrs Madhu Sharma, you have been my pillar of strength. 
You made me who I am today, I love you mom with all my heart. 
To my dad, Mr Nagendra Sharma, my hero. Thank you for supporting me through 
joys and tears. So much of me is made of what I learned from you.  
To my partner, Mr. Arzan Polishwalla. Your extraordinary love, friendship and 
humour, I will always cherish. I am truly blessed to have you by my side.  
To Mrs Satyavati Singh, you will always be in my heart.  
 
 
 
 
 
 
 
 
 
 
 
 4 
 
Acknowledgment 
 
 
I would like to thank my supervisor Dr Russell Collighan for his support, guidance 
and time throughout this course. His expertise in the field and guidance has helped 
me tremendously. Thankyou for sharing your knowledge. 
I gratefully acknowledge Prof. Martin Griffin for giving me this opportunity to work 
with him and his efficient team. His insight and productive comments have always 
been deeply appreciated.  
I would also like to thank Dr. Wang Zhuo for her energetic support and 
understanding during my research.  
I am thankful to Dr Andrew Dewitt for his encouragement.  
A special thank you to Dr. Darius Kavaliauskas, you have truly been an inspiration. 
Thank you for all your support.   
I am also grateful to Gill Pilfold and Matthew Richards for their assistance.  
A very big thank you to Mrs Meenakshi Rehani, for being such a wonderful mentor 
and an amazing friend.  
I would like to thank my friends Dr. Vidya Rajasekaran, Dr Vinod Nadella, Andrea 
Costanzi for sharing this experience with me. 
Lastly I would like to thank my sisters, Priyanka Parmar and my lucky mascot Ekta 
Singh for always being there for me. 
 
 
 
 
 5 
 
Table of contents 
Thesis summary ...................................................................................................... 2 
Dedication ............................................................................................................... 3 
Acknowledgment ..................................................................................................... 4 
List of Abbreviations .............................................................................................. 12 
List of figures ......................................................................................................... 13 
List of Tables ......................................................................................................... 20 
Chapter 1 ................................................................................................................. 21 
Introduction .............................................................................................................. 21 
1.1 Introduction ..................................................................................................... 22 
1.2 Mechanism of cross linking ............................................................................. 22 
1.3 Types of Transglutaminase ............................................................................. 23 
1.3.1 TG1 or Keratinocyte Transglutaminase........................................................ 23 
1.3.2 TG2 or tissue transglutaminase ................................................................... 24 
1.3.3 TG3 or epidermal transglutaminase ............................................................. 24 
1.3.4 TG4 or prostate transglutaminase ................................................................ 25 
1.3.5 TG5 .............................................................................................................. 25 
1.3.6 Factor XIIIA .................................................................................................. 26 
1.3.7 Protein 4.2 .................................................................................................... 27 
1.3.8 TG6 or TGM Y ............................................................................................. 27 
1.3.9 Tranglutaminase 7/ TGZ .............................................................................. 28 
1.4 Structure of transglutaminase ......................................................................... 31 
1.5 Tissue Transglutaminase (TG2) ...................................................................... 32 
1.6 Structure of TG2 ............................................................................................. 33 
1.6.1 Catalytic site ................................................................................................. 33 
1.6.2 Calcium binding site ..................................................................................... 34 
1.6.3 Nucleotide pocket ........................................................................................ 35 
1.6.4 Fibronectin binding site ................................................................................ 36 
1.6.5 Heparin binding site ..................................................................................... 36 
1.7 Localisation and cellular distribution ............................................................... 37 
1.8 Secretion of TG2 ............................................................................................. 38 
1.9 Regulation of TG2 activity ............................................................................... 40 
1.10 Roles of TG2 ................................................................................................. 42 
 6 
 
1.10.1 GTPase ...................................................................................................... 42 
1.10.2 Kinase activity ............................................................................................ 42 
1.10.3 TG2: protein disulphide isomerase ............................................................ 42 
1.10.4 Cell adhesion ............................................................................................. 43 
1.11 TG2 involvement in pathological and disease state ...................................... 44 
1.11.1 Wound Healing .......................................................................................... 44 
1.11.2 Neurodegenerative Disease ....................................................................... 44 
1.11.2.1 Huntington’s disease ............................................................................... 45 
1.11.2.2 Parkinson’s disease ................................................................................ 45 
1.11.2.3 Alzheimer’s disease ................................................................................ 45 
1.11.3 Fibrosis ...................................................................................................... 46 
1.11.4 Coeliac disease .......................................................................................... 47 
1.11.5 Cancer ....................................................................................................... 47 
1.12 TG2 inhibitors ................................................................................................ 48 
1.12.1 Competitive amine inhibitors ...................................................................... 48 
1.12.2 Reversible inhibitors ................................................................................... 49 
1.12.3 Irreversible inhibitors .................................................................................. 49 
1.13 FRET (Förster Resonance Energy Transfer) ................................................ 49 
1.13.1 Green fluorescent protein ........................................................................... 51 
1.13.2 Crystal Structure of GFP ............................................................................ 53 
1.13.3 GFP mutants .............................................................................................. 55 
1.14 Classification of GFPs ................................................................................... 56 
1.15 Intra-molecular FRET .................................................................................... 58 
1.16 Inter-molecular FRET .................................................................................... 59 
1.17 Mechanism of FRET ..................................................................................... 59 
1.18 FRET quantification techniques .................................................................... 60 
1.18.1 Donor de-quenching................................................................................... 60 
1.18.2 Acceptor enhanced emission ..................................................................... 61 
1.18.3 Donor acceptor emission peak ratio ........................................................... 61 
1.19 FRET measurement ...................................................................................... 62 
1.20 Potential problems in FRET experiments ...................................................... 62 
1.20.1 Measurement difficulties ............................................................................ 62 
1.20.2 Problems with construction and validation of fusion proteins ..................... 64 
 7 
 
AIMS ..................................................................................................................... 66 
Chapter 2 ................................................................................................................. 67 
Material and Methods ............................................................................................... 67 
2. METHODS ........................................................................................................ 68 
2.1 Media Recipe .................................................................................................. 68 
2.1.1 LB Broth ........................................................................................................ 68 
2.1.2 LB Agar ........................................................................................................ 68 
2.2 Buffer Recipes ................................................................................................ 68 
2.2.2 6x DNA loading buffer .................................................................................. 68 
2.2.3 Laemmli Buffer ............................................................................................. 69 
2.2.4 Cracking buffer ............................................................................................. 69 
2.2.5 Coomassie Blue stain .................................................................................. 69 
2.2.6 SDS electrode running buffer ....................................................................... 69 
2.2.7 SDS transfer buffer ...................................................................................... 69 
2.3 10x dNTPs ...................................................................................................... 69 
2.4 SDS polyacrylamide Gel ................................................................................. 70 
2.5 General chemicals .......................................................................................... 70 
2.6 Primers ............................................................................................................ 70 
2.7 General Techniques ........................................................................................ 72 
2.7.1 Preparation of competent cells using calcium chloride ................................ 72 
2.7.2 Transformation ............................................................................................. 73 
2.7.3 Blue White screening procedure .................................................................. 74 
2.7.4 Cracking procedure ...................................................................................... 74 
2.7.5 Plasmid preparation ..................................................................................... 74 
2.7.6 Phenol Chloroform Extraction of DNA .......................................................... 75 
2.7.7 Isopropanol precipitation .............................................................................. 75 
2.7.8 Ethanol precipitation..................................................................................... 76 
2.7.9 Agarose gel electrophoresis ......................................................................... 76 
2.7.9.1 Agarose gel ............................................................................................... 76 
2.7.9.2 Agarose gel purification (Low melting point gel) ........................................ 77 
2.7.10 DNA quantification ..................................................................................... 77 
2.8 Cloning Vectors ............................................................................................... 77 
2.9 Dephosphorylation of DNA .............................................................................. 78 
 8 
 
2.10 Ligation reaction ............................................................................................ 78 
2.11 Restriction Digestion ..................................................................................... 78 
2.12 PCR reactions ............................................................................................... 79 
2.13 Touchdown PCR ........................................................................................... 79 
2.14 Colony PCR .................................................................................................. 80 
2.15 Sequencing reactions.................................................................................... 81 
2.16 Klenow 3’end infilling..................................................................................... 81 
2.17 Expression and purification of Recombinant TG2 ......................................... 82 
2.18 Chromatographic purification of His-tagged proteins using His GraviTrap 
column (GE Healthcare). ...................................................................................... 82 
2.19 Gradient purification using GE AKTA prime FPLC ........................................ 83 
2.20 Desalting by gel filtration ............................................................................... 83 
2.21 SDS-PAGE ................................................................................................... 83 
2.22 Western blotting of SDS PAGE separated proteins ...................................... 84 
2.23 Protein Assay ................................................................................................ 85 
2.24 Transglutaminase Activity assay ................................................................... 85 
2.25 Detection of TG2 antigen using ELISA.......................................................... 86 
2.26 Binding of TG2 to Heparin-Sepharose .......................................................... 86 
2.27 Trypsin Digestion Assay ................................................................................ 87 
2.28 Conformation dependent protease digestion ................................................ 87 
2.29 FRET reactions ............................................................................................. 88 
Chapter 3 ................................................................................................................. 89 
Construction of CFP-TG2-YFP recombinant protein in bacterial system.................. 89 
3.1 Introduction ..................................................................................................... 90 
3.2 RESULTS ....................................................................................................... 93 
3.3 PCR amplification ........................................................................................... 93 
3.3.1 CFP amplification ......................................................................................... 94 
3.3.4 YFP amplification ......................................................................................... 95 
3.3.4 TG2 amplification ......................................................................................... 96 
3.4 Cloning amplified products into pSTBlue-1 ..................................................... 97 
3.4.1 Identification of recombinant pSTBlue-1 plasmids. ...................................... 97 
3.4.2 CFP cracking ............................................................................................... 98 
3.4.3 YFP cracking ................................................................................................ 99 
3.4.5 TG2 cracking .............................................................................................. 100 
 9 
 
3.5 Cloning of CFP, YFP and TG2 into expression vector pTrcHisB .................. 101 
3.6 Cloning CFP into pTrcHis B .......................................................................... 102 
3.7 Screening of recombinant CFP-pTrcHisB plasmids ...................................... 104 
3.8 Analysis of selected colonies of recombinant CFP-pTrcHis B clones. .......... 106 
3.9 Orientation of CFP into pTrcHisB .................................................................. 107 
3.10 Colony PCR ................................................................................................ 109 
3.11 Nucleotide sequencing ................................................................................ 110 
3.12 Cloning of TG2 into CFP-pTrcHis B ............................................................ 110 
3.13 Restriction digestion of CFP-pTrcHisB 12 and TG2-pSTblue1 plasmid ...... 112 
3.14 Screening of CFP-TG2-pTrcHisB ligated colonies. ..................................... 114 
3.15 Nucleotide sequencing of CFP-TG2-pTrcHisB clones ................................ 115 
3.16 Test BglII digest of CFP-TG2 clones ........................................................... 118 
3.17 YFP cloning into CFP-TG2 pTrcHisB .......................................................... 118 
3.18 HindIII digestion of YFP-psTBlue1 plasmid ................................................. 119 
3.19 EcoRI digestion of YFP-psTBlue1 plasmid ................................................. 120 
3.20 EcoRI digestion of CFP-TG2-pTrcHisB plasmid ......................................... 123 
3.21 Screening of recombinant CFP-TG2-YFP-pTrcHisB clones. ....................... 124 
3.22 Restriction digestion test on selected CFP-TG2-YFP-pTrcHisB clones. ..... 125 
3.23 Discussion ................................................................................................... 127 
Chapter 4 ............................................................................................................... 130 
Expression and characterisation of construct ......................................................... 130 
4.1 Introduction ................................................................................................... 131 
4.2 Expression of CFP-pTrcHisB ........................................................................ 132 
4.3 Expression and Purification of CFP-TG2-YFP recombinant protein .............. 133 
4.4 Chromatographic purification of His-tagged proteins using His GraviTrap 
column ................................................................................................................ 133 
4.5 Fractions of protein purified on His GraviTrap column .................................. 134 
4.6 Gradient purification using GE AKTA prime FPLC ........................................ 135 
4.6.1 Western blot analysis of 20mM-200mM imidazole gradient eluted fractions
 ............................................................................................................................ 136 
4.6.2 25mM-500mM imidazole gradient eluted fractions ..................................... 139 
4.6.3 30mM-500mM imidazole gradient eluted fractions ..................................... 140 
4.6.4 Steep 25mM-200mM imidazole gradient eluted fractions .......................... 144 
4.7 Control CFP-TG2 recombinant protein purification ....................................... 145 
 10 
 
4.7.1 Western blot analysis of control CFP-TG2 purification eluted fractions ..... 146 
4.8 Control wild type TG2-pET30ek/LIC purification (wild type TG2) .................. 146 
4.9 Binding of TG2 to Heparin-Sepharose .......................................................... 147 
4.9.1 Western blot analysis of CFPTG2YFP purification through heparin-
Sepharose column .............................................................................................. 149 
4.9.2 Western blot analysis of wild type TG2 purification eluted using heparin-
Sepharose column .............................................................................................. 150 
4.9.3 Western blot analysis of CFPTG2 purification eluted fractions .................. 151 
4.9.4 Downstream cleaning of Ni-affinity purified protein using Heparin column. 153 
4.10 Affinity purification of control pET30Ek/LIC TG2 using GE AKTA prime FPLC
 ............................................................................................................................ 154 
4.10.1 Purified wild type TG2 through heparin column ....................................... 155 
4.11 Affinity purification of CFP-TG2-YFP using GE AKTA prime FPLC ............ 157 
4.11.2 Purified CFP-TG2-YFP fractions through heparin column ....................... 158 
4.12 Conformational changes due to effect of monodansyl cadaverin, biotin 
cadaverin, inhibitors R281 / R283 ....................................................................... 160 
4.12.1 Effect of Biotin cadaverin (BTC) ............................................................... 160 
4.12.2 Effect of monodansyl cadaverin ............................................................... 163 
4.12.3 Effect of Inhibitors R281 and R283 .......................................................... 166 
4.12.4 R281 and wild type................................................................................... 166 
4.12.5 R283 and wild type................................................................................... 167 
4.12.6 R281 and CFP-TG2-YFP recombinant protein ........................................ 169 
4.13 Presence of TG2 antigen by ELISA ............................................................ 172 
4.14 Biotin-cadaverine incorporation into N,N’-dimethylcasein ........................... 173 
4.15 Biotin-cadaverine incorporation into Fibronectin ......................................... 173 
4.16 Calcium activation assay ............................................................................. 174 
4.17 GTP inhibition curve .................................................................................... 176 
4.18 Discussion ................................................................................................... 178 
Chapter 5 ............................................................................................................... 180 
FRET analysis ........................................................................................................ 180 
5.1 Introduction ................................................................................................... 181 
5.2 FRET data analysis ....................................................................................... 182 
5.2.1 Effect of GTP on conformation using FRET analysis ................................. 182 
5.3 Control CFP-TG2 recombinant protein FRET analysis ................................. 186 
 11 
 
5.4 Effect of Calcium on conformation using FRET analysis............................... 191 
5.5 Control CFP-TG2 recombinant protein FRET analysis ................................. 195 
5.6 Comparison of Calcium activity curve and FRET efficiency .......................... 200 
5.7 Discussion ..................................................................................................... 201 
Chapter 6 ............................................................................................................... 202 
Construction of CFP-TG2-YFP recombinant protein in mammalian system ........... 202 
6.1 Introduction ................................................................................................... 203 
6.2 PCR amplification ......................................................................................... 204 
6.3 CFP-TG2-YFP amplification .......................................................................... 204 
6.4 Cloning amplified products into pSTBlue-1 ................................................... 206 
6.5 His-CFP-TG2-YFP cracking .......................................................................... 206 
6.6 NotICFP-TG2-YFP cracking .......................................................................... 207 
6.7 Cloning of CFP-TG2-YFP construct into expression vector pcDNA3.1- ........ 209 
6.8 Cloning NotCFP-TG2-YFP and HisCFP-TG2-YFP into pcDNA3.1- .............. 210 
6.9 Screening of recombinant CFP-TG2-YFP-pcDNA3.1- plasmids ................... 213 
6.10 Discussion ................................................................................................... 217 
Chapter 7 ............................................................................................................... 218 
Discussion .............................................................................................................. 218 
References ............................................................................................................. 229 
 
  
 12 
 
List of Abbreviations 
ATP Adenosine 5'- triphosphate 
APP Amyloid precursor protein 
BTC Biotin Cadaverin 
CaCl2 Calcium Chloride 
CD Celiac disease 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
DTT Dithiothreitol 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylene diamine tetra acetic acid 
EGTA Ethylene glycol tetra acetic acid 
FCS Fluorescence correlation spectroscopy 
FN Fibronectin 
FXIII Factor XIII 
FXIII A Factor XIII subunit A 
FXIII B Factor XIII subunit B 
GDP Guanosine 5'diphosphate 
RhTG2Recombinant human transglutaminase 
GFP Green fluorescent protein 
GTP Guanosine 5'- triphosphate 
GTPase Guanosine 5'- triphosphatase 
HRP Horseradish peroxidase 
HS Heparan sulphate 
IgG Immunoglobulin 
IGF1insulin like growth factor 1 
IL-6 Interleukin - 6 
IκB Inhibitor of -κB 
IPTG isopropyl-beta-D-thiogalactopyranoside 
kDa Kilo Dalton 
MDC Monodansyl Cadaverin 
MMP matrix metalloproteinases 
NFκB Nuclear factor kappa - light chain enhancer of activated B cells 
OPD o-phenylenediamine 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
PDI Protein disulphide isomerase 
PKCα protein kinases c alpha 
PMA α phorbol 12, 13 didecanole 
PMSF Phenylmethylsulfonyl fluoride 
PNRC Perinuclear recycling compartment 
SCR Small consensus repeat 
SDS Sodium dodecyl sulphate 
SDS- PAGE Sodium dodecyl sulphate- polyacrylamide gel electrophoresis 
TEMED N, N, N’, N’-tetramethylene diamine 
TG Transglutaminase 
TG2 Tissue transglutaminase 
TGFβ1 Transforming growth factor beta 1 
X-gal 5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside 
 13 
 
List of figures 
Figure 1.1 Crystal structure of GDP bound (closed conformation) and inhibitor bound 
TG (open conformation). 
Figure 1.2 Calcium binding sites. 
Figure 1.3 Secretion of cytoplasmic TG2. 
Figure 1.4 Trafficking of TG2 into the extracellular matrix via syndecan shedding. 
Figure 1.5 Timeline of major developments of GFP   
Figure 1.6 Structure of monomeric WT GFP 
Figure 1.7 Chromophore structures of CFP and YFP 
Figure 1.8 Intramolecular FRET. 
Figure 1.9 Intermolecular FRET. 
Figure 1.10 Cross-talk. 
Figure 1.11Bleed-through 
Figure 3 Overview of the cloning strategy 
Figure 3.1 Agarose gel electrophoresis of amplified products using primers CFP 
For3/Rev3. 
Figure 3.2 Agarose gel electrophoresis of amplified products using primers YFP 
For2/Rev2. 
Figure 3.3 Agarose gel electrophoresis of amplified products using primers TG2 
For/Rev. 
Figure 3.4 Agarose gel electrophoresis of the cracking procedure performed on the 
selected CFP colonies after Blue White screening. 
Figure 3.5 Agarose gel electrophoresis of the cracking procedure performed on the 
selected YFP colonies after Blue White screening 
 14 
 
Figure 3.6 Agarose gel electrophoresis of the cracking procedure performed on the 
selected TG2 colonies after Blue White screening 
Figure 3.7 Agarose gel electrophoresis of the purified plasmid of pTrcHis B.  
Figure 3.8 Agarose gel electrophoresis of the digestion of purified CFP using Bam HI 
and Bgl II.  
Figure 3.9 Agarose gel electrophoresis of the digestion of the purified pTrcHis B 
plasmid using Bam HI. 
Figure 3.10A and 3.10B Agarose gel electrophoresis of the cracking procedure 
performed on the selected CFP-pTrcHis B clones. 
Figure 3.11 Agarose gel electrophoresis of the purified plasmid of CFP-pTrcHis B 
clones. 
Figure 3.12 Agarose gel electrophoresis of the BamHI/EcoRI digestion of the purified 
CFP-pTrcHis B clones. 
Figure 3.13 Agarose gel electrophoresis of the colony PCR. 
Figure 3.14 Agarose gel electrophoresis of the purified plasmid of CFP-pTrcHis B 
clones 12 and TG2-pSTblue 1 purified plasmid. 
Figure 3.15 Agarose gel electrophoresis of EcoRI/BglII digested CFP-pTrcHis B 12 
and TG2-pSTBlue1 purified plasmid. 
Figure 3.16 Agarose gel electrophoresis of gel purified plasmid of CFP-pTrcHis B 
clones 12 and TG2-pSTblue 1 purified plasmid. 
Figure 3.17 Agarose gel electrophoresis of the cracking procedure performed on the 
selected CFP-TG2-pTrcHisB clones. 
Figure 3.18 Agarose gel electrophoresis CFP-TG2-pTrcHisB clones which were 
treated with Klenow fragment and re-ligated 
Figure 3.19 Agarose gel electrophoresis showing a test BglII digested of re-ligated 
clones. 
 15 
 
Figure 3.20 Agarose gel electrophoresis of the digestion of the purified YFP-
pSTBlue1plasmid using HindIII. 
Figure 3.21 Agarose gel electrophoresis of the double digestion of the purified YFP-
pSTBlue1plasmid using EcoRI/HindIII. 
Figure 3.22 Agarose gel electrophoresis of the double digestion of CFP-TG2-
pTrcHisB plasmid using HindIII/EcoRI. 
Figure 3.23A and 23B Agarose gel electrophoresis of the cracking procedure 
performed on the selected CFP-TG2-YFP-pTrcHisB clones. 
Figure 3.24 Agarose gel electrophoresis of the double digestion of the purified CFP-
TG2-YFP-pTrcHisB clones. 
Figure 4.1 SDS PAGE analysis of expression of CFP by CFP-pTrcHisB clones. Lane 
1 is the BLUeye prestained protein ladder. 
Figure 4.2 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Novablue cells and purified using His GraviTrap column (GE Healthcare). 
Figure 4.3 Western blot analysis of CFP-TG2-YFP recombinant protein purification 
using His GraviTrap column (GE Healthcare). 
Figure 4.4 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Figure 4.5 Western blot analysis of CFP-TG2-YFP recombinant protein purification 
using Ni-NTA column. 
Figure 4.6 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Figure 4.7 Western blot analysis of CFP-TG2-YFP recombinant protein purification 
using Ni-NTA column using 25-500mM imidazole gradient elution. 
Figure 4.8 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
 16 
 
Figure 4.9 Western blot analysis of CFP-TG2-YFP recombinant protein purification 
using Ni-NTA column using 30-500mM imidazole gradient elution. 
Figure 4.10 SDS PAGE analysis CFP-TG2-YFP recombinant protein using a shallow 
gradient of 20ml. 
Figure 4.11SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Figure 4.12 Western blot analysis of CFP-TG2-YFP recombinant protein purification 
using Ni-NTA column. 
Figure 4.13 SDS PAGE analysis CFP-TG2 control recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Figure 4.14 Western blot analysis of CFP-TG2 recombinant protein purification using 
Ni-NTA column over a 20-200mM imidazole gradient elution 
Figure 4.15 SDS PAGE analysis Control wild type TG2-pET30ek/LIC recombinant 
protein expressed in Rosetta cells and purified using Ni-NTA column (GE AKTA 
prime FPLC). 
Figure 4.16 Western blot analysis of CFP-TG2-YFP recombinant protein purification 
over heparin sepharose column. 
Figure 4.17 Western blot analysis of wild type recombinant protein purification over 
heparin sepharose column. 
Figure 4.18 Western blot analysis of control CFP-TG2 recombinant protein 
purification over heparin sepharose column. 
Figure 4.19 SDS PAGE analysis of wild type TG2 protein purification using Ni 
column. 
Figure 4.20 SDS PAGE analysis of purified fractions of wild type TG2 protein 
purification using heparin column. 
Figure 4.21 SDS PAGE analysis of CFP-TG2-YFP recombinant protein purification 
using Ni column. 
 17 
 
Figure 4.22 SDS PAGE analysis of purified fractions of CFP-TG2-YFP recombinant 
protein purification using heparin column 
Figure4.23 SDS PAGE analysis of BTC treated wild type TG2.   
Figure 4.24SDS PAGE analysis of BTC treated CFP-TG2-YFP recombinant protein 
Figure 4.25 SDS PAGE analysis of MDC treated wild type TG2. 
Figure 4.26 SDS PAGE analysis of BTC treated CFP-TG2-YFP recombinant protein. 
Figure 4.27 SDS PAGE analysis of R281 treated wild type recombinant TG2 protein. 
Figure 4.28 A and B SDS PAGE analysis of R283 treated wild type recombinant TG2 
protein. 
Figure 4.29 A and B SDS PAGE analysis of R281 treated wild type recombinant TG2 
protein. 
Figure 4.30 Detection of TG2 antigen using ELISA 
Figure 4.31Comparison of specific activity of RhTG2 and purified CFP-TG2-YFP 
recombinant with respect to biotin cadaverin incorporation into N, N’-dimethylcasien.  
Figure 4.32 Comparison of specific activity of RhTG2 and purified CFP-TG2-YFP 
recombinant with respect to biotin cadaverin incorporation into fibronectin. 
Figure 4.33 Dose-response curve of transglutaminase activity for calcium with values 
plotted on a logarithmic scale. 
Figure 4.34 Figure Dose-response curve of transglutaminase activity for GTP with 
values plotted on a logarithmic scale. 
Figure 5.1 Effect of increasing concentration of GTP on CFP emission analysing 
CFP-TG2-YFP recombinant protein 
Figure 5.2 Effect of increasing concentration of GTP on YFP emission analysing 
CFP-TG2-YFP recombinant protein. 
Figure 5.3 Effect of increasing concentration of GTP on CFP excitation YFP 
emission analysing CFP-TG2-YFP recombinant protein. 
 18 
 
Figure 5.4 Effect of increasing concentration of GTP on CFP emission analysing 
control CFP-TG2 recombinant protein. 
Figure 5.5 Effect of increasing concentration of GTP on CFP excitation YFP 
emission analysing control CFP-TG2 recombinant protein. 
Figure 5.6 Effect of increasing concentration of GTP on FRET.  
Figure 5.7 Effect of increasing concentration of GTP on FRET efficiency. 
Figure 5.8 Effect of increasing concentration of calcium on CFP emission analysing 
CFP-TG2-YFP recombinant protein 
Figure 5.9 Effect of increasing concentration of calcium on YFP emission analysing 
CFP-TG2-YFP recombinant protein 
Figure 5.10 Effect of increasing concentration of calcium on CFP excitation YFP 
emission analysing CFP-TG2-YFP recombinant protein. 
Figure 5.11 Effect of increasing concentration of calcium on CFP emission analysing 
control CFP-TG2 recombinant protein 
Figure 5.12 Effect of increasing concentration of calcium on CFP excitation YFP 
emission analysing CFP-TG2 recombinant protein. 
Figure 5.13 Effect of increasing concentration of calcium on FRET.  
Figure 5.14 Effect of increasing concentration of calcium on FRET efficiency 
Figure 5.15 Comparison of calcium activity and FRET efficiency. 
Figure 6.1 Agarose gel electrophoresis of amplified CFP-TG2-YFP plasmid using 
forward primers NotICFP and HispTrc and YFP Rev2 primer 
Figure 6.2 Agarose gel electrophoresis of the cracking procedure performed on the 
selected His CFP-TG2-YFP colonies after Blue White screening 
Figure 6.3 Agarose gel electrophoresis of the cracking procedure performed on the 
selected NotI CFP-TG2-YFP colonies after Blue White screening 
Figure 6.4 Agarose gel electrophoresis of the purified plasmid of pcDNA3.1-. 
 19 
 
Figure 6.5 Agarose gel electrophoresis of the digestion of the His-CFP-TG2-YFP5 
plasmid using NotI and HindIII. 
Figure 6.6 Agarose gel electrophoresis of the digestion of the purified pcDNA3.1- 
plasmid using NotI and HindIII. 
Figure 6.7 Agarose gel electrophoresis of the cracking procedure performed on the 
selected NotICFP-TG2-YFP-pcDNA3.1- colonies after transformation. 
Figure 6.8 NotICFP-TG2-YFP-pcDNA3.1- colonies after transformation.  
Figure 6.9 Agarose gel electrophoresis of the cracking procedure performed on the 
selected His-CFP-TG2-YFP-pcDNA3.1- colonies after transformation. 
 
 
 
 
 
 
 
 
 
 20 
 
List of Tables 
Table 1 Members of the transglutaminase family. 
Table 2 Wide range of fluorescent proteins available 
 
 
 
 
 
 
 
 21 
 
 
Chapter 1  
Introduction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
Transglutaminase 
1.1 Introduction 
Transglutaminases are multifunctional enzymes that cross-link proteins to form high 
molecular weight aggregates. This post-translational modification of proteins occurs 
through an acyl-transfer reaction between the γ-carboxamide group of a protein or 
peptide bound glutamine and the free ε-amino group of a lysine. The resulting cross-
linked protein aggregates impart strength to tissues and enhance resistance to 
chemical and proteolytic degradation. Transglutaminase are involved in protein 
crosslinking and polyamidation which regulate cellular functions like apoptosis, 
extracellular matrix assembly, and stabilisation of skin epidermis.(Griffin et al., 2002)  
1.2 Mechanism of cross linking 
The calcium dependent cross linking reaction was well investigated in the 1960s by 
Jack Folk and the enzymatic reaction was depicted to follow a ping-pong 
mechanism. This reaction is a two step reaction where by the enzyme primarily 
recognises a glutamine bound peptide and interacts via the sulphur of the cysteine 
(C277) residue resulting in the formation of a thioester acyl intermediate with the 
release of ammonia. The second half of the reaction involves the intermediate 
undergoing a nucleophilic attack by a primary amine or water molecule. The 
unfavourable hydrolytic reaction results in the formation of glutamic acid and is called 
deamination. The alternate favourable transamidation reaction occurs when a 
primary amine acts an acyl acceptor. This reaction can result in either incorporation 
of primary amines into proteins or crossing linking of proteins depending on the 
second substrate.  The formation of iso-peptide bonds between donor and acceptor 
is particularly significant due to their property for being resistant to proteolytic and 
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chemical damage. Apart from this direct cross linking small polyamine are also 
involved in indirect crosslinking involving polymerisation of polyamine such as 
putrescine (Tsai et al., 1998),(Griffin et al., 2002). 
1.3 Types of Transglutaminase 
Transglutaminase (EC 2.3.2.13) is classified as follows 
E.C. 2 Transferase 
E.C. 2.3 Acyltransferase 
E.C. 2.3.2 Aminoacyltransferase 
E.C. 2.3.2.13 ProteinGlutamineGammaGlutamlytransferase 
Transglutaminases are found in both eukaryotes and prokaryotes, including 
microorganisms(Kanaji et al., 1993), invertebrates(Singh and Mehta, 1994), 
plants(Del Duca et al., 1995), amphibians(Zhang and Masui, 1997), fish(Yasueda et 
al., 1994), and birds(Puszkin and Raghuraman, 1985). Mammalian 
transglutaminases are calcium dependent whereas bacterial transglutaminase are 
not regulated by cofactors. 
All types of transglutaminase illustrate substrate specificity. Different TGs can 
recognise same protein substrate but differ in affinity and specificity.  At the genetic 
level, nine members of the mammalian transglutaminase family have been identified, 
of which seven have been characterised at the protein level.  
1.3.1 TG1 or Keratinocyte Transglutaminase 
TG1 in proliferating cells exists as a membrane-bound 106kDa form but in terminally 
differentiating cells undergoes proteolysis to fragments of 67kDa, 33kDa and 10kDa . 
(Kim et al., 1995) TG1, expressed at basal levels in proliferating keratinocytes, is 
exponentially induced and activated by tarazotene induced protein 3 (TIG3) during 
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the differentiating phase of keratinocytes. It contributes to the cornified envelope 
formation by anchoring to the inner surface of plasma membrane via amino terminal 
lipid linkage. (Sturniolo et al., 2005) Apart from keratinocytes it is found to be 
expressed in epithelial tissue of the lung, kidney and liver at adherens junctions and 
also reported in myocardial microvascular endothelial cells and are involved in 
maintaining structural integrity.(Hiiragi et al., 1999) TG1 is involved in the cross 
linking of cell envelope proteins where during terminal differentiation of keratinocytes 
the plasma membrane bound TG1 is activated. Besides cross linking of keratins TG1 
has been found to support the attachment of cell envelope proteins to the lipid 
envelope by cross linking terminal ω hydroxyceramides.(Iismaa et al., 2009) 
1.3.2 TG2 or tissue transglutaminase 
TG2 is 80kDa protein and is the most widely studied member of the family.TG2 
cross-links cell surface fibronectin to promote cell-matrix interactions and are also 
associated with noncovalent bonding of integrins to fibronectin. This function is 
important in cell adhesion and in fibronectin assembly. (Wang et al., 2010) 
1.3.3 TG3 or epidermal transglutaminase 
TG3 is a 77 kDa inactive zymogen which on activation by cathepsin L is converted 
into its active form (50/27kDa)(Kim et al., 1990). It is involved in the cross linking of 
hair structural protein; e.g.  trichohyalin to form keratin intermediate filament matrix 
protein and also participates in cell envelope formation.(Tarcsa et al., 1997) It is 
observed that TG3 knockout mice do not show adverse effects, except for a delay is 
skin barrier formation before birth which is normalised until birth and irregular hair 
follicle function(Thiebach et al., 2007, Iismaa et al., 2009). TG3 cross links loricrin 
and SPRs (small proline rich proteins) during cell envelope formation in corneocytes 
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and may be involved in cross linking structural proteins of hair. Association of TG3 
genetic variants with disease conditions have not been reported in humans (Stacey 
et al., 2014). It is known to play a pathological role in dermatitis herpetiformis (celiac 
disease)(Rose et al., 2009) 
1.3.4 TG4 or prostate transglutaminase 
TG4 is predominantly distributed and expressed in the prostate gland and has been 
indicated to be involved in prostate cancer. Dubbink et al has reported the androgen 
supported upregulation of TG4. (Dubbink et al., 1996) TG4 exhibits both 
transamidase and GTPase activity similar to that of TG2. (Spina et al., 1999 )It is 
known to mask antigenicity of sperm cells by regulating immune responses in the 
female genital tract of rabbits.(Mukherjee et al., 1983) It is reported to be associated 
with prostate cancer cell growth and increases migration and invasiveness of these 
cells. It is also involved in membrane micromotion, cell-matrix adhesion, tumor –
endothelial interaction and epithelial mesenchymal transition. It is referred to as a 
potential biomarker to differentiate between aggressive and nonaggressive cancer. 
(Jiang and Albin, 2011) (Cao et al., 2013) 
1.3.5 TG5  
TG5 is an 81kDa transglutaminase and is activated upon proteolytic processing and 
its expression found in upper layers of the epidermis and human hair follicle.(Candi 
et al., 2002) It is observed in the epithelial mesenchymal transition state of 
keratinocytes with substrates like loricrin, involucrin, SPR3 and is co-localised with 
vimentin.(Candi et al., 2001) A mutation in TG5 resulting in the loss of function has 
been implicated to cause APSS or acral peeling skin syndrome. There is a higher 
expression of TG5 in the skin of APPS patients where the enzyme is found between 
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the granular layer and the stratum corneum and localised to the position of the split. 
(Cassidy et al., 2005) Sequence analyses of APPS families have revealed two 
missense mutations p. T109M and p. G113C in affected individuals. (Bowden, 2011) 
1.3.6 Factor XIIIA  
FXIII is a heterotetramer found in the plasma comprising of two subunit A (83kDa), 
which belongs to the transglutaminase family, and two regulatory subunit B (80kDa) 
of the small consensus repeat (SCR) protein family.(Lehthinen et al., 2004) Subunit 
A is the catalytic domain and subunit B is the carrier protein. FXIII finds important 
functions both inside and outside the cell, predominantly present in the plasma, 
noncovalently bound to fibrinogen.  Subunit B is known to play a role in stabilising 
subunit A and a mutation in subunit B leads to deficiency of subunit A. (Saito et al., 
1990) The carrier subunit B also contributes by regulating the conversion of Plasma 
FXIII (pFXIII) to pXIIIa/(activated form) and binding the pFXIII  heterotetramer 
zymogen to fibrinogen. During the activation of pFXIII the detaching of subunits A 
and B is initiated by thrombin and enhanced by polymers of fibrin. The dissociation of 
subunits is governed by calcium binding followed by a conformational change that 
results in access to the active site cysteine for crosslinking reaction to follow.  It also 
incorporates plasminogen activator inhibitor-2 which prevents fibrinolysis and 
increases resistance during blood coagulation.(Ritchie et al., 2000) (Verderio et al., 
2005) Apart from being found in blood platelets (Puszkin and Raghuraman, 1985) it 
has been reported that FXIIIA is associated with macrophages, (Törőcsik et al., 
2005) and plays a role in wound healing, bone development and tumor progression.  
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1.3.7 Protein 4.2 
Protein 4.2 is the catalytically inactive member of the transglutaminase family due to 
substitution of active cysteine with alanine. It is found in the cells of erythroid lineage 
and the protein has a myristoyl and palmitoyl group attached to it. It is associated 
with the association of erythrocyte membrane to the cytoskeleton via ankyrin and 
Band3. (Iismaa et al., 2009) Band 4.2 is suggested to be involved in providing 
stability and flexibility of RBCs and patients with deficiency suffer from spherocytosis 
and to an extent haemolytic anemia. (Zhu et al., 1998) Another intriguing fact that 
differentiates protein 4.2 is that it binds to ATP and not GTP. (Azim et al., 1996) In 
4.2 knockout mice the RBCs were observed to be smaller than normal as an effect of 
membrane loss and altered cation concentrations. They are also observed to be 
spherical due to lack of lipid anchoring and are more fragile.  (Iismaa et al., 2009) 
1.3.8 TG6 or TGM Y 
TG6 has been shown to have restricted expression pattern and is expressed in the 
neural tissue and is associated with pathogenesis of gluten sensitivity-related 
neurological problems.(Hadjivassiliou et al., 2008) TG6 has been found to have high 
specific activity in the absence of proteolytic processing and is sensitive to oxidative 
inactivation. Similar to TG2, TG6 require calcium binding for activation and data 
suggests potential to function as a guanine nucleotide exchange factor in signalling. 
Expression of TG6 was enhanced on induction of cell death by metal ion chelation in 
Neuro 2a cells relating the increase in TG6 expression during cerebral cortex 
development to programmed cell death. It is also suggested that TG6 may play an 
important role in neurons involved in motor control. (Thomas et al., 2013) TG6 is 
associated with gluten ataxia(Cascella et al., 2013) 
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1.3.9 Tranglutaminase 7/ TGZ 
TG7 is known to be expressed in osteosarcoma cells, dermal fibroblasts, 
erythroleukemia cells, primary keratinocytes, testis, skin, brain kidney, etc. TG7 is 
also known to be similar to TG2 in terms of structural requirements and calcium 
binding. The catalytic core comprise of Cys-279, His-338 and Asp-361. TG7 was 
observed that similar to TG5, Tyr at 538 is replaced by His. It is also present on the 
same chromosome 15q15.2 along with TG5 and band 4.2.(Grenard et al., 2001b) 
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Member of TG 
family 
Gene 
location 
Function Molecular 
mass 
Tissue expression Distribution 
Epidermal 
transglutaminase 
Chromosome 
20 q11-12 
Involved in cornified cell 
envelop formation during 
terminal differentiation of 
keratinocytes. 
 
Keratinization of 
developing hair. 
77kDa Squamous 
epithelium 
Cytosol 
Factor XIII Chromosome 
6 p24-p25 
Associated with blood 
clotting and wound 
healing 
 
Bone metabolism (ECM 
deposition and osteoblast 
differentiation) 
83kDa Monocytes, 
macrophages, dermal 
dendrocytes, 
astrocytes, 
chondrocytes, 
oesteoblasts, 
osteocytes 
Cytosol and 
extracellular matrix 
Tissue 
transglutaminase 
Chromosome 
20 q11-12 
Involved in cell survival, 
cell differentiation, matrix 
stabilization, cell 
adhesion, apoptosis, 
transmembrane signalling   
80kDa Ubiquitous Cytosol, nucleus, 
membrane, cell 
surface, extracellular, 
mitochondria 
Keratinocyte 
transglutaminase 
Chromosome 
14 q11.2 
Assembly of cornified cell 
envelope during terminal 
differentiation of 
keratinocytes (epidermal 
barrier formation) 
106kDa  keratinocytes Plasma membrane, 
cytosol 
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Table 1: Members of the transglutaminase family.
 
Prostate 
transglutaminase 
Chromosome 
3 p22-p21.33 
Involved in formation of 
rodent copulatory plug 
and semen coagulation  
77kDa Prostate Extracellular, seminal 
plasma 
TG 5 Chromosome 
15 q15.2 
Associated with 
keratinocyte 
differentiation, cornified 
envelope formation  
81kDa Female reproductive 
tissue, skeletal 
muscle, epithelial 
barrier lining 
Cytosol 
Erythrocyte-bound 
4.2 
Chromosome 
15 
Inactive as an enzyme. 
Function is unknown but 
is suggested to be 
essential to stabilize 
erythrocyte membrane 
integrity, involved in 
scaffolding. 
72kDa Erythrocyte 
membrane, foetal 
liver, spleen 
Erythrocyte plasma 
membrane (RBCs) 
TG6 Chromosome 
15 q15.2 
Central nervous system 
Development and motor 
function 
78kDa Skin epidermis and 
hair follicle 
Not defined 
TG7 Chromosome 
15 q15.2 
Not characterized 71kDa Ubiquitous 
(lung/testis) 
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1.4 Structure of transglutaminase 
Cysteine, histidine and aspartate/asparagine are the three amino acids that comprise 
the catalytic triad, which is conserved among all active members of the 
transglutaminase family (with the exception of erythrocyte Band 4.2, which contains 
alanine in place of the active site cysteine and hence is catalytically inactive). Other 
conserved amino acids in the TG family are Trp241, Trp332 and Thr360 (numbered for 
TG2). The TG isoenzymes differ in terms of substrate specificity and how the 
enzyme activity is regulated. GTP acts an inhibitor for tissue (TG 2), epidermal (TG 
3) and prostate (TG 4) transglutaminase. Proteolytic cleavage of the connecting loop 
(between the catalytic core and C-terminal barrel 1) is essential for the activity of TG 
3 whereas cleavage at this site leads to inactivation of TG 2 and Factor XIIIa. 
(Pinkas et al., 2007)Factor XIIIa is activated by thrombin cleavage of an N-terminal 
inhibitory peptide. 
Using TG2 as an example, the structure is organised into four distinct domains, NH2-
terminal β sandwich (aa 1-139), Core domain (aa140-454) and COOH- terminal β 
barrels 1 (aa 479-584) and 2 (aa 586-687). These domains are highly conserved 
among other members of the TG family, with keratinocyte TG and Factor XIIIa 
having an additional pro-peptide sequence.  
Domain 1 is folded into a β structure comprising of an initial flexible loop, five tightly 
packed anti-parallel strands (B2-B6) and two additional strands B1 and B7. 
Domain 2 or core domain contains the catalytic site and other regulatory sites. It 
comprises the GTP binding site involving Ser171 and Lys173 on the surface, guarded 
by two β strands (B8 and B9) which move up and down exposing this site. The core 
domain also comprises four additional β strands (B10-B13). Apart from this, three α-
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helixes pointing towards the catalytic triad and one α-helix protects the Ca2+ binding 
region (Ser449, Pro446, Glu451 and Glu452) 
Domain 3 is made up of six β strands and on β turn and domain 4 made up of seven 
anti-parallel β strands. Domain 3 and 4 protect the core domain thus regulating 
exposure of the active site.  When Ca2+ binds, the structure unfolds disturbing the 
connecting loop. The resulting dislocation of domains 3 and 4 exposes the active site 
followed by transamination reaction (Griffin et al., 2002). 
 
Figure 1.1 Crystal structure of GDP bound (closed conformation) and inhibitor 
bound TG (open conformation). A) Represents the different domains of TG2 
B)Closed conformation of GDO bound TG2 C)Open conformation of TG2 
showing the Ca2+ binding sites. (Bergamini et al., 2011) 
 
1.5 Tissue Transglutaminase (TG2) 
TG2 is the most ubiquitously expressed and most extensively studied member of the 
TG family. Like other mammalian transglutaminases, TG2 is a calcium dependent 
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enzyme. TG2 is found intracellularly in the cytosol, at the cell membrane and in the 
nucleus and is also associated with the extracellular matrix. The primary function of 
TG2 is transamidation.  
1.6 Structure of TG2 
1.6.1 Catalytic site 
The crystal structures of TG2 bound with GDP, ATP and inhibitors have supported 
the understanding of the multi-functionality of TG2 depending on its structure. The 
catalytic triad is the site of transamidating activity comprised of Cys-277, His-335 and 
Asp-358. The guanine nucleotide binding site is found between the catalytic core and 
the first β barrel domain. Tyr-516 and its loop from β-barrel domain regulate the 
accessibility of Cys-277 to substrates. (Liu et al., 2002) Mutation of Cys-277 to serine 
inactivates the transamidation function of TG2.(Mian et al., 1995) This mutation also 
affects the GTP/GDP binding ability and increases the tendency of the protein to 
remain in its open conformation. (Begg et al., 2006) During the transamidation 
reaction residues W241 and W332 are critically important to stabilize the 
intermediate form. Mutation at W241A is known to abolish the transamidating activity 
but does not affect the GDP/GTP binding but mutation W332F decreases its ability to 
bind GDP/GTP. (Murthy et al., 2002) Mutation of T360A promotes the deamination 
reaction of TG2 as its affects the regulation of the acyl acceptors. (Pinkas et al., 
2007) Cys-277 forms hydrogen bonds with Y516 which is known to promote stability 
of TG2 in its closed conformation. A substitution of Y516 with phenylalanine (Y516F) 
promotes TG2 to its open conformation(Begg et al., 2006).(Gundemir et al., 2012) 
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 1.6.2 Calcium binding site 
Although the crystal structure of TG2 bound to calcium has not been solved, X ray 
crystallography has revealed FXIIIa and TG3 calcium bound structures.(Fox et al., 
1999, Ahvazi et al., 2003) X ray crystallography of calcium bound FXIIIa revealed 
that the calcium binding pocket is 10Å from barrel1 and regulates the exposure of 
the active site by inducing dynamical changes along Tyr-560. It is proposed that 
during crystallisation, factorXIII is in its inactive form. (Fox et al., 1999) 
Transglutaminase 3 binds to three calcium ions responsible for stability of the 
enzyme and opening the channel to the active site and thereby controlling access of 
substrates to the active site.(Ahvazi et al., 2003) Based on structural homology and 
site directed mutagenesis, studies have been undertaken to predict the calcium 
binding sites of TG2. It is evaluated that there are 6 calcium binding sites within the 
catalytic domain. Apart from importance S2 and S3 calcium binding sites (similar to 
TG3) S4 (149 YLDSEEERQEY) and S5 (432 GRDEREDIT) are equally important. 
Mutations at these sites lead to a total inactivation. A “sequential mechanism” is 
involved in binding of calcium to TG2 that is the binding of one calcium ion promotes 
or triggers the binding of additional calcium ions. Mutations at site 228 
VNCNDDQGV 236 prevents this additional binding of other calcium ions without 
altering the GTPase activity.(Kiraly et al., 2009) 
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Figure 1.2 Calcium binding sites. In this figure represents the 4 domains of 
TG2, N-terminal (blue), core domain (red), β-barrel1 (cyan) and β-barrel2 (red). 
The calcium binding sites (grey), active site is represented using red spheres 
and bound GTP indicated by purple spheres.  
1.6.3 Nucleotide pocket 
The nucleotide binding pocket involving residues of the catalytic and β barrel domain 
is common to both GTP and ATP binding. This pocket is comprised of ten residues 
with Ser482 and Arg580 specifically binding guanine indicating stronger binding to 
TG2 and efficient inhibition of TG2 activity by GTP than ATP.(Jang et al., 2014, Han 
et al., 2010) A mutation R580A completely abolishes its GTP/GDP binding activity by 
decreasing affinity for both but has an opposite effect on GTP hydrolysis 
rate.(Gundemir and Johnson, 2009) Other residues like Ser171 and Lys173 play a 
critical role in the direct association with GTP binding.(Iismaa et al., 2000)   
It has been suggested that under normal physiological conditions TG2 remains 
catalytically inactive intracellular (low calcium and high GTP) and extracellularly (due 
 36 
 
to association with integrins). It remains inactive until induced upon by stress. (Siegel 
et al., 2008) The exact control mechanisms to support this, despite favourable 
conditions for TG2 activity outside the cell, still need further investigation. TG2 also 
has 5 intramolecular disulphide bridges which play a role in the redox state and 
regulation of TG2 activity. Disulphide bonds between C370 and C371 and between 
C370 and C230 were found to inactive the transamidating activity of TG2.(Gundemir 
et al., 2012) 
1.6.4 Fibronectin binding site 
The interaction of TG2 and fibronectin is important in cell adhesion, cell migration, 
matrix stabilisation and signalling. The fibronectin binding site is located in the N 
terminal domain and has been mapped to 88 WTATVVDQQDCTLSLQLTT 106. This 
is a hairpin like structure of antiparallel β strands 5 and 6 of the β sandwich domain. 
Amino acids site Asp94 and Asp97 are key residues of TG2 for fibronectin 
interaction. Mutagenesis of Asp94 or Asp97 to Ala result in reduction of fibronectin 
binding affinity and substitution of both with Ala leads to a further decrease in affinity. 
Mutation of other residues of antiparallel β strands 5 and 6 such as Cys98Ala does 
not affect fibronectin binding. Asp94 and Asp97 are conserved among other 
mammalian transglutaminases whereas Trp88 and Ala90 residues are conserved 
among the other seven transglutaminases. This indicates the uniqueness of TG2 
with respect to its interaction with fibronectin, which is not seen with other 
transglutaminases.(Hang et al., 2005)   
1.6.5 Heparin binding site 
TG2 has a high affinity for cell surface heparin sulphate proteoglycans (HSPG) and 
syndecan-1 and syndecan-4 play a critical role in cell surface shedding of heparin 
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sulphates for translocation of TG2 into the extra cellular matrix(ECM). Mutations 
K205A and R209A showed a loss of binding affinity for heparin indicating that Lys-
205 and Arg-209 play a direct role in high affinity binding to heparin. It is also 
suggested the heparin sulphate binding site of TG2 202 
KFLKNAGRDCSRRSSPVYVGR 222 is essential for the translocation of TG2 to the 
extracellular compartment via cell surface shedding of HS. Heparin affinity 
chromatography showed that TG2 when in its compact GTP bound form binds with 
higher affinity as compared to its open conformation (inhibitor R281 treated) (Wang 
et al., 2012).   
1.7 Localisation and cellular distribution 
TG2 is predominantly present in the cytoplasm. It is also found in the mitochondria 
and the nucleus(Lesort et al., 1998) whereas no TG2 is detected in the endoplasmic 
reticulum or Golgi apparatus. TG2 is transported into the nucleus by interaction with 
importin α3 (Peng et al., 1999) and is found associated with chromatin. TG2 is 
involved in mitochondrial functions such as apoptosis. It also exhibits protein 
disulphide isomerase (PDI) activity and is involved in the assembly of respiratory 
chain complexes in the mitochondria.(Park et al., 2010) TG2 is also externalised 
both on the plasma membrane and into the ECM. Upon externalisation TG2 exhibits 
both enzymatic and non-enzymatic functions. It is known to cross link ECM proteins 
and regulates the interactions of cells with each other and the extracellular matrix. It 
is also associated with regulating non covalent interactions involving integrins, 
syndecan 4 and growth factor receptors. It also plays a role in cell survival and 
apoptotic responses both inside and outside the cell.  
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1.8 Secretion of TG2 
 TG2 is externalised from fibroblasts, osteoblasts, endothelial, smooth muscle cells, 
monocytes and macrophages and is found in the extracellular matrix. TG2 also lacks 
secretory signals or hydrophobic domains that direct externalisation. TG2 does not 
follow the conventional ER/Golgi-dependent pathway as TG2 lacks a signal peptide. 
A fraction of TG2 is associated with membranes. TG2 is also associated with 
fibronectin and heparin sulphates and these are likely to affect the retention of TG2 
on the cell surface rather than its export. It was proposed earlier that TG2 is secreted 
as a soluble protein and then gets associated with the cell surface and ECM but now 
it is clear that this is not the case and it first appears on the outside of the plasma 
membrane and is then translocated to the ECM. A study by Zemskov et al. (2011) 
proposed an alternative mechanism. By using inhibitors including brefeldin and 
tunicamycin to block secretion via the ER/golgi pathway, they showed that TG2 was 
still externalised. Also the use of sodium chlorate and glyburide which inhibit 
unconventional secretion of FGF2 and IL-1β respectively do not interfere with the 
secretion of TG2. Even the application of heat shock and copper chelator 
tetrathiomolybdate did not stop TG2 from being externalised. The rate of 
externalisation was reduced by the use of N ethylmaleimide. It is also certain that 
TG2 maintains its association with membranes during the secretion. The study 
proposed the secretion of TG2 by a vesicle-mediated route where the protein 
maintains its association with the intracellular membrane with the aid of Ca2+. Prior to 
externalisation, cytoplasmic TG2 first binds to phosphoinositides to be recruited to 
the endosomal membrane. The delivery of endosomal bound TG2 inside vesicles 
requires the recruitment of ATP.  It then attaches to the recycling endosomal marker 
Rab11 in the perinuclear recycling compartment (PNRC). TG2 was also found to be 
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associated with β1 integrins in the PNRC and is then delivered to the cell surface as 
a complex with recycled β1 integrins. Proteins VAMP3 and SNAP23 SNARE are 
involved in the TG2-endosome fusion with plasma membrane. (Zemskov et al., 
2011)  
 
 
Figure 1.3 Secretion of cytoplasmic TG2 involving phospholipid-dependent 
delivery into recycling endosomes.(Belkin, 2011) 
Interestingly in 2012 Wang et al, demonstrated that syndecan-4 bound TG2 in its 
closed conformation is deposited into the extracellular matrix by syndecan shedding. 
It was shown that matrix metalloproteinases, MMP-2 and MMP-9 are recruited for 
this deposition. TG2 deposition into the matrix was regulated by heparan sulfate 
shedding. It  was restricted by treatment with PKCα inhibitor Go6976, upregulated by 
treatment with α-phorbol-12,13-didecanoate (PMA) and abolished by removal of 
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heparan sulfate chains. It was indicated that TG2 is retained at the cell surface 
associated with heparan sulphate in its compact conformation until syndecan 
sheddingand  deposition into the ECM. In the ECM, the TG2 structure opens up due 
to calcium. (Wang et al., 2012)  
 
 
(Wang et al., 2012) 
Figure 1.4 Trafficking of TG2 into the extracellular matrix via syndecan 
shedding. Cell surface TG2 associated with syndecan-4 is deposited into ECM 
by syndecan shedding. PKCα acts a intraceullar signalling molecule for 
activating syndecan-4 shedding. TG2 adapts to its open conformation once 
shed from cell surface.  
1.9 Regulation of TG2 activity 
It is known that under normal physiological conditions, extracellular TG2 adopts a 
closed conformation due to GTP inhibition and integrin binding in spite of the high 
calcium concentrations. In case of stress (physical or chemical injury) TG2 adopts its 
open active conformation. (Pinkas et al., 2007) Inside the cell TG2 functions as a G 
protein in phospholipase C signal transduction.(Nakaoka et al., 1994) Outside the 
cell TG2 plays as important role in the ECM by binding to cell surface integrins and 
fibronectin.(Akimov et al., 2000) TG2 is sensitive to redox changes which result in 
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oxidation and inactivation of TG2. The redox sensitive cysteine triad comprises of 
Cys-230, Cys-370 and Cys-371. Cys-370 can form disulphide bonds with either Cys-
230 or Cys-371 which leads to inactivation. This disulphide bond formation is 
influenced by the presence of calcium which protects against formation of Cys230-
Cys370 and Cys370-Cys371 disulphide bonds. (Stamnaes et al., 2009) Evidence 
suggests that TG2 activity is also regulated by nitric oxide. In the absence of 
calcium, 8 cysteine residues were nitrosylated with no disruption in TG2 activity 
whereas in the presence of calcium, 15 cysteine residues were nitrosylated with 
inhibition of TG2 activity.(Lai et al., 2001) This inhibitory regulation of TG2 by nitric 
oxide is reversible and affects matrix cross-linking and activation of TGFβ-1, which is 
important in fibrogenesis and tissue scarring. (Telci et al., 2009) TG2 regulation is 
also affected by binding of calreticulin that down regulates both GTPase and TGase 
activity. (Feng et al., 1999) It was also found that at low calcium concentrations 
sphingosylphosphocholine (lyso-SM) was able to activate TG2 in the presence of 
phospholipid vesicles. Lyso-SM induces a conformational change in the protein that 
affects the calcium binding without affecting substrate binding ability. (Lai et al., 
1997) In the cytoplasm of a healthy cell, the ATP concentration is 8-11mM, part of 
which may be in bound form. The GTP concentration in the cytosol of living cells is 
around 50-300µM with an estimated free GTP concentration of100µM. The free Ca2+ 
concentration inside the cell is only about 100-200nM. In this state, the TG2 activity 
within the cytosol is inhibited (Smethurst and Griffin, 1996). The intracellular average 
GTP/Calcium ratio (~150µM/~100nM) is sufficient to keep TG2 in a relatively latent 
state as a transamidase(Gundemir et al., 2012). Structurally, domains 3 and 4 of 
TG2 are involved in this interaction where they mediate GTP and 
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phosphatidylinositide binding. It was also found that the Ca2+ binding protein 
calreticulin is associated with TG2 and leads to down regulation of the GTP binding.  
1.10 Roles of TG2 
1.10.1 GTPase 
TG2 can bind and hydrolyse GTP, a function involved in signal transduction. Initial 
studies suggested that TG2 was implicated in signalling from α1B/D adrenergic 
receptors to downstream effectors like δ1 isoform of phospholipase C 
(PLCδ1)(Murthy et al., 1999) GTP is known to inhibit the transamidase activity of 
TG2 (Achyuthan and Charles, 1987).  
1.10.2 Kinase activity 
TG2 also has intrinsic kinase activity. TG2 is associated with the cell membrane 
where it phosphorylates insulin like-growth factor- binding protein-3 (IGFBP-3), 
thereby enhancing the binding affinity towards IGF-1 (insulin like growth factor). 
Increasing the concentration of calcium leads to inhibition of kinase activity, and also 
promotes the cross-linking activity of TG2. The exact mechanism of this is not fully 
understood. Apart from IGFBP-3, TG2 has been reported to be involved in the 
phosphorylation of histones, retinoblastoma protein and oncoprotein p53. (Mishra 
and Murphy, 2004) 
1.10.3 TG2: protein disulphide isomerase 
TG2 has protein disulphide isomerase (PDI) activity. PDI activity is usually found in 
the endoplasmic reticulum where it forms disulphide bridges within polypeptides. 
This function is important in the folding of protein by the re-arrangement of disulphide 
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bonds, in order to achieve proper conformational state. It has been demonstrated 
that TG2 was able to catalyse the refolding of disulphide bond-scrambled RNase 
(inactive) by the rearrangement of disulphide bonds. The PDI and transamidation 
activities of TG2 are independent of each other. Also, PDI activity does not require 
Ca2+ and is not inhibited by the presence of nucleotides. It has been suggested that 
TG2 may function as a PDI in a moderately reducing environment as found in the 
cytosol. (Hasegawa et al., 2003) 
1.10.4 Cell adhesion 
TG2 acts as a cell adhesion protein by binding to matrix fibronectin and cell surface 
heparan sulphates. TG2 is localised into the extracellular matrix after cell damage 
and stress, where it plays an important role in matrix remodelling and stabilisation of 
the ECM proteins. It is also found to play an important role in integrin-mediated cell 
adhesion, spreading, migration, survival, differentiation, ECM (extracellular matrix) 
contraction, and fibronectin matrix deposition (Belkin, 2011). Various ECM proteins 
such as fibronectin, fibrinogen, collagen, vitronectin, osteopontin and laminin-
nidogen complexes are cross-linked by cell surface TG2. TG2 interacts with the 
gelatin-binding domain of fibronectin, consisting of modules I6II1,2I7-9, which are 
distinct from the integrin-binding sites on fibronectin. During cell adhesion, the β1, β3 
and β5 subunits of integrins interact with TG2-bound fibronectin, forming stable 
ternary structures. Syndecan-4 (one of the major group of cell surface heparan 
sulphate proteoglycans) binds to fibronectin and participates with integrin α5β1 in 
focal adhesion formation and actin cytoskeleton organisation. The binding of TG2 to 
fibronectin and subsequent binding to heparan sulphate chains of syndecan-4 
promotes RGD-independent cell adhesion. (Telci et al., 2008). 
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1.11 TG2 involvement in pathological and disease state 
Extracellular TG2 is involved in inflammatory situations such as in wound healing, 
tissue fibrosis, autoimmune condition; neurodegenerative disease and cancer.  
1.11.1 Wound Healing 
TG2 activity is found to increase both intracellularly and extracellularly during wound 
healing and stabilisation. In conditions of tissue damage and cellular stress, TG2 is 
externalised, where it binds to fibronectin fibrils or plasma fibronectin. The ability of 
TG2 to form non-reducible multimers of ECM-fibronectin leads to the stabilisation of 
the ECM. The TG2-fibronectin complex can restore loss of cell adhesion following 
the inhibition of the classical fibronectin ArgGlyAsp (RGD)-dependent adhesion 
pathway mediated by α5 β1 integrin receptors. TG2 also cross links collagen, leading 
to rapid synthesis of fibrils and formation of a stable substratum for cell adhesion 
(Collagen types 1 and 3). TG2 also activates TGFβ1, thereby upregulating 
proliferation and synthesis of ECM. During the inflammatory phase of wound healing, 
an increase in TG2 activity has been reported particularly associated with 
macrophage adhesion and migration.(Verderio et al., 2005) 
1.11.2 Neurodegenerative Disease 
TG2 is found to be expressed in a number of neural cells and is suggested to be 
involved in the development of the nervous system. (Monsonego et al., 1997) TG2 is 
involved in forebrain maturation and increased activity is observed at the start of 
neuronal differentiation or brain growth spurt (BGS)(Bailey and Johnson, 2004) 
Neurodegenerative disorders are known to be linked to disturbed calcium signalling. 
β-amyloid peptide is implicated in In Alzheimer’s which is neurotoxic and is produced 
as a result of processing of amyloid precursor protein(APP). TG2 is suggested to be 
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involved in these disorders by facilitating the stabilisation of such toxic aggregates. It 
is also observed that in pathogenesis of neurodegenerative disorders like 
Parkinson’s, Huntington’s, Alzheimer’s and schizophrenia demonstrate abnormalities 
in calcium homeostasis. (Palotas et al., 2004)   
1.11.2.1 Huntington’s disease is an inherited disease due to CAG repeat 
expansion mutation where as compared to normal population (6-35 repeats) over 40 
repeats is observed in Huntington’s patients. (Gusella et al., 1993) TG2 is indicated 
to contribute to Huntington’s by inhibition of aggregate formation and promoting 
formation soluble protein complexes of mutant htt protein.(Michalik and Van 
Broeckhoven, 2003) In TG2 knockout studies it was observed that the Huntington’s 
disease transgenic mice showed an increase in life span and improved motor 
dysfunction.  (Ruan and Jonhson, 2007) 
1.11.2.2 Parkinson’s disease is the loss of neurons in the substantia nigra of the 
brain. These neurons regulated dopamine and a loss of these neurons develops 
disease state with symptoms of tremor, stiffness in muscles and slow movement. 
(Rascol et al., 2003) Significant amount of TG2 is detected in the membrane and 
cytosol extracts from substantia nigra. (Citron et al., 2002) TG2 cross links α-
synuclein and facilities formation of high molecular weight aggregates into insoluble 
cytoplasmic inclusions also known as Lewy bodies. This is followed by degeneration 
of dopamine neurons in the substantia nigra.(Andringa et al., 2004) (Ruan and 
Jonhson, 2007)  
1.11.2.3 Alzheimer’s disease is an age-related disorder involving memory loss, 
behaviour changes, and speech related difficulties. Alzheimer’s disease is 
associated with the cross-linking of beta amyloid peptide to form insoluble 
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aggregates to form senile plaques found in the brain. TG2 is found to cross link beta-
amyloid peptide to form multimers and leads to amyloid deposition and amyloidosis. 
(Dudek and Johnson, 1994) In the neocortex and hippocampus shows the presence 
of neurofibrillary tangles. Tau protein aggregates into soluble paired helical filaments 
and further covalently cross-linked by transglutaminase to form insoluble PHFs. 
(Johnson et al., 1997a) 
1.11.3 Fibrosis 
Tissue destruction seen with the heart, lung, liver, kidney and skin due to fibrosis is a 
result of excessive production of collagenous extracellular matrix and accumulation 
of fibroblasts. The expression of fibroblast and α-smooth muscle actin is seen by 
“fibroblastic loci” composed of myofibroblasts and contractile cells. It has been 
previously found that cytokine transforming growth factor (TGFβ) is known to 
regulate the differentiation process of fibroblasts into myofibroblasts. (Broekelmann 
et al., 1991)Unlike normal physiology, these myofibroblasts fail to undergo apoptosis 
and the excessive deposition of collagen and fibronectin is seen in tissue.  
Myofibroblast survival is regulated by TGFβ and endothelin-1 via protein kinase B 
activation. (Kulasakaran et al., 2009) TG2 is known to contribute to fibrosis by cross-
linking collagen and fibronectin in the ECM. (Verderio et al., 2004) TG2 mediated 
nuclear histone crosslinking is observed in liver fibrosis. Osteonectin is also a 
substrate of TG2 and is  upregulated during fibrosis. TG2 (Grenard et al., 2001a) 
TG2 has also been implicated in kidney fibrosis. (Johnson et al., 1997b) An increase 
in TG2 expression is seen patients of idiopathic pulmonary fibrosis. Production of 
TGFβ in alveolar macrophages is involved in the onset of pulmonary fibrosis which in 
turn promotes TG2 crosslinking activity. (Olsen et al., 2011)  
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1.11.4 Coeliac disease 
Coeliac disease is an inflammatory disorder of the small intestine due to gluten 
sensitivity found in wheat, barley and rye. Coeliac disease is associated with 
damage to the epithelial cells (IECs), destruction of small intestine villi, crypt 
hyperplasia and lymphocytic infiltration caused as a result of the immune response 
against specific gluten antigens. Coeliac disease is also marked by the development 
of autoantibodies (IgA and IgG) specific for tissue transglutaminase /TG2. Within the 
lumen of the gut, proline residues in gluten proteins cause them to be resistant to 
breakdown by intestinal proteases. TG2 is known to deamidate gluten fragments and 
convert glutamine residues to glutamate and triggering increased binding affinity to 
HLA-DQ2 and HLA-DQ8 (Arentz-Hansen et al., 2000). CD4+T cells also show 
preferred affinity towards deamidated peptides(Wal et al., 1998). (Jabri and Sollid, 
2009) It is also suggested autoantibodies targeted against TG2 disturb angiogenesis 
and promote disorganisation of the actin cytoskeleton in endothelial and vascular 
mesenchymal cells.(Myrsky et al., 2008)  
1.11.5 Cancer 
The involvement of TG2 in cancer progression has further developed interest in this 
enzyme. The GTP binding and transamidating properties of TG2 are associated with 
proliferation of the malignant cells into the surrounding tissues.  (Collighan and 
Griffin, 2009)  Inflammatory responses play an important role in tumour initiation, 
promotion, invasion and metastasis. During tissue injury, cytokines and growth 
factors like TGF-β1, TNF-α and IL-6 are secreted which induce TG2 expression. 
TG2 is down regulated in primary tumours which aid matrix destabilisation and 
thereby supporting angiogenesis and tumour invasion. TG2 is found to be up 
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regulated in secondary metastatic tumours. (Mehta et al., 2010) (Kotsakis and 
Griffin, 2007) The importance of TG2 is seen in various stages of tumour 
progression. Intracellular TG2 is observed to act as a pro-apoptotic factor through 
the cross-linking of intracellular proteins such as pRB, and also anti-apoptotic signals 
by activating the NF kappa B pathway (Mann et al., 2006). Extracellular TG2 
interacts with fibronectin via integrins involved in cell survival by inducing anti-
apoptotic protein Bcl-2. TG2 also binds to fibronectin through an RGD independent 
pathway via syndecan 4 thereby rescuing the cells from cell death. (Collighan and 
Griffin, 2009, Kotsakis and Griffin, 2007) Depending on the ECM composition the cell 
surface TG2 favours or opposes cell migration. The over-expression of MT-MMPs 
(membrane type matrix metalloproteinases) results in degradation of TG2, thereby 
suppressing cell adhesion and locomotion on fibronectin, whereas fibronectin 
protected cell surface TG2 from MT1-MMP digestion, promoting cell adhesion and 
locomotion(Belkin et al., 2001) (Collighan and Griffin, 2009). 
1.12 TG2 inhibitors 
The implication of TG2 in various diseases has led to development of peptidomimetic 
TG2 inhibitors. Depending on their mode of inhibition TG2 inhibitors are classified as 
competitive amine inhibitors, reversible inhibitors and irreversible inhibitors.  
1.12.1 Competitive amine inhibitors 
These inhibitors compete with natural amine substrates. In the presence of 
competitive inhibitors TG2 proceeds with its transamidation reactions but the iso-
peptide bond formed is between the glutamine substrate and the introduced amine 
inhibitors rather than its natural lysine residue. Some examples of such inhibitors 
include putrescine, monodansylcadaverine, 5-(biotinamido)pentylamine and 2-
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mercaptoethylamine. These inhibitors are commercially accessible, found to be non 
toxic to cells and chemically stable.(Siegel and Khosla, 2007)  
1.12.2 Reversible inhibitors 
TG2 cofactors, GTP, GDP and Zn2+ are known to act as reversible inhibitors by 
hindering the access to the enzyme active site without any covalent modifications. 
(Lai et al., 1998) Similarly allosteric inhibitors having a thieno [2,3-d]pyrimidin-4-one 
acylhydrazide backbone are slow-binding competitive inhibitors that target the GTP 
binding site. (Duval et al., 2005, Case and Stein, 2007)  
1.12.3 Irreversible inhibitors 
This class of inhibitors tend to target the active site and result in covalent 
modification of TG2 thereby preventing the binding of substrates. This includes 
inhibitors like iodoacetamide, 3-halo-4,5-dihydroisoxazoles and 6-diazo-5-oxo-
norleucine (DON) (Siegel and Khosla, 2007). 
Griffin et al demonstrated the synthesis of cell permeable TG2 inhibitors R283 and 
cell impermeable inhibitors R294 and R281 that interfere with TG2 transamidation 
reaction by targeting the cysteine of the active site (Griffin et al., 2008). 
 
1.13 FRET (Förster Resonance Energy Transfer) 
In order to investigate the involvement of proteins in a disease state and develop 
drug targets it is critical to address fundamental questions like the structure of the 
protein, its expression and regulation, its dynamic interaction with other 
biomolecules, its localisation and its potential role within a cell. To answer these 
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questions some approaches include structural studies (e.g. X ray crystallography, 
NMR spectroscopy) expression proteomics (e.g. immunoassays, mass 
spectroscopy) and functional analysis (enzyme kinetics studies, development of 
fusion protein). The dynamic interaction of proteins and protein regulation that are 
implicated in human diseases can be analysed using different approaches. Förster 
Resonance Energy Transfer (FRET) also referred to as Fluorescence Resonance 
Energy Transfer permits the study of interactions between molecules in proximity, 
beyond the scope of light microscopic resolution. FRET can be used as a tool to 
visualize reactions in live cells that have the potential to give a better understanding 
to address these questions. This allows us to derive information of a protein and its 
interactions that best represents the actual reactions happening within the cell as 
compared to in-vitro methods. There are few alternate methods to study protein 
interactions that involve direct detection of interactions. For example, co-precipitation 
requires the removal of the proteins from their normal cellular environment. Proteins 
may behave differently once extracted from their natural environment and in turn 
affect analysis. Other limitations include fixing of cells (which restrains dynamic 
measurements of live cells), spatial resolution limits (diffraction limit of conventional 
optical microscopy) and lack of precise labelling strategies. These limitations can be 
overcome using FRET. It is also worth considering FRET before getting into animal 
testing and clinical trials as it provides cheaper and faster method to address some 
questions if not all regarding the pathogenesis of a disease at protein level. (Piston 
and Kremers, 2007) FRET provides another approach to analyse the regulation of 
TG2 via its large conformation change induced by calcium and GTP binding. FRET 
would also allow the titration of the calcium and GTP to observe this conformational 
change of TG2 that is critical for its regulation. This in turn could help bridge the 
 51 
 
understanding as to how TG2 is implicated in various diseases and help in the 
development of better drug targets. FRET is the non-radiative transfer of electronic 
excitation energy between a pair of fluorophores, i.e. a fluorescent donor and 
acceptor molecule separated by a distance of 10 to 100Å (inter-chromophoric 
distance). FRET imaging microscopy not only enables us to visually localise the 
fluorescent protein within a living cell but also allows measurement of changes in 
FRET corresponding to cellular events at a millisecond time resolution. When two 
fluorophores are sufficiently close, such that the emission spectrum of the donor 
overlaps the excitation spectrum of the acceptor, energy flows via dipole-dipole 
coupling (resonance) from one molecule to another leading to a FRET signal (Wang 
and Wang, 2009). In other words this transfer of energy is reflective of the reduction 
of fluorescence intensity of the donor, a decrement in its excited state lifetime and in 
the presence of a fluorescent acceptor, a ‘re-emission’ at its respective 
wavelength.(Heim and Tsein, 1996)  FRET-based imaging microscopy can be used 
as a sensitive probe of protein-protein interactions and protein conformational 
changes in vivo. Real time in vivo imaging of dynamic molecular events provides a 
crucial insight into biological mechanisms as well as physiological functions of the 
cell. (Truong and Ikura, 2001) To construct a FRET based biosensor the gene of a 
bioluminescent protein is fused with that of a target molecule such that the resultant 
recombinant protein emits fluorescence reflecting the target protein and its 
interactions.(Wang and Wang, 2009)  
1.13.1 Green fluorescent protein  
Green fluorescent protein (GFP) is a protein that was first purified with another 
bioluminescent protein, aequorin, obtained from Aequorea Victoria jellyfish 
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(Shimomura et al., 1962). The major advances of GFP and its applications have 
been indicated in Figure 1.5 with columns indicating the number the scientific 
articles. GFP can be expressed in a variety of cells emitting fluorescence without 
being associated with a cofactor. A biosensor constructed incorporating GFP is 
known to retain the fluorescent properties of the GFP and the biochemical function of 
the original host. On addition of an appropriate signal peptide this GFP fused 
recombinant protein can be targeted to specific organelles. Lately many GFP 
mutants have been produced having different spectral properties, which can be used 
as donors and acceptors in the construction of a FRET based biosensor. (Truong 
and Ikura, 2001).  In 1994 Martin Chalfie et al expressed GFP in E.coli using a T7 
promoter system and discovered it fluoresced. Bacterial cells were grown in the 
presence of inducer isopropyl-β-D-thiogalactoside (IPTG) and were detected under a 
ultraviolet (UV) source. Previous methods to study gene expression and protein 
distribution were dependent on the introduction of exogenous substrates or co-
factors whereas use of GFP is autonomous. It can also be used as a marker of 
transformation as it not found to hamper cell growth or function.  (Chalfie et al., 1994) 
The use of GFP to tag proteins was made possible in living cells with the discovery 
of GFP and the principle that it preserved its fluorescent properties when produced in 
living organisms. Advances have been made to use fluorescent proteins as 
indicators of biological events. The use of organic dye labels to investigate FRET for 
cyclic AMP (cAMP) mediated pathways was implemented by Roger Tsein in 1991 
(Adams et al., 1991). However organic dyes were substituted by genetically encoded 
fluorescent proteins due to difficulties with covalent labelling and cellular injection of 
organic dyes. The introduction of GFP as a tool for FRET studies launched the need 
to engineer new fluorescent proteins with enhanced characteristics. Advances have 
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been made to develop new fluorescent proteins emitting light from blue to red range 
of visible spectrum. GFP has been known to impact other biophysical fluorescence 
methods including fluorescence correlation spectroscopy (FCS), fluorescence cross-
relation spectroscopy (FCCS), fluorescence recovery after photo-bleaching (FRAP) 
which can be applied to investigate intracellular events. GFP also contributes to 
techniques like fluorescence life-time imaging (FLIM), high-resolution photo-
activation localisation microscopy (PALM). Cloning target protein that is labelled 
with fluorescent proteins has provided an innovative tool for studies related in cell 
biology, physiology and medicine. (Day and Davidson, 2012) 
Figure 1.5 Timeline of major developments of GFP  (Chudakov et al., 2010)  
1.13.2 Crystal Structure of GFP 
Wild type GFP has a size of 238-aa (25kDa). The chromophore of GFP, p-
hydroxybenzylideneimidazolinone, is well protected by 11 β-barrel strands (Figure 
1.6 - represented in green), making the molecule stable at physiological environment 
 54 
 
of living organisms resistant to detergents, organic solvents and proteases(Ward and 
Bokman, 1982). The internal irregular helix of chromophore is well guarded by the β 
strands and threaded by an α helix (represented in red) that form a cylinder like 
structure extending about 42Å long and 24Å in diameter. The placement of the 
chromophore contributes to the high quantum yield of fluorescence; small Stoke’s 
shift and inability of O2 to quench the excited state.   The key amino acids Ser65 –
Tyr66-Gly67 undergo conformational changes to form a mature chromophore by 
‘internal cyclization’ and 1,2-dehydrogenation of the Tyr. (Wang and Wang, 2009) 
GFP absorbs blue light at 395nm and a small peak at 475nm (ionised chromophore) 
and emits green light at 508nm (Brejc et al., 1997). 
         (Brejc et al., 1997) 
Figure 1.6 Structure of monomeric WT GFP. The compact 11β strands forming 
a cylinder like structure as shown in green, the α-helices shown in red and the 
ball-and stick model indicating the chromophore   (Brejc et al., 1997). 
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1.13.3 GFP mutants 
There is a diverse range of available fluorescent proteins extending nearly the entire 
visible spectrum (Table 2) providing exclusive markers to simultaneously examine 
multiple cellular events and they can be used as donor: acceptor FRET pairs (Heim 
and Tsein, 1996).  GFP based proteins are designed to be structurally stable and 
relatively inert.  
 
Table 2 Wide range of fluorescent proteins available.                                      
Selected dimeric and tetrameric FPs indication T, tetrameric; D, dimeric; B−, 
low brightness; Ps−, low photostability; pH−, low pH stability; Ag−, 
aggregation; Ps+, high photostability; pH+, high pH stability; mat+, fast 
maturation; B+, high brightness.(Chudakov et al., 2010) 
 
Given the wide options of fluorescent proteins; some basic requirements for 
successful application for imaging experiments includes the efficient expression of 
the protein in the appropriate system, its signal should be bright enough for detection 
and should not oligomerize when co-expressed with protein of interest. The mutant 
of GFP used should be photostable and when used in association with each other 
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should have minimal crosstalk in their excitation and emission spectra. Generally 
fluorescent proteins are optimised for expression in mammalian cells but some 
proteins may differ in their efficiency of folding and maturation. Expression of 
fluorescent proteins in bacterial cells does give a good indication of the efficiency of 
a system. Bacterial cell expression of fluorescent proteins helps in early 
determination of potential folding inefficiencies and provides useful information on 
notable variations between different expression systems  (Shaner et al., 2005).  
1.14 Classification of GFPs 
On the basis of chromophores GFP variants can be classified into seven different 
classes:  
Class 1 wild type mixture of neutral phenol and anionic phenolate having two 
chemically distinct species one having major excitation peak at 395nm,emission 
peak at 508nm and second minor peak at 475nm, emission at 503nm. Even though 
this class can be visualised by exposure to UV using a blocking filter, scattering, 
autofluorescence and tissue damage provides an inconvenience. Excitation at 
470nm would certainly be preferable in this case but anionic chromophore comprises 
only 15% of the total chromophores.  
Class 2 GFP proteins have phenolate anions in the chromophore such as Ser65Thr 
mutant having enhanced brightness and having excitation peak at 489nm and 
emission peak at 511nm. This class of mutants fold efficiently when expressed at 
room temperature and below.  
Class 3 or neutral phenol having excitation peak at 399nm and emission at 511nm 
having a large Stokes’ shift.  
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Class 4 or phenolate anion with stacked π electron system have the longest 
wavelengths as His, Trp, Phe and Tyr residues at position 203 increase excitation to 
516nm and emission 529nm. They are also called as yellow fluorescent proteins.  
Class 5 or indole chromophores derived by Tyr66Trp having indole instead of phenol 
having excitation and emission wavelengths at 436nm and 476nm. They are also 
referred to as cyan fluorescent proteins due to their blue emission.  
Imidazole chromophores or Class 6 are derived by substitution of Tyr66His and 
introducing an imidazole ring, having 383nm excitation and 447nm emission. This 
class is also called blue fluorescent proteins and has disadvantages like low 
quantum yield, high bleaching susceptibility.  
Class 7 or phenyl chromophore or Tyr66Phe have very little applications due to such 
short wavelength which excitation at 360nm and emission at 442nm. (Tsein, 1998) 
One of the most promising FRET pairs derived from mutagenesis of GFP is 
CFP (cyan fluorescent protein) and YFP (yellow fluorescent protein) because of the 
high quantum yield and enhanced photostability. CFP and YFP refer to the generic 
class of cyan and yellow mutants. CFP is a Tyr66Trp (figure 1.7) mutant of GFP 
which creates an excitation peak of 436nm and an emission peak 476nm. YFP was 
designed by introducing a Thr203Tyr (figure1.7) mutation in GFP which results in a 
π-π stacking interaction between Tyr203 and Tyr66 creating excitation and emission 
peaks of 516nm and 529nm respectively.  This CFP-YFP pair allows FRET to be 
detected at larger distances as compared to other FRET FP (fluorescent protein) 
pairs. 
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Figure 1.7 Chromophore structures of CFP and YFP (Shaner et al., 2007)    
1.15 Intra-molecular FRET 
When both the donor chromophore and acceptor chromophore are fused on the 
same host molecule which undergoes transition between open and closed 
conformations, intramolecular FRET is known to occur. The efficiency of FRET is 
dependent on the relative orientation and distance between the donor and acceptor 
chromophores.(Li et al., 2006) A larger FRET signal is generated when both the 
chromophore are oriented parallel to each other and shorter the distance between 
them. 
     (Kevin and Mitsuhiko, 2001) 
Figure 1.8 Intramolecular FRET. Both donor and acceptor chromophores are 
present on same host molecule. 
 59 
 
 1.16 Inter-molecular FRET 
FRET biosensors created by the fusion of donor and acceptor fluorescent proteins 
on two separate interacting proteins, inter-molecular FRET is known to occur. When 
these two fusion proteins interact the fluorescent proteins are bought closer together 
and create an inter-molecular signal. Such biosensors have been used to study 
protein associations for example the interaction of G protein coupled receptors 
(GPCR) with G proteins. (Li et al., 2006) 
 
       (Kevin and Mitsuhiko, 2001) 
Figure 1.9 Intermolecular FRET. Both donor and acceptor chromophores are 
fused on different macromolecules. When protein A and protein B interact, 
FRET occurs, when they dissociate FRET diminishes.  
1.17 Mechanism of FRET 
There are three basic requirements for FRET to work efficiently. These include 
separation distance, angular dependence and spectral overlap. Since FRET involves 
dipole dipole interactions the efficiency of energy transfer varies as the inverse of the 
sixth power of the distance that separates the fluorescent molecules. In other words 
the FRET efficiency decreases rapidly with an increase in the separation distance. 
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The second requirement is the angular dependence where the efficiency is 
dependent on the favourable alignment of the electromagnetic dipoles of the donor 
emission and acceptor absorption. This angular dependence of the dipole 
interactions is denoted by orientation factor k2. Depending on the orientation value of 
k2 from 0 to 4. Although it is difficult to measure k2 in most experiments the 
orientations of the fluorescent protein tags randomize over the time-scale 
measurements. k2 is often assumed to be two thirds. Lastly the spectral overlap is a 
basic requirement such that the fluorophores must share a strong overlap between 
the donor emission spectrum and the absorption spectrum of the acceptor. CFP and 
YFP are often used due to the large spectral overlap. However this also generates 
background fluorescence that is detected in the acceptor emission channel. This is 
due to the direct excitation of the acceptor by donor excitation wavelengths and 
donor emission signal that bleeds into the FRET detection channel. (Day and 
Davidson, 2012) 
1.18 FRET quantification techniques 
FRET can be measured either by the increase of the acceptor fluorescent emission 
or the decrease of the donor fluorescent emission. Apart from intensity based 
techniques there are other methods of measuring FRET too. Some of the commonly 
used techniques include  
1.18.1 Donor de-quenching 
This technique involves the use of photobleaching to destroy the acceptor and then 
measuring the increase in fluorescence intensity of the donor. Due to the absence of 
the acceptor the energy transfer between the donor and acceptor can no longer 
occur and thereby FRET can be measured as an increase in the donor emission. 
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The photobleaching process is irreversible hence measurements can be taken just 
once from a sample. The difference in fluorescence intensity of the donor pre and 
post photobleaching can be used to measure FRET directly as 
FRETeff = (Dpost – Dpre)/Dpost 
Where Dpost is the fluorescence intensity of the donor after photobleaching and Dpre is 
the fluorescence intensity of the donor before photobleaching.  (Lieca, 2007) 
1.18.2 Acceptor enhanced emission 
Instead of measuring the decrease in fluorescence of the donor, an increase in 
fluorescence of the acceptor is measured during FRET as the donor fluorophore 
transfers energy to the acceptor fluorophore. In this method contamination due to 
cross talk and bleed through are calculated separately from acceptor only and donor 
only samples. These contaminating values are then subtracted from the total 
fluorescent signal measured from the donor plus acceptor samples.  
1.18.3 Donor acceptor emission peak ratio 
This method involves the comparison of donor acceptor peak fluorescence ratios 
with and without FRET.(Miyawaki and Tsein, 2000) As FRET occurs the 
fluorescence intensity of the donor will decrease and that of the acceptor will 
increase. The ratio between the acceptor intensity over the donor intensity before 
FRET will be smaller than the ratio during FRET. This is a good method for 
measuring changes at a distance as measurement of this ratio can be quickly 
determined at the emission peak of each fluorophore.  
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1.19 FRET measurement 
To experimentally measure efficiency (E). FRET, the differential decrease or 
increase of the donor and acceptor intensity respectively is determined. 
Eapp = (DA / D+DA) x E 
Where Eapp is the apparent FRET efficiency of the system, 
DA is the concentration of donor-acceptor pair 
D is the concentration of free donor and 
A is the concentration of free acceptor 
Likewise FRET can be measured also by the increase in acceptor emission 
Eapp = (DA / A+DA) x E 
 
1.20 Potential problems in FRET experiments 
1.20.1 Measurement difficulties 
It is worth noting that FRET measurements are usually based on certain 
assumptions. For example, re-absorption of donor fluorescence by the acceptor is 
considered to be negligible using mutants with low fluorophore densities. 
Contamination due to “background light” must also be considered and subtracted 
from calculation by setting a control blank region for measurement. Some common 
contaminating factors include cross talk.  
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While analysing FRET it is observed that the donor emission spectrum overlaps the 
acceptor excitation spectrum. But the excitation spectrum overlap or emission 
spectrum overall is to an extent unavoidable and unfavourable as the smaller Stoke’s 
shift and FRET pair getting excited by the same excitation light to different levels. 
This is referred to as cross talk and commonly observed as the direct excitation of 
the acceptor by donor excitation light.  
 
Figure 1.10 Cross-talk. Spectra of donor (blue) and acceptor (yellow) 
fluorophores are superimposed. Solid lines respresent excitation spectra and 
dotted lines represent emission spectra. The overlap between donor and 
acceptor excitation spectra indicated by shaded area representing cross-talk. 
 
Cross talk can be determined by comparing the fluorescence intensities of an 
acceptor only sample excited using donor excitation light.  
Another essential consideration is “bleed-through” which is the overlapping of 
emission spectrums of donor and acceptor. This is where fluorescence emission of 
the donor fluorophore overlaps the emission range of the acceptor.  
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Figure 1.11 Bleed-through Spectra of donor (blue) and acceptor (yellow) 
fluorophores are superimposed. Excitation spectra shown as dotted curve and 
emission spectra shown as solid curve. The shaded area representing donor 
bleed-through emissions in the acceptor range. 
 
Bleed through is estimated by analysing the emission range of the donor. (Takanishi 
et al., 2006) 
1.20.2 Problems with construction and validation of fusion proteins  
An interesting study conducted to study the effect of calcium binding to calmodulin, 
which causes subsequent binding of calmodulin to other proteins. In this study 
calmodulin-M13 peptide was fused with fluorescent proteins BFP and mutant S65T. 
The construct was expressed in bacteria and FRET analysed. A variety of mutations 
such as deletion, insertions and amino acids substitutions were analysed for 
fluorescence. It was discovered that many variants of the wild-type construct showed 
improper folding resulting in abolishment of fluorescence, possibly being proteolysed 
in bacteria or during the purification process. It was noted that trial and error was 
adopted to obtain fusions that express well and to avoid precipitation or 
proteolysis.(Miyawaki and Tsein, 2000) Further analysis of intact mutants response 
to calcium revealed dramatic differences in FRET efficiency due to single amino  
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acid substitutions. Uncertainty whether fusing two fluorescent proteins rigidly without 
the extra spacers at boundaries or introduction of Gly-Gly spacers, showed the 
construct without spacers to have improved FRET efficiency. Measuring FRET 
directly from bacterial colonies, in this case, by soaking with calcium followed by 
EGTA in presence of calcium ionophore was performed. The drawback of this 
method was the dependency of signal on size of colony, uncertainty of exposure of 
proteins to reagents and misfolding and/or proteolysis inside bacteria. Fluorescence 
activated cell sorting could not be applicable in this case for comparing changes in 
fluorescence in response to calcium. (Miyawaki and Tsein, 2000) 
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AIMS 
The main objective of this project is to construct a FRET TG2 biosensor from which a 
better understanding about the conformation of TG2 in both solution and cell 
systems can be examined. To analyse this conformational change with respect to 
binding of TG2 to calcium and GTP suitable fluorescent proteins would be fused on 
the N and C terminii of TG2. This construct will be further analysed for activity and it 
was proposed to characterise fluorescence changes depending on the conformation.  
In order to do this, the following tasks were planned:  
• Construction of a TG2 FRET sensor by PCR and cloning methods.  
Suitable primers would be designed to PCR amplify the fluorescent protein 
genes allowing assembly of the fusion in a bacterial expression vector. 
• The TG2 FRET sensor would be affinity purified using the bacterial 
expression system and characterised in terms of TG2 activity and regulation 
by Ca2+ and GTP.  
• The ability to bind to fibronectin, heparan sulphate proteoglycans and ability to 
act as a mammalian cell adhesion protein would also be assessed using 
simple binding assays. 
• Characterisation of the fluorescent properties of the purified TG2 fusion with 
respect to alterations in FRET due to conformational changes. 
• TG2 fusions would also be attempted be subcloned into a mammalian 
expression plasmid  
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Chapter 2  
Material and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68 
 
2. METHODS 
2.1 Media Recipe 
2.1.1 LB Broth 
1 % (w/v) Tryptone (Melford, UK), 0.5 %(w/v) Yeast Extract(Oxoid, UK), 1 %(w/v) 
Sodium Chloride (Sigma Aldrich, UK) 
2.1.2 LB Agar 
1% (w/v) Tryptone (Melford, UK), 0.5% (w/v) Yeast Extract(Oxoid, UK), 1% (w/v) 
Sodium Chloride (Sigma Aldrich, UK), 2% (w/v) Granulated Agar (Melford, UK) 
LB broth and LB Agar were autoclaved at 121°C for 20 minutes. Media was then 
cooled to below 50°C and antibiotic such as Ampicillin (final concentration 100 µg/ml) 
or Kanamycin (final concentration 30µg/ml) were added.  
2.2 Buffer Recipes  
2.2.1 Tris Acetate EDTA (TAE) buffer 
1x TAE buffer was prepared using Melford, UK 10 x stock solution (0.4M Tris, 0.1M 
Acetate, 0.01M EDTA pH8.2) by dilution with deionised water. 
2.2.2 6x DNA loading buffer 
DNA loading buffer was prepared using 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 0.25% (w/v) Xylene cyanol. Aliquots were made and stored at 
-20°C.  
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2.2.3 Laemmli Buffer 
125mM Tris-HCl, pH6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 10% (v/v) 2-β-
mercaptoethanol and 0.004% (w/v) bromophenol blue) 
2.2.4 Cracking buffer  
Cracking buffer (2X) was freshly prepared using 5M NaOH, 10% (w/v) SDS and 10g 
sucrose, deionised water for final volume of 50ml. 
2.2.5 Coomassie Blue stain  
0.05% (w/v) Coomassie Brilliant Blue R-250 (Thermo Scientific, UK) was dissolved in 
50% (v/v) methanol (Fisher Scientific), 10% (v/v) acetic acid (Fisher Scientific, UK). 
2.2.6 SDS electrode running buffer 
Tris glycine running buffer was prepared using 25mM Tris, 192mM glycine, 
0.1%(w/v) SDS 
2.2.7 SDS transfer buffer 
SDS transfer buffer pH9.7 was prepared using 48.8mM Tris, 39mM glycine and 20% 
(v/v) methanol 
2.3 10x dNTPs 
100mM of dTTP, 100mM of dGTP, 100mM of dATP and 100mM of dCTP were 
introduced into sterile nuclease free water. Appropriate aliquots were made and 
stored at -20°C.  
 
 70 
 
2.4 SDS polyacrylamide Gel 
Separating gel (10%w/v) pH 8.8 was prepared using 0.75M Tris, 0.2% (w/v)SDS 
stock solution. Stacking gel (3%w/v) pH6.8 was prepared using 0.2M Tris, 0.2% 
(w/v) SDS stock solution. Polymerisation was initiated by addition of 10%(w/v) 
ammonium persulphate (freshly prepared) and 10µL N,N,N’,N’-
Tetramethylethylenediamine (TEMED) 
2.5 General chemicals 
Recombinant human tissue transglutaminase (insect cells) was obtained from 
Zedira. Cub7402 antimouse monoclonal was purchased from Thermo Fisher. ID10 
and TG2 inhibitors were a kind gift from Dr. Collighan, Aston University.  
2.6 Primers 
Primers were designed using Primerselect software (Lasergene, DNAStar) and 
obtained from Sigma, UK.  
Primer sequences 
 
• Forward primer for Cyan Fluoroscent Protein/CFP (CFP For3) 
 
5’  A G A T C T A A T G G C C C T G T C C A A C A A G  3’  
        BglII 
 
• Reverse primer for Cyan Fluoroscent Protein/CFP (CFP Rev3) 
5’  G G A T C C C C G A A G G G C A C C A C G G A G G  3’  
      BamHI 
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• Forward primer for Yellow Fluoroscent Protein/YFP (YFP For2) 
5’ G A A T T C T A T G G C C A C A A G C A A G C A C G G C  3’ 
      EcoRI 
          
• Reverse primer for Yellow Fluoroscent Protein/YFP (YFP Rev2) 
5’ A A G A T T C A G G A C A G G G C G C T G G G G A A G 3’ 
                HindIII 
 
• Forward primer for TG2 (TG2 For) 
5’ A G A T C T C A A T G G C C G A G G A G C T G G T C T T A G 3’ 
       BglII 
 
• Reverse primer for TG2 (TG2 Rev) 
5’ G A A T T C C C G G C G G G G C C A A T G A T G A C A T T C 3’ 
                          EcoRI   
 
• Forward primer for CFP-TG2-YFP (NotICFP) 
5’ G C G G C C G C A C C A T G G C C C T G T C C A A C A A  3’ 
                               NotI   
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• Forward primer for His-tag pTrcHisB-CFP-TG2-YFP (HispTrc) 
5’  G C G G C C G C A C C A T G G G G G G T T C T C A T C  3’ 
                                         NotI   
Sequencing primers 
• sp6 sequencing primer 
 
5’  A  T  T  T  A  G  G  T  G  A  C  A  C  T  A  T  A  G  A  A   3’ 
 
• T7 Pro sequencing primer 
 
5’  T  A   A  T  A  C  G  A  C  T  C  A  C  T  A  T  A  G  G  G  3’  
 
2.7 General Techniques 
2.7.1 Preparation of competent cells using calcium chloride 
5ml of LB broth with Rosetta 2(DE3) or DH5α cells were grown overnight at 37°C 
using a benchtop orbital shaker. For inoculation, 1ml of this overnight grown culture 
was added to 100ml of LB broth and incubated at 37°C for about 4 hour 
(approximately 0.4 OD at 600nm). Cells were pelleted by centrifugation at 5000 rpm 
at 4°C for 10 min. Cell media was discarded and cell pellet was gently resuspended 
in ¼ volume of ice-cold 100mM MgCl2 taking at least 3 to 5 min for this step. Cell 
suspension was centrifuged at 4000 rpm at 4°C for 10min. The cell pellet was 
resuspended in 1/20 volume of ice cold 100mM CaCl2. Then 9/20 volume of ice cold 
100mM CaCl2 was added to the cell suspension and placed on ice for 20 min. The 
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cell suspension was then centrifuged at 4000 rpm at 4°C for 10 min. the cell pellet 
was resuspended in 1/50 volume of sterile ice cold 85mM CaCl2, 15% glycerol w/v. 
For long term storage, aliquots of 100µL of this cell suspension were made into 
sterile 1.5mL microcentrifuge tubes and stored at -80°C.  
2.7.2 Transformation  
Transformation was carried out using heat-shock method. Agar plates with 
appropriate antibiotic (Ampicillin final concentration 100 µg/ml or Kanamycin final 
concentration 30µg/ml) were freshly prepared to carry out transformation. 100µL 
aliquots of Rosetta 2/DH5α cells (made competent using CaCl2 method) were 
removed from -80°C and immediately placed on ice to thaw ice for approximately 5-
10 min. 5µL of plasmid DNA was added to competent cells and gently mixed by 
flicking the bottom of centrifuge tube a few times. The same was done for positive 
control using control plasmid to ensure transformation efficiency. The mixture was 
incubated on ice for 20 min. Heat shock was performed at 42°C for 45sec using a 
water bath. The cells were immediately placed back on ice for 5 min. After incubation 
on ice, 900µL of LB medium or SOC medium was introduced into the transformation 
reaction and placed for 60min in a shaking incubator (225 rpm) at 37°C. 
Approximately 15min before plating, agar plates were kept inverted at 37°C in an 
incubator. Using a sterile spreader, 20µL of transformation reaction was evenly 
distributed onto an agar plate containing appropriate antibiotic for selection. 
Remaining reaction was similarly spread onto a plate. The plates were then placed 
inverted in an incubator overnight at 37°C.   
Using Novablue competent cells, transformation was carried out according to 
manufacturer’s instructions.  
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2.7.3 Blue White screening procedure 
For blue white screening of recombinants the above transformation was followed. 
After heat shock and cooling on ice, SOC/LB medium was introduced to the 
competent cells. The ampicillin agar plates also included IPTG and X gal. 50mg/ml 
X-gal in dimethyl formamide and 100mM IPTG in water were spread and allowed to 
soak on ampicillin plates 30 min prior to plating cells.    
2.7.4 Cracking procedure 
Cracking procedure was carried out for screening bacterial colonies and for rapid 
analysis of plasmid. After transformation, individual colonies were streaked onto a 
freshly prepared agar plate with appropriate antibiotic and grown overnight at 37°C in 
an incubator. 50µL of 10mM EDTA, pH 8.0 was dispensed into a sterile 1.5ml 
eppendorf tubes. Using sterile pipet tips individual colonies were picked and 
smeared into the microcentrifuge tubes. Freshly prepared 2X cracking buffer (50µL) 
was used to resuspend the cells by vortexing. The samples were then heated at 
70°C using a waterbath for approximately 5min. After cooling to room temperature, 
samples were mixed with 1.5µL of 4M KCl and 0.5µL of 0.4% bromophenol blue. 
The samples were incubated on ice for 5min. Samples were then centrifuged at 
16,000 x g using a benchtop refrigerated centrifuge for 3min at 4°C. Carefully 
avoiding the precipitate, 20µL of the supernatant was run on a 1% agarose gel to 
rapidly estimate plasmid size. Appropriate colonies were further grown for plasmid 
preparation and restriction digestion analysis.    
2.7.5 Plasmid preparation 
A single colony of bacteria was grown overnight in LB medium containing antibiotic 
at 37°C using a benchtop orbital shaker. Plasmid was purified using Promega 
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Wizard Plus minipreps DNA purification kit. The centrifugation protocol was followed 
according to manufacturer’s instructions. The eluted DNA was stored at -20°C for 
subsequent use.  
2.7.6 Phenol Chloroform Extraction of DNA 
An equal volume of Phenol:Chloroform:Isoamyl alcohol pH 8.05 (25:24:1) was added 
to DNA solution very carefully. The mixture was vortexed and a milky white 
suspension was observed due to denaturing of proteins into the hydrophobic phase. 
This was followed by centrifugation at 12,000 x g for 5 min at room temperature. 
Three distinct phases were observed after centrifugation, top aqueous layer 
containing DNA of interest, a disc-like interface of denatured proteins and bottom 
organic layer of lipids. Using a pipette the top aqueous layer was removed into a 
fresh centrifuge tube. Care was taken to avoid pipetting the interface layer along with 
aqueous layer. This step was repeated to remove any residual protein until no visible 
interface phase was observed. To the recovered aqueous phase equal part of 
Chloroform:Isoamyl alcohol (24:1) was mixed to remove residual phenol. 
Centrifugation was repeated at 12,000 x g for 5 min at room temperature. The top 
aqueous layer was removed into a fresh centrifuge tube for further processing.   
2.7.7 Isopropanol precipitation  
To the DNA sample, 1/10th volume of 3M sodium acetate (pH 5.2) was added. To 
this 1 x volume of ice cold isopropanol (100%) was added. The mixture was placed 
at -20°C for 15 min to allow precipitation. To pellet the DNA, the mixture was 
centrifuged at 4°C at 12,000 x g for 5 min. The supernatant was decanted gently 
without disturbing the pellet. The pellet was then washed with 1ml 70% ice cold 
ethanol very gently by slowly inverting the tube. This was followed by centrifuging at 
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4°C at 12,000 x g for 2 min. The supernatant was decanted and the wash with 70% 
ethanol was repeated. After decanting the supernatant the pellet was air dried. The 
DNA pellet was resuspended in nuclease free water by vortexing and stored at -20°C 
for further use.   
2.7.8 Ethanol precipitation  
DNA was precipitated by adding 1/10th volume of 3M sodium acetate (pH 5.2) and 2 
x volume of ice cold absolute ethanol. The mixture was vortexed and placed on ice 
for 30 min. To pellet the DNA the mixture was centrifuged at 4°C at 12, 000 x g for 
15min. The supernatant was gently discarded without dislodging the pellet. The 
pellet was further processed by washing with 70% ice-cold ethanol. After centrifuging 
at 4°C at 12,000 x g for 2 min, the supernatant was discarded. This wash with 
ethanol was repeated. The pellet was air dried and resuspended in nuclease free 
water.  
2.7.9 Agarose gel electrophoresis 
2.7.9.1 Agarose gel 
Agarose gels (1% w/v) were prepared using Molecular Biology Grade-High gel 
strength agarose by Melford and run using 1x TAE buffer. Agarose was melted in its 
appropriate gel mixture by heating for 1min and cooled by running under cold water. 
Ethidium bromide (final concentration 0.2µg/ml) was introduced to the cooled gel 
before pouring into the gel tray. The gel was incubated for about 20min for 
solidification at room temperature. DNA samples were loaded using 6x DNA loading 
buffer.  Novagen perfect DNA marker 0.05-10Kb (or NEB 2-log DNA ladder 0.1-10.0 
kb) was loaded to determine the size of DNA fragment. The agarose gel was run at 
 77 
 
100V for about 40min. DNA was visualised using Syngene G:Box Chemi Fluorescent 
and Chemiluminescent imaging system.  
2.7.9.2 Agarose gel purification (Low melting point gel)  
Agarose gels (1.5% w/v) were prepared using Melford low melting point agarose and 
run using 1 x TAE buffer. Ethidium bromide (final concentration 0.2 µg/ml) was 
added to the cooled gel before pouring into the gel tray. The gel was solidified at 
room temperature for 20 min and kept at 4°C for 30min. DNA samples were loaded 
using 6x loading buffer and Novagen perfect DNA marker 0.05-10Kb was the 
preferred DNA marker. The low melting point gel was run at 75v over 60min. Using 
Syngene G:Box Chemi Fluorescent and Chemiluminescent imaging system the DNA 
fragments were visualised. DNA fragment of interest was excised using sterile 
scalpel blades and weighed into a microcentrifuge tube. Using Promega SV gel and 
PCR Clean Up kit DNA was purified using the centrifugation protocol according to 
manufacturer’s instructions. Purified DNA was run on a test 1% w/v agarose gel.  
2.7.10 DNA quantification 
DNA was quantified using IMPLEN NanoPhotometer.  
2.8 Cloning Vectors 
pTrcHis B (Invitrogen)   
pAM cyan1-c1 (Invitrogen) (CFP) 
pZs Yellow1-N1 was a kind gift from Dr.Eric Hill ,Aston University, UK (YFP) 
pcDNA3.1 CT GFP:hTG2  was a kind gift from Dr. Russell Collighan, Aston 
Univesity,UK  
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pSTBlue-1 (Novagen) 
pcDNA 3.1- (Invitrogen) was a kind gift from Dr. Eric Hill, Aston University 
2.9 Dephosphorylation of DNA 
Reaction was performed in 1x Antarctic Phosphatase reaction buffer containing 
0.1mM ZnCl2 according to manufacturer’s instructions. The enzyme was employed 
to remove 5’ phosphate and prevent vector self-ligation. 50ng of Purified DNA was 
treated with 1unit Antarctic phosphatase and incubated at 37°C for 30 min and heat 
inactivated at 70°C for 5min. Using the Promega SV gel and PCR Clean Up kit DNA 
was re-purified before proceeding to ligation.  
2.10 Ligation reaction 
Ligation reaction was setup using 50ng of appropriate vector DNA and a 3-fold molar 
excess of insert in a final reaction volume of 20µL. NEB T4 DNA ligase (1 Weiss 
unit) was the preferred ligase supplied with 10x DNA ligase reaction buffer 
containing ATP. The reaction was incubated overnight at 16°C; alternatively set up at 
room temperature for 2 hours.  Appropriate ligation controls were set up. “Self-
ligation control” reaction was set up omitting addition of insert into reaction to 
distinguish clones during cracking procedure. A “no ligase” control was also setup.  
2.11 Restriction Digestion 
Appropriate restriction enzymes (including BamHI, BglII, EcoRI, HindIII, PvuI, NotI) 
were obtained from Promega or NEB, supplemented with 10X reaction buffer. 
Restriction digest reaction was set up using 50ng of appropriate DNA and reaction 
was set up at 37°C for 4 hours.  While setting up double digest, sequential digestion 
was the preferred protocol using the Promega SV gel and PCR Clean Up kit DNA 
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before proceeding to the second restriction digestion. A test 1% agarose gel was run 
to analyse restriction digestion products at the end of reaction.  
2.12 PCR reactions 
PCR reactions were set up using Finnzymes Phusion High-Fidelity DNA polymerase 
(unless stated otherwise). Phusion High Fidelity polymerase was provided with 5x 
Phusion HF buffer containing 1.5mM MgCl2. Reaction was set up using 100µM 
dNTPs, 0.5µM of appropriate forward and reverse primer, 0.5ng of template DNA. 
Total reaction volume was set up to 50µL using nuclease free water. PCR reaction 
was optimised at initial denaturation at 98°C for 2 min, followed by 35 cycles of  
98°C for 45s 
65°C for 1min 
72°C for 1 min, 
Followed by a final extension step 72°C for 10min. This was the standard reaction 
set-up unless otherwise stated and was set up in MWG biotech Aviso Thermal 
cycler. 
2.13 Touchdown PCR 
Towndown PCR was set up using Novagen KOD HOT start polymerase provided 
with a 10x reaction buffer to minimize nonspecific amplification. The PCR reaction 
was set up using 1x buffer, 25mM MgSO4, 100mM dNTPs, forward and reverse 
primer (final concentration of 0.3µM), template DNA and 0.02U/µl of KOD Hot start 
DNA polymerase. The final reaction volume was 50µL. The PCR reaction was 
initiated with 95°C for 2 min. Followed by 8 cycles of, 
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95°C for 1 min 
70°C for 1 min; with a 1°C decrement of annealing temperature with every round 
until it reached optimum annealing temperature of about 62°C 
The next stage of PCR involved 35 cycles of  
95°C for 1 min 
62°C for 1 min 
72°C for 4 min,  
Followed by a final extension step at 72°C for 10min.    
2.14 Colony PCR 
Colony PCR was employed to determine the orientation of the insert into the vector 
while screening transformants. PCR amplification was set up using forward primer of 
vector and reverse primer of insert to produce amplicon of desired size only if the 
insert was in correct orientation. The PCR reaction was setup using Phusion Hot 
Start II DNA polymerase using 5x Phusion reaction buffer, 100µM dNTPs, 0.5µM of 
appropriate forward and reverse primer, 1.0U of Phusion Hot Start II DNA 
polymerase. To this mixture add a small amount of appropriate colony. The PCR 
reaction was set up by heating at 95°C for 2 min to lyse bacterial cells. This was 
followed by 35 cycles of  
95°C for 45sec 
52°C for 1min 
  72°C for 3 min 
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And a final extension step for 10min at 72°C. A test 1% agarose gel was used to 
analyse the results of the colony PCR.  
2.15 Sequencing reactions 
Samples for sequencing were sent to the Functional Genomic laboratory at 
University of Birmingham for analysis. The samples were subjected to Big dye 3 
chain terminal reaction (functional genomic laboratory at University of Birmingham) 
according to manufacturer’s instructions.  
2.16 Klenow 3’end infilling 
Klenow fragment was employed to infill 3’ end of DNA fragment inorder to shift the 
reading frame. Thermo scientific Klenow fragment (1unit) was mixed with 10x 
reaction buffer containing 50mM MgCl2 and 10mM DTT. To the reaction 0.05mM 
dNTP mix was added along with 2µg of DNA and reaction volume was made upto 
20µL using nuclease free water.  
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 5’---A G C   T C G   A G A T C T   C A A   T G G  ---3’ 
  3’---T C G   A G C  T C T  A G A  G T T   A C C ---3’ 
  BglII digestion 
5’---A G C  T C G A        G A T C T C A A T G G---3’ 
  3’---T C G A G C T C T A G        A G T T A C C ---3’ 
  Religated Klenow fragment 
5’--- A G C T C G A G A T C G A T C T C A A T G G ---3’ 
 3’---T C G A G C T C T A G C T A G A G T T A C C---3’ 
 
2.17 Expression and purification of Recombinant TG2 
20ml of LB medium was inoculated with E. coli BL21 (DE3) recombinant CFP-TG2-
YFP at 37°C for 4 hours. Cultures were diluted 1:20 into LB medium and then 
induced with 0.1 mM IPTG overnight at 16°C in an orbital shaking incubator. Cells 
were harvested by centrifugation at 10000g for 15min at 4°C, dissolved in Laemmli 
buffer and subjected to SDS-PAGE analysis.  
2.18 Chromatographic purification of His-tagged proteins using His GraviTrap 
column (GE Healthcare). 
 500 ml of induced E. coli culture was prepared as above. Cells were resuspended in 
10 ml of ice-cold 50mM Tris, 1mM EDTA, 1mM DTT and 5mM imidazole, pH7.5 and 
chilled on ice. Cells were lysed by sonication for six periods of 30 seconds at 18µm 
amplitude (with 1 minute of chilling on ice in between) using MSE Soniprep 150 
sonicator. Cell debris was removed by centrifugation at 20000g for 30 minutes at 
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4°C. The clarified lysate was applied to a 1 ml GE Healthcare His GraviTrap column 
equilibrated in 50mM Tris HCl, 1 mM EDTA,1mM DTT, 5 mM imidazole pH7.5 (buffer 
A). After loading the lysate the column was washed with Buffer A followed by a wash 
using 50mM Tris HCl, 1mM EDTA, 1mM DTT, 20mM imidazole pH7.5. Fractions (0.5 
ml) were collected into microcentrifuge tubes at room temperature by elution with 
buffer B (50mM Tris HCl, 1 mM EDTA, 200 mM imidazole) and stored immediately 
on ice. 
2.19 Gradient purification using GE AKTA prime FPLC 
The Ni-NTA column (GE Healthcare) was washed and equilibrated with buffer A 
(50mM Tris, 1mM EDTA, 1mM DTT, 5mM imidazole and 500mM NaCl). The clarified 
lysate was diluted 1:1 using buffer A and loaded onto the column at 1ml/min flowrate. 
The column was then washed with approximately 15ml buffer A (unless absorbance 
is near to zero) and fractions were collected as wash fractions. This was followed by 
elution step. 2ml fractions were eluted and collected over an imidazole gradient from 
20mM to 500mM imidazole over 40mls (unless stated otherwise) 
2.20 Desalting by gel filtration 
GE Healthcare PD-10 desalting columns which are packed with Sephadex G25 
Medium were used for this technique. The gravity protocol was used for separation 
of molecules according to manufacturer’s instructions.       
2.21 SDS-PAGE 
SDS-PAGE analysis was performed using a 3% (w/v) polyacrylamide stacking gel 
and a 10% (w/v) polyacrylamide separating gel at 125volts. 30% solution 
Acrylamide/Bis acrylamide (29:1) was used as a stock solution. Separating gel was 
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made using 2.5ml of 30%(w/v) acrylamide/bis-acrylamide solution, 2.5ml Tris SDS 
pH8.8 solution,5ml distilled water,10% of ammonium persulphate and 10µL TEMED. 
200ul of isopropanol was poured on top of the resolving gel to level the upper 
surface. The gel was allowed to polymerise at room temperature for 40 minutes. To 
remove the isopropanol after polymerisation the upper surface was washed with 
distilled water and blotted dry using whatmann filter paper. Stacking gel was 
prepared using 0.5ml of 30% (w/v) acrylamide/bis-acrylamide solution, 1.25ml of 
Tris/SDS pH6.8 and 3.25ml of distilled water. Using 10% ammonium persulphate 
and 10µL TEMED the polymerisation was initiated.  Gel was polymerised at room 
temperature for 45 minutes. Protein samples were quantified and 20µg of protein 
was mixed to 2x or 6x Laemmli loading buffer. GE Healthcare Amersham Full - 
Range Rainbow Molecular Weight marker- RPN800E was the marker of choice. 
Coomassie Brilliant Blue R250 was used to stain the gels for about 4 hours on a 
rotatory shaker. Destaining was performed by boiling the gel in distilled water until 
clear bands were observed. 
2.22 Western blotting of SDS PAGE separated proteins 
Transfer of separated proteins onto a nitrocellulose membrane was done 
electrophoretically using BioRad Mini-PROTEAN 3 wet blot system. Assembly of the 
apparatus was done according to manufacturers’ instructions. Air bubbles trapped 
during the assembly were removed using a western blot roller. The electrophoretic 
transfer was performed at 150mA for 2 hours in a pre-chilled transfer buffer. After 
transfer, membrane was blocked using 5% (w.v) Marvel dried milk powder in 1x 
TBS-Tween at room temperature for 1 hour. Blots were then incubated overnight at 
4°C with primary antibody (CUB 7402 or 1D10) in blocking buffer. This was followed 
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by washing the membrane three times (10minutes each) using TBS-Tween and one 
wash with PBS. The membrane was then incubated with secondary HRP-conjugated 
antibody (anti-mouse) in blocking buffer for 2 hours at room temperature. The 
membrane was then washed three times (10minutes each) with TBS-Tween followed 
by one wash with PBS. The HRP conjugate of the secondary antibody was treated 
with ECL chemiluminescence substrate according to manufacturer’s instructions and 
blots were developed using Syngene G:Box Chemi Fluorescent and 
Chemiluminescent imaging system.  
2.23 Protein Assay 
Protein concentrations were determined using the Bio-Rad Dc Protein Assay 
Reagent A (25 µl) and Reagent B (200 µl). Change in the absorbance was measured 
using the absorbance plate reader at 750nm. Appropriate fractions were pooled.  
2.24 Transglutaminase Activity assay 
Biotin-cadaverine incorporation into N,N’-dimethylcasein or fibronectin 
96 well plates were coated with 100µl of 100mg/ml N, N’ dimethylcasein (or 5µg/ml 
fibronectin) in 100mM TrisHCl, pH8 overnight at 4°C. The plates were then washed 
with TBS-tween three times. Reaction was prepared using 100µL of 50mM TrisHCl 
pH7.4 containing TG2 samples with 0.1mM biotin-cadaverine, 10mM CaCl2 and 
1mM DTT. Reactions were performed in triplicates. For positive control 400ng of 
recombinant TG2 was used and recombinant TG2 containing 0.1mM biotin-
cadaverine, 10mM EDTA was set up as the negative control. After 2 hours of 
incubation at 37°C, the plate was washed with TBS-tween three times. Blocking was 
performed using 3% heat inactivated BSA in Tris pH7.4 for 30min at 37°C. For the 
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detection of biotin-cadaverine incorporation, the plate was incubated with 1:1000 
extravidin peroxidise conjugate in 3% BSA in TrisHCl pH7.4.Colour was developed 
used SIGMAFAST OPD (o-Phenylenediamine dihydrochloride) tablets and 
terminated with addition of 50µl 3N HCl and absorbance was read at 490nm on a 
spectrafluor plate reader.    
2.25 Detection of TG2 antigen using ELISA 
96 well plates were coated with 50µL of 5µg/ml fibronectin overnight at 4°C. Wells 
were washed with 100µL of 50mM Tris-HCl, pH7.4. Using of 3% BSA in PBS, pH 7.4 
was used to block wells at 37°C for 30min. wells were then washed three times with 
1xPBS and 50µg of protein in 1xPBS and 2mM EDTA was applied to each well and 
incubated at 37°C for 1 hour. This was followed by a washing with 1xPBS performed 
three times. Wells were blocked for 30min at 37°C using 3% BSA in PBS and then 
incubated for 2 hours with Cub7402 or 1D10 (1:1000 dilution in blocking buffer) at 
37°C. The wells were washed 3 times with 1xPBS and anti-mouse 
IgG(1:1000dilution in blocking buffer) was incubated for 2 hours at 37°C.  Wells were 
washed three times with PBS, pH7.4. Colour was developed used SIGMAFAST 
OPD (o-Phenylenediamine dihydrochloride) tablets and terminated with addition of 
50µl 3N HCl and absorbance was read at 490nm on a spectrafluor plate reader.    
2.26 Binding of TG2 to Heparin-Sepharose 
20ml  of LB medium containing antibiotic was inoculated from glycerol stock stored 
at -80°C.Cells were allowed to grow overnight at 37°C using a benchtop orbital 
shaker. 400ml of LB broth was inoculated with the 20ml overnight culture of E.coli 
Rosetta2 CFPTG2YFP, cCFPTG2, pET30Ek/LIC TG2 and grown for 4 hours at 
37°C. This is followed by inducing cells with 1mM IPTG at 16°C overnight. Cells 
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were centrifuged at 10000g for 15 min at 4°C. Cells were resuspended in cold 50mM 
Tris, 1mM EDTA, 1mM DTT pH 7.5 (bufferA) and thereafter sonicated on ice for 6 
sonication cycles of 30sec each with 1min cooling over ice. The cell lysate was 
centrifuged at 20000g for 30 min at 4°C. 5ml GE Healthcare Heparin column was 
equilibrated using buffer A and the clarified lysate was loaded onto the column. 
Purification was performed using protocol by Wang et al, 2012.The column was 
washed with 25ml of buffer A and 1ml fractions were eluted with a linear gradient of 
increasing NaCl concentration from 0 to 0.5M. Every alternate fraction of the gradient 
was run on a SDS page and analysed by western blotting.  
2.27 Trypsin Digestion Assay 
Purified recombinant TG2 protein was digested with trypsin using protocol adapted 
from Fesus et al (2013). Purified protein was eluted in 20mM Tris, 300mM NaCl and 
10% glycerol using PD-10column.  3µg of purified protein was mixed with trypsin at 
concentrations including 80ng, 0.4µg, 0.8µg, 1.6µg, 3.2µg and 8µg. The reaction 
was incubated for 2h on ice and terminated by addition of laemmli buffer. The 
samples were boiled and resolved by SDS-PAGE. Control reactions including no 
trypsin digestion and pre- treated inhibitor treated samples were set up similarly.  
2.28 Conformation dependent protease digestion  
Purified recombinant TG2 was pre-treated with increasing amounts of Monodansyl 
cadaverin (MDC). After treatment samples were subjected to trypsin digestion and 
incubated for 2h. The reaction was stopped by boiling with laemmilli buffer for 5 min 
over a waterbath. The samples were resolved by SDS PAGE and analysed by 
staining with coomassie blue. 
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2.29 FRET reactions 
FRET reactions performed using increasing concentration of calcium and GTP were 
performed using black 96 well immune plates (Thermo Scientific) and read using 
SpectraMAX GeminiXS microplate spectroflurometer.  
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Chapter 3 
Construction of CFP-TG2-
YFP recombinant protein 
in bacterial system 
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3.1 Introduction  
For the construction of TG2 FRET based sensor, fluorescent proteins CFP and YFP 
were designed to fuse at the N and C terminal of TG2. This chapter goes through the 
step by step strategy for cloning. CFP, TG2 and YFP plasmid were PCR amplified 
and first cloned individually into the cloning vector pSTBlue-1. The components are 
then individually assembled into expression vector pTrcHisB. CFP and YFP are 
mostly commonly used in the construction of FRET based sensors. During the 
course of this chapter different DNA polymerases are used inorder to achieve 
optimum amplification. Once cloned into the vector the resulting recombinant clones 
are first analysed using an alkaline lysis procedure to verify the plasmid size before 
further analysis. The cloning strategy into pTrcHis B is represented below (Figure 3). 
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Figure 3 Overview of the cloning strategy showing the stepwise assembly of the TG2 FRET construct in expression 
vector pTrcHisB (vector map shown i). Step 1 showing the cloning of CFP into the BamHI site of pTrcHisB present in 
the multiple cloning site (MCS shown in ii) as represented by the red arrow. Step 2 showing the cloning to TG2 into 
pTrcHisB-CFP. Step 3 showing the cloning of YFP into pTrcHis-CFP-TG2. The Vector map of pTrcHisB showing the 
HisTag and multiple cloning site highlighted in red circles. The restriction sites present on CFP, TG2, YFP used for 
cloning are indicated by blue arrows. Both Step 2 and Step 3 are directional cloning. The red box represents the final 
TG2 FRET construct in pTrcHisB with the His tag at the N terminal of the construct. 
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3.2 RESULTS                                                               
3.3 PCR amplification  
Reactions were performed in triplicates in MWG Biotech Aviso Thermal cycler to 
avoid over-representation of polymerase-induced errors. Thermal cycling conditions 
were optimised for maximum amplification yield and specificity.  
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3.3.1 CFP amplification 
Using primers CFP For3 and CFP Rev3, with the commercially available vector pAM 
cyan1-c1 as template, amplification was obtained as seen in Lanes 2, 3,  4 (Figure 
3.1). Bands of correct size of about 0.7Kb were seen. Conditions for PCR were 
optimised to be initial denaturation at 98°C for 2 min, followed by 35 cycles of 98°C 
for 45 s, 65°C for 1 min, 72°C for 1 min, followed by a final extension step at 72°C for 
10 min using Phusion Hot start polymerase.  
 
 
 
Figure 3.1 Agarose gel electrophoresis of amplified products using primers 
CFP For3/Rev3. Lane 1 represents the 2-log marker DNA. Lane 2, 3, 4 showing 
the amplified CFP which is 0.7 Kb in size. 
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3.3.4 YFP amplification 
Using primers YFP For2 and YFP Rev2, with the commercially available vector 
pZs Yellow1- N1 as template, amplification was obtained as seen in Lanes 2, 3, 4 
(Figure 3.2). Bands of correct size of about 0.7Kb were seen. Conditions for PCR 
were optimised to be initial denaturation at 98°C for 2 min, followed by 35 cycles 
of 98°C for 45 s, 65°C for 1 min, 72°C for 1.5 min, followed by a final extension 
step at 72°C for 10 min using Phusion Hot start polymerase.  
 
 
Figure 3.2 Agarose gel electrophoresis of amplified products using primers 
YFP For2/Rev2. Lane 1 represents the 2-log marker DNA. Lane 2, 3, 4 showing 
the amplified YFP which is 0.7 Kb in size.  
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3.3.4 TG2 amplification 
Using primers TG2 For and TG2 Rev, with the vector pcDNA 3.1 CT GFP:hTG2 as 
template, amplification was obtained as seen in Lanes 2, 3, 4, 5, 6, 7 (Figure 3.3). 
Bands of correct size of about 2Kb were seen. Conditions for PCR were optimised to 
be initial denaturation at 98°C for 2 min, followed by 35 cycles of 98°C for 45 s, 65°C 
for 1 min, 72°C for 3 min, followed by a final extension step at 72°C for 10 min using 
Phusion Hot start polymerase.  
 
 
Figure 3.3 Agarose gel electrophoresis of amplified products using primers 
TG2 For/Rev. Lane 1 is the 2-log marker DNA. Lane 2, 3, 4, 5, 6, 7 showing the 
amplifiedTG2 which is 2 Kb in size.  
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3.4 Cloning amplified products into pSTBlue-1 
3.4.1 Identification of recombinant pSTBlue-1 plasmids.  
Using the pSTBlue-1 blunt cloning kit the amplified products of CFP, TG2 and YFP 
were ligated into pSTBlue-1 and transformed into NovaBlue competent cells. 
Blue/white screening was performed by spreading transformed cells onto plates 
containing 100µg/ml ampicillin, 100µM IPTG and 50µg/ml X-gal. White colonies, 
potentially containing inserted DNA, were screened for increased size compared to 
the empty vector pSTBlue-1 using a simple alkaline lysis procedure followed by 
agarose DNA electrophoresis (cracking). 
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3.4.2 CFP cracking  
Following Blue/White screening, 14 white colonies were selected for the cracking 
procedure. A blue colony (parent pSTBlue-1) was also selected as a negative control 
for cracking. All samples were then run on an agarose gel for further analysis. All 
plasmids which were of a larger size than the parent pSTBlue-1 (blue colony) were 
selected for nucleotide sequencing. From Figure 3.4, clones CFP 4, CFP 6, CFP 7, 
CFP 11 and CFP 13 were larger than parent vector and were further analysed by 
sequencing. 
 
Figure 3.4 Agarose gel electrophoresis of the cracking procedure performed 
on the selected CFP colonies after Blue White screening. Lane 1 is the 2-log 
marker DNA. Lanes 2 to 15 showing CFP clones 1-14. Lane 16 showing the 
blue colony representing a negative control for selection.  CFP 4, 6, 7, 11 and 
13 were selected for sequencing. 
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3.4.3 YFP cracking 
Similarly for YFP, 14 white colonies were selected for the cracking procedure. A blue 
colony was also selected as a negative control for cracking. All samples were then 
run on an agarose gel for further analysis. All plasmids which were bigger than 
parent vector (blue colony) were selected for nucleotide sequencing. From the gel 
Figure 3.5, clones YFP 3, YFP 7, YFP 8, YFP 9, YFP 10, YFP 11, YFP 12 and YFP 
14 were larger than parent vector and were further analysed by sequencing. 
 
 
Figure 3.5 Agarose gel electrophoresis of the cracking procedure performed 
on the selected YFP colonies after Blue White screening. Lane 1 is the 2-log 
marker DNA. Lanes 2 to 15 showing YFP clones 1-14. Lane 16 showing the 
blue colony representing a negative control for selection.  YFP 3, 7, 8, 9, 10, 11, 
12, 14 were selected for sequencing. 
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3.4.5 TG2 cracking  
For TG2, 7 white colonies were selected for the cracking procedure. A blue colony 
was also selected as a negative control for cracking. All samples were then run on 
an agarose gel for further analysis. All plasmids which were bigger than parent 
vector (blue colony) were selected for nucleotide sequencing. From the gel Figure 
3.6, clones TG2 1, TG2 4, TG2 5 and TG2 7 were larger than parent vector and were 
further analysed by sequencing. 
 
 
Figure 3.6 Agarose gel electrophoresis of the cracking procedure performed 
on the selected TG2 colonies after Blue White screening. Lane 1 is the 2-log 
marker DNA. Lanes 9 to 15 showing TG2 clones 1-7. Lane 16 showing the blue 
colony representing a negative control for selection.  TG2 1, 4, 5, 7 were 
selected for sequencing. 
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On analysing the cracking agarose gel results, plasmids which were larger than the 
parent pSTBlue1 vector were selected for sequencing. Using the Promega Wizard 
Plus minipreps DNA purification Kit, plasmid purification was performed on the 
selected clones of CFP, YFP and TG2. These plasmids were then digested using 
EcoRI to test for inserts of the correct size (EcoRI digests close to each side of the 
cloning site in pSTBlue-1).  
 
3.5 Cloning of CFP, YFP and TG2 into expression vector pTrcHisB 
pTrcHis B vector was transformed into NovaBlue competent cells. Colonies were 
selected from the plate and then grown individually in 5ml LB broth containing 
ampicillin at 37˚C in orbital shaking incubator overnight. Using the Promega Wizard 
Plus minipreps DNA purification Kit, plasmid purification was performed. The pTrcHis 
B purified plasmid was run on an agarose gel as showing Figure 3.7.  
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Figure 3.7 Agarose gel electrophoresis of the purified plasmid of pTrcHis B. 
Lane 1 is the 2-log marker DNA. Lanes 2, 3, 5, 6, 7, 8 showing pTrcHis B 
purified plasmid of about 4.4 Kb. 
3.6 Cloning CFP into pTrcHis B 
CFP was digested from the pSTBlue-1 plasmid using Bam HI and Bgl II. A double 
digestion was performed and the reaction was set up using buffer B (Promega). Gel 
electrophoresis (Figure 3.8) revealed the 0.7 Kb CFP insert released after digestion. 
pTrcHis B was digested using Bam HI only, with gel elecrophoresis (Figure 3.9) 
showing undigested pTrcHis B and digested pTrcHis B (4.4 Kb). On digestion the 
purified undigested plasmid runs faster as it is super coiled but when digested a 
band about 4.4 Kb long was seen.  
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Figure 3.8 Agarose gel electrophoresis of the digestion of purified CFP using 
Bam HI and Bgl II. Lane 1 is the 2-log marker DNA. Lanes 2 shows the digested 
plasmid. A 0.7Kb long band is seen which represents the CFP insert. 
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Figure 3.9 Agarose gel electrophoresis of the digestion of the purified pTrcHis 
B plasmid using Bam HI. Lane 1 is the 2-log marker DNA. Lanes 2 shows the 
undigested pTrcHis B plasmid and the digested plasmid of about 4.4 Kb in 
Lane 3. 
The digested pTrcHis B and CFP were extracted and purified from a low melting 
point agarose gel. The purified pTrcHis B was further treated with Antarctic 
phosphatase to remove 5’ phosphates and prevent religation. Further a ligation 
reaction was performed using Quick ligase to ligate pTrcHis B and CFP and was 
then transformed into Novablue competent cells. 
Cracking procedure was repeated on the colonies grown. Clones showing plasmids 
of the right size were then selected for plasmid purification and then subjected to a 
restriction digest to determine orientation.  
3.7 Screening of recombinant CFP-pTrcHisB plasmids 
The screening of recombinant CFP-pTrcHis B plasmids were performed by analysing 
20 transformed colonies via cracking procedure. Negative control used was 
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pTrcHisB colony. Plasmids which were larger than cloning vector pTrcHisB were 
selected as seen in Figure 3.10A and 3.10B. Based on size of the plasmid, three 
different colonies were expected. Firstly, plasmids similar to size of negative control 
representing pTrcHisB only. Second representing desired CFP insert into pTrcHisB 
and third representing concatemers (false positive) which represent multiple copies 
of the CFP insert sequence. Concatermers may be a result of DNA insert: plasmid 
ratio not being optimum. To differentiate and narrow down colony 3, 5, 6, 7, 8, 12 
and 15 were grown for plasmid preparation and further restriction digestion.    
 
Figure 3.10A and 3.10B Agarose gel electrophoresis of the cracking procedure 
performed on the selected CFP-pTrcHisB clones. Figure A, Lane 1 and Lane15 
are the 2-log marker DNA. Lanes 2 to 13 showing CFP-pTrcHisB clones 1-12. 
Lane 14 and Lane 15 represent the parent cloning vector pTrcHisB(negative 
control). Figure B, Lane 1 and 14 is the 2-log marker DNA. Lane 2 and Lane 5 
represent the parent cloning vector pTrcHisB (negative control). Lanes 6 to 13 
showing CFP-pTrcHisB clones 13-20. CFP-pTrcHisB 3, 5, 6, 7, 8, 12 and 15 
were selected for further analysis.   
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3.8 Analysis of selected colonies of recombinant CFP-pTrcHis B clones.  
CFP-pTrcHis B clones 3, 5, 6,7 8,12 and 15  were selected from the agar plate and 
then grown individually in 5ml LB broth containing ampicillin at 37˚C in orbital 
shaking incubator overnight. Using the Promega Wizard Plus minipreps DNA 
purification Kit, plasmid purification was performed. The pTrcHis B purified plasmid 
was run on a test agarose gel as shown below figure 3.11. Negative control of 
pTrcHis B was also simultaneously grown and a plasmid was purified and run on 
same gel. Negative control pTrcHis B plasmid was confirmed to be about 4.4Kb. 
Expected size of CFP-pTrcHis B clones should be about 5.1Kb and was observed in 
clones 3, 5, 12, 13 and 15.These plasmids were further analysed for the orientation 
of CFP into pTrcHis B. 
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Figure 3.11 Agarose gel electrophoresis of the purified plasmid of CFP-pTrcHis 
B clones 3, 5, 6, 7, 8, 12, 13 and 15. Lane 1 is the 2-log marker DNA. Lanes 2 to 
9 showing clones 3, 5, 6, 7, 8, 12, 13 and 15. Expected size of clones should be 
about 5.1Kb. Lane 10 and 11 showing pTrcHis B purified plasmid of about 4.4 
Kb. 
 
 
3.9 Orientation of CFP into pTrcHisB 
Since the CFP fragment has Bgl II/ Bam HI ends, the Bam HI site will be destroyed 
at the 5’ end of the gene. Restriction digests of the CFP-pTrcHis B clones with Bam 
HI and any other enzyme 3’ of the CFP in the pTrcHis B multiple cloning site (in this 
case Eco RI) would reveal its orientation. On digestion with Bam HI and Eco RI the 
plasmid was linearized indicating the correct orientation. 
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Plasmids of clones 3, 5, 6, 7, 8, 12 and 15 were digested with BamHI and EcoRI to 
reveal orientation of CFP into pTrcHisB (figure 3.12). Clones 3, 5,12 and 15 were 
found to be of correct size as compared to negative control pTrcHisB vector. Out of 
these, clones 3,5 and 12 were found to have correct orientation. Clone 15 digestion 
with BamHI/EcoRI reveals a smaller band of the size of CFP to cut out, indicating 
wrong orientation of CFP into pTrcHisB. Clone 3,5 and 12 clones were further 
assesed for protein expression, colony PCR and sequence analysis.  
CFP 
pTrcHisB 
CFP 
pTrcHisB 
Correct orientation 
BamHI destroyed at 
5’ end  
 BamHI/EcoRI 
digestion 
 plasmid linearizes 
Wrong orientation 
 BamHI/EcoRI 
digestion  
 CFP cuts out 
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Figure 3.12 Agarose gel electrophoresis of the BamHI/EcoRI digestion of the 
purified CFP-pTrcHisB clones. Lane 1 is the 2-log marker DNA. Lanes 2 to 8 
represents undigested plasmid of clones 3, 5, 7, 8, 12, 15 and negative control 
pTrcHisB plasmid. Lanes 9 to 16 show the BamHI/EcoRI double digested 
plasmids of clones 3, 5, 6, 7, 8, 12, 15 and control pTrcHisB vector. 
 
3.10 Colony PCR  
Colony PCR was set up using pTrcHisB forward primer (HispTrc) and CFP-pTrcHis 
B clones 3, 5 and 12 (Figure 3.13). If CFP was correctly orientated into pTrcHis B 
during cloning it was expected to result in successful amplification of CFP. Clone 3 
and clone 5 did not show successful amplification of CFP whereas clone 12 
subjected to colony PCR showed amplification of CFP. Agarose gel electrophoresis 
revealed a band of about 0.7Kb using clone 12 as a template for colony PCR.  
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Figure 3.13 Agarose gel electrophoresis of the colony PCR performed using 
clones 3, 5 and 12 colonies as template DNA. Clone 12 showed amplification of 
CFP using pTrcHisB forward primer, indicating correct orientation.  
3.11 Nucleotide sequencing  
CFP-pTrcHisB clones 3. 5 and12 was further analysed by nucleotide sequencing. 
Clone 12 was confirmed to be of right sequence and orientation. CFP-pTrcHisB 
clone 12 plasmid was stored at -80°C for further experiments. Glycerol stock 
bacterial culture was stored -80°C.  
3.12 Cloning of TG2 into CFP-pTrcHis B 
CFP-pTrcHisB 12 clone was grown in 5ml LB broth containing ampicillin at 37˚C in 
orbital shaking incubator overnight. Using the Promega Wizard Plus minipreps DNA 
purification Kit, plasmid purification was performed. TG2-pSTblue1 plasmid was also 
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grown for plasmid purification. Undigested plasmids CFP-pTrcHisB 12 and TG2-
psTBlue1 were run on a 1% (w/v) agarose gel (figure 3.14). CFP-pTrcHisB purified 
plasmid above 5.1Kb but supercoiled plasmid runs faster.  
 
Figure 3.14 Agarose gel electrophoresis of the purified plasmid of CFP-pTrcHis 
B clones 12 and TG2-pSTblue 1 purified plasmid. Lane 1 is the 2-log marker 
DNA. Lanes 2 and 3 represents CFP-pTrcHisB 12 plasmid Expected size of 
clones should be about 5.1Kb. Lane 3 showing TG2-pSTblue-1 purified 
plasmid.  
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3.13 Restriction digestion of CFP-pTrcHisB 12 and TG2-pSTblue1 plasmid 
CFP-pTrcHis B 12 purified plasmid and TG2-pSTblue 1 purified plasmid was 
digested with EcoRI and BglII digest in buffer D (Promega) for 4 hours at 37°C. The 
digested products were analysed on a test agarose gel (1%w/v) (figure 3.15).  EcoRI 
digestion of CFP-pTrcHis B and TG2-psTBlue1 is seen in Lanes 4 and 5. EcoRI 
digestion of CFP-pTrcHis B 12 linearizes the plasmid. EcoRI digestion of TG2-
pSTblue-1 was successful as a 2Kb lower band is observed representing TG2. The 
EcoRI digested plasmids were then digested with BglII. Lane 6 represents BglII 
digestion of EcoRI cut CFP-pTrcHisB 12 plasmid and Lane 7 represents the same 
for TG2-pSTblue1 plasmid. These digested plasmids were then purified on a low 
melting point agarose gel and a test 1% agarose gel was run to confirm purification 
(Figure 3.16). The gel purified plasmids were then ligated using T4 DNA ligase. A 
control ligation was setup using only purified CFP-pTrcHisB 12 plasmid (self-
ligation).  
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Figure 3.15 Agarose gel electrophoresis of EcoRI/BglII digested CFP-pTrcHisB 
12 and TG2-pSTBlue1 purified plasmid. Lane 1 is the 2-log marker DNA. Lanes 
2 and 3 represents purified plasmids (undigested). Lane 4 showing EcoRI 
digestion of CFP-pTrcHisB 12 clone. Lane 5 representing EcoRI digestion of 
TG2-pSTblue-1 plasmid. Lane 6 and 7 indicate the BglII digestion of previously 
digested (EcoRI) plasmids of CFP-pTrcHisB and TG2-psTblue1 plasmid 
respectively.   
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Figure 3.16 Agarose gel electrophoresis of gel purified plasmid of CFP-pTrcHis 
B clones 12 and TG2-pSTblue 1 purified plasmid. Lane 1 is the 2-log marker 
DNA.  Lane 2 indicating gel purified BglII/EcoRI digested CFP-pTrcHisB 12 
plasmid. Lane 3 representing purified TG2 cut out after BglII/EcoRI digestion of 
TG2-pSTblue1 plasmid.  
3.14 Screening of CFP-TG2-pTrcHisB ligated colonies.  
Ligation of purified CFP-pTrcHisB 12 vector and TG2 insert using T4 DNA ligase 
resulted in 15 colonies after transformation in Novablue competents cells. No 
colonies were seen in self ligated CFP-pTrcHisB12 vector as expected. These 15 
colonies were then analysed using a cracking procedure and plasmids were run on 
an agarose gel (figure 3.17). Out of 15 transformed colonies CFP-TG2-pTrcHisB 
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clones 2, 3, 4, 11, 12, 14 and 15 were seen to be of the correct size.  Other clones 
were of 2Kb size indicating insert only.  A test BglII/EcoRI digest was performed on 
these selected clones to make sure we can cut out TG2 again. Clone 12, 14, and 15 
were then analysed by nucleotide sequencing.  
 
Figure 3.17 Agarose gel electrophoresis of the cracking procedure performed 
on the selected CFP-TG2-pTrcHisB clones. Lane 1 is the 2-log marker DNA. 
Lanes 2 to 16 showing CFP-pTrcHisB clones 1-15. Clones 2, 3, 5, 11, 12, 14 and 
15 were found to be of correct size. After test digest of these clones with 
BglII/EcoRI clones 12, 14 and 15 were selected for nucleotide sequencing.  
3.15 Nucleotide sequencing of CFP-TG2-pTrcHisB clones 
Nucleotide sequencing revealed an addition ‘C’ base pair in front of TG2 sequence. 
This disturbed the reading frame of CFP-TG2-pTrcHisB clones. The clones were 
then digested with BglII and Klenow fragment infilling was performed. The clones 
were then re-ligated and transformed into Novablue competent cells (Figure 3.18). 
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As a result of this Klenow filling the BglII restriction site of TG2 was destroyed. A test 
gel was then performed with BglII to ensure that the plasmid does not get digested 
(figure 3.19). The resulting clones were then confirmed to have right sequence by 
nucleotide sequence analysis.   
CFP-TG2 cloning into pTrcHisB infilled using Klenow fragment 
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Figure 3.18 Agarose gel electrophoresis CFP-TG2-pTrcHisB clones which were 
treated with Klenow fragment and re-ligated. Lane 1 represents 2-log DNA 
marker. Lanes 2 to 7 represents clones 1 to 6 which is after treatment with 
Klenow and re-ligated.  
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3.16 Test BglII digest of CFP-TG2 clones  
 
Figure 3.19 Agarose gel electrophoresis showing a test BglII digested of re-
ligated clones indicated in Figure 3.18. Lane 1 indicates the 2-log DNA marker. 
Lane 2 to 7 represent the BglII digested clones 1 to 6. Clones 1 to 6 were not 
digested with BglII.  
 
3.17 YFP cloning into CFP-TG2 pTrcHisB  
YFP was digested from the pSTBlue-1 plasmid using HindIII and EcoRI. A sequential 
digestion was performed and the reaction was set up using buffer 2 (NEB). Gel 
electrophoresis (Figure3.20 and Figure 3.21) revealed the 0.7 Kb YFP insert 
released after digestion. CFP-TG2-pTrcHisB was digested similarly with HindIII and 
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EcoRI, with gel electrophoresis (Figure 3.21 and 3.22) showing double digested 
CFP-TG2-pTrcHisB and a control EcoRI only digest.  
3.18 HindIII digestion of YFP-psTBlue1 plasmid 
YFP-pSTBlue-1 plasmids were purified and subjected to HindIII digestion using 
buffer 2(NEB) at 37°C for 4 hours. A test gel was run to analyse the digestion, which 
revealed successful digestion of plasmid resulting in YFP being cut out (0.7Kb) and 
upper band representing parent pSTblue1 vector(figure 3.20). The lower 0.7Kb band 
was then purified on a low melting point agarose gel (1.5%w/v) and purified using 
Promega SV gel and PCR Clean Up kit.  
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Figure 3.20 Agarose gel electrophoresis of the digestion of the purified YFP-
pSTBlue1plasmid using HindIII. Lane 1 is the 2-log marker DNA. Lanes 2 and 3 
shows the purified undigested YFP-pSTBlue1 plasmids. Lane 4 and 5 show the 
HINDIII digested plasmid, 0.7Kb band of YFP cuts out and upper band 
represents cut pSTblue1 parent vector. 
3.19 EcoRI digestion of YFP-psTBlue1 plasmid 
The above (Figure 3.20) YFP 0.75 Kb insert DNA was then subjected to second 
digestion using EcoRI (NEB) in buffer 2 for 4 hours at 37°C. A control digestion of 
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YFP-pSTblue 1 plasmid using only EcoRI was set up to ensure the efficiency of the 
enzyme. Figure3.21 also represents digestion of CFP-TG2-pTrcHisB plasmid 
digestion using HindIII. It was observed that EcoRI digestion of YFP insert (HindIII 
digested) was successful as the control digestion cut out YFP insert (0.75Kb). CFP-
TG2-pTrcHisB plasmid digestion with HindIII was confirmed (Figure3.22). 
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Figure 3.21 Agarose gel electrophoresis of the double digestion of the purified 
YFP-pSTBlue1plasmid using EcoRI/HindIII. Lane 1 is the 2-log marker DNA. 
Lanes 2 shows purified CFP-TG2-pTrcHisB plasmid. Lane  3 shows the purified 
undigested YFP-pSTBlue1 plasmids. Lane 4 presents EcoRI/HindIII digestion 
of YFP-psTblue-1 with YFP band seen at 0.75Kb. Lane 5 show the control 
EcoRI digestion of YFP-psTblue1 plasmid, 0.75Kb band of YFP cuts out and 
upper band represents cut pSTblue1 parent vector. Lane 6 shows HindIII 
digestion of CFP-TG2-pTrcHisB plasmid.  
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3.20 EcoRI digestion of CFP-TG2-pTrcHisB plasmid 
The CFP-TG2-pTrcHisB plasmid previously digested with HindIII was then digested 
with EcoRI (NEB) in buffer 2 for 4 hours at 37°C. A control CFP-TG2-pTrcHisB 
EcoRI only digest was simultaneously set up and resolved on a 1% (w/v) agarose ge 
(figure 3.22)l.  It was observed that the control digestion showed some amount of 
uncut CFP-TG2-pTrcHisB plasmid (lower band).  
 
Figure 3.22 Agarose gel electrophoresis of the double digestion of CFP-TG2-
pTrcHisB plasmid using HindIII/EcoRI. Lane 1 is the 2-log marker DNA. Lanes 2 
shows double digested CFP-TG2-pTrcHisB plasmid of about 7.15Kb. Lane 3 
shows the control EcoRI digestion of CFP-TG2-pTrcHisB plasmid.  
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3.21 Screening of recombinant CFP-TG2-YFP-pTrcHisB clones.  
The double digested CFP-TG2-pTrcHis B plasmid and double digested YFP plasmid 
were extracted and purified from a low melting point agarose gel. Further a ligation 
reaction was performed using T4 DNA ligase and was then transformed into 
Novablue competent cells. A control self ligation (CFP-TG2 –pTrcHisB ligation) was 
also treated similarly.  21 transformed colonies were picked and further analysed by 
cracking procedure. Figure 3.23A and B reveals that all transformed colonies when 
run on test agarose gel show correct size of CFP-TG2-YFPpTrcHisB. The self 
ligated vector (CFP-TG2-pTrchisB) transformed colonies were analysed on the same 
gel (Figure 3. 23). An increase in size of plasmid (0.75Kb increase) was seen as 
compared to self ligated vector indicating the presence of YFP. Clones that indicated 
a larger plasmid size as compared to control were selected; clone 5, 6, 11, 12, 14, 
and 15. These were further grown and analysed.  
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Figure 3.23A and 3.23B. Agarose gel electrophoresis of the cracking procedure 
performed on the selected CFP-TG2-YFP-pTrcHisB clones. Figure A, Lane 1 
and Lane16 are the 2-log marker DNA. Lanes 2 to 13 showing CFP-TG2-YFP-
pTrcHisB clones 1-12. Lane 14 and Lane 15 represent the cloning vector CFP-
TG2-pTrcHisB (negative control). Figure B, Lane 1 is the 2-log marker DNA. 
Lane 7 represents the parent cloning vector pTrcHisB (negative control). 
Lanes 2 to 6 showing CFP-TG2-YFP-pTrcHisB clones 13-17. CFP-TG2-YFP-
pTrcHisB clone 5, 6, 11, 12, 14 and 15 were selected for further analysis.  
 3.22 Restriction digestion test on selected CFP-TG2-YFP-pTrcHisB clones. 
Clone 5, 6, 11, 12, 14, 15 (figure 3.23) were selected from the agar plate and then 
grown individually in 5ml LB broth containing ampicillin at 37˚C in orbital shaking 
incubator overnight. Plasmids were isolated for further analysis. A test digest of 
these clones with HindIII and EcoRI should ideally result in YFP being cut out. With 
this in mind, clone5, 6, 11, 12, 14, 15 were digested with HindIII/EcoRI for 4 hours at 
37°C. The digested products were run on a 1% (w/v) agarose gel and revealed 
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successful excision of YFP as seen by the 0.75Kb band (figure 3.24). The clones 
were further analysed by nucleotide sequencing. All clones were found to be of 
correct sequence.  
 
 
 
Figure 3.24 Agarose gel electrophoresis of the double digestion of the purified 
CFP-TG2-YFP-pTrcHisB clones. Lane 1 is the 2-log marker DNA. Lanes 2 to 7 
shows purified CFP-TG2-pTrcHisB plasmids of clone 5, 6, 11, 12, 14 and 15. 
Lane 8 to 13 presents HindIII and EcoRI double digestion. The digestion 
resulted in excision of YFP as seen at 0.75Kb. These clones were further sent 
for nucleotide sequencing.  
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3.23 Discussion 
The first part of the project was the construction of the TG2 FRET construct. In order 
to achieve this, the amplification of individual genes of CFP, YFP and TG2 was PCR 
amplified. One of the bottlenecks of this project was the PCR amplification of these 
fragments. In order to successfully amplify the CFP gene a variety of annealing 
temperatures were tried. In order to optimise the PCR amplification different reaction 
conditions were tested including the use of different polymerase, first including Pfu 
DNA polymerase. An attempt to alter the magnesium ion concentration to 1.5mM, 
3.5mM and 6.5mM in its buffer to help stabilise the primer/template duplexes and 
reduce non-specific binding did not result in PCR amplification. By varying 
concentrations of DMSO from 1 to 10% didn’t work and resulted in no amplification. 
The use of Taq polymerase with lower initial denaturation temperature also resulted 
in no amplification. It was then attempted to use a new vector for CFP, pAmcyan1-
C1 and designed new primers accordingly. The PCR conditions for CFP were then 
optimised at initial denaturation at 98°C for 2 min, followed by 35 cycles of 98°C for 
45 s, 65°C for 1 min, 72°C for 1 min, followed by a final extension step at 72°C for 10 
min using Phusion Hot start polymerase. Similar PCR amplification was performed 
for TG2 and YFP.  For TG2, conditions for PCR were optimised to be initial 
denaturation at 98°C for 2 min, followed by 35 cycles of 98°C for 45 s, 65°C for 1 
min, 72°C for 3 min, followed by a final extension step at 72°C for 10 min using 
Phusion Hot start polymerase. For YFP, conditions for PCR were optimised to be 
initial denaturation at 98°C for 2 min, followed by 35 cycles of 98°C for 45 s, 65°C 
for1 min, 72°C for 1.5 min, followed by a final extension step at 72°C for 10 min 
using Phusion Hot start polymerase. 
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The amplified PCR products were then sub-cloned into pSTblue-1, which is 
compatible with any DNA polymerase since the cloning kit contains a blunt ending 
step, and contains SP6/T7 promoters for in vitro transcription and sequencing. It also 
has dual EcoRI sites flanking the insert and also provides ampicillin selection. 
Utilising T4 DNA ligase, ligation reaction was set up effectively which favourably links 
sticky and blunt ends and also seals gaps in the phosphodiester backbone. This 
ligase is known to utilise ATP as the cofactor which is present in Quick buffer. The 
ligated reactions were transformed into E.coli Novablue competent cells. Cracking 
procedure was performed on selected white colonies and a blue colony used a 
negative control. Analysing the cracking results, all clones showing plasmids which 
were bigger than parent vector (blue colony) were sent for sequencing. 
After the three components including CFP, TG2 and YFP were cloned and sequence 
confirmed in pSTblue-1, the assembly into pTrcHisB expression vector was 
performed. pTrcHis B expression vector was appropriately chosen for high levels of 
expression of recombinant protein using the trc promoter. The use of pTrcHisB 
expression vector also allowed the purification of recombinant proteins using 
immobilised metal affinity chromatography. CFP was inserted into the BamHI site of 
pTrcHisB. Orientation of CFP cloning into pTrcHisB was important and clones of 
correct orientation were short-listed based on restriction digestion with BamHI/BglII. 
The clones were further analysed on protein expression. No difference in protein 
expression was seen among the selected clones probably as CFP was optimised for 
mammalian expression. The cloning of TG2 and YFP into pTrcHisB was directional 
cloning. One of the problems faced during cloning of TG2 into pTrcHisB when the 
CFP-TG2-pTrcHisB clones were found to be of incorrect sequence due to the 
additional extra ‘C’ base pair in front of TG2 sequence. In order to save time, this 
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problem was solved using 3’ end infilling. The sequence was then confirmed to have 
correct reading frame by nucleotide sequencing. The cloning of YFP was 
straightforward and the entire construct (CFP-TG2-YFP-pTrcHisB) was ready to be 
further analysed for expression.  
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Chapter 4 
Expression and 
characterisation of 
construct 
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4.1 Introduction 
After the cloning was completed, the construct was tested for its ability to retain 
properties of TG2. The recombinant protein was attempted to be expressed and 
purified over a nickel column. During the purification of recombinant CFP-TG2-YFP 
many conditions of elution were tried to find out the best optimum purification 
protocol. This construct was tested for its ability to be affected by the use of TG2 
inhibitors. Since TG2 is known to bind to heparin sepharose, the constructed 
recombinant FRET sensor was also tested for its ability to bind to heparin 
sepharose.TG2 activity was assess by incorporation of biotin cadaverin into 
fibronectin and N,N’dimethyl casein. Interestingly activity was TG2 was assessed 
with increasing concentration of calcium and GTP and then compared to RhTG2 and 
FRET control CFP-TG2.  
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4.2 Expression of CFP-pTrcHisB 
A time course expression of CFP-pTrcHis B plasmid transformed into Novablue cells 
was set up. A single colony of Clone 3, 5 and 12 (figure 4.1) was inoculated in 2ml of 
LB broth containing ampicillin (50µg/ml) and grown overnight at 37°C in an orbital 
shaker. A 50ml culture was setup using this 1/10th volume of this overnight grown 
culture. Cells were grown at 37°C for 4 hours until mid-log phase and then induced 
with 1mM IPTG. 1ml sample were collected prior to IPTG induction as time zero 
sample. Samples were then collected after every one hour for and treated according 
to Invitrogen’s Pilot expression protocol of pTrcHis recombinant protein. SDS page 
analysis of recombinant protein expression (CFP-pTrcHis B) showed expression of 
CFP at 30kDa but there was no difference seen in expression between clones 3, 5 
and 12 as seen in figure 4.1.  
 
Figure 4.1 SDS PAGE analysis of expression of CFP by CFP-pTrcHisB clones. 
Lane 1 is the BLUeye prestained protein ladder. These clones were further 
sent for nucleotide sequencing.  30kDa protein is seen expressed in clones 3, 
5 and 12. No significant difference was observed in expression between the 
clones. These clones were further analysed by nucleotide sequencing.  
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4.3 Expression and Purification of CFP-TG2-YFP recombinant protein 
CFP-TG2-YFP clone 5 was randomly selected (all clones figure4.1 were found to be 
of correct sequence), inoculated in 5 ml of LB with ampicillin (50µg/ml) and grown 
overnight at 37°C using an orbital shaker. This overnight gown culture was 
inoculated into 500ml of LB with ampicillin and grown for 4 hours until OD is about 
1.0 at 600nm. The cells were then induced with 0.1mM IPTG and using the 
purification protocol cell lysate was applied to His Gravitrap column (GE Healthcare).  
 
4.4 Chromatographic purification of His-tagged proteins using His GraviTrap 
column 
CFP-TG2-YFP recombinant protein was expressed in Novablue cells and protein 
purification was performed using His GraviTrap columns. The recombinant protein 
was eluted using 10mls of elution buffer containing 200mM imidazole. The collected 
1ml fractions were analysed using SDS-PAGE analysis (figure 4.2) to check 
expression and purification. It was observed that protein of correct size of about 
135kDa was seen fractions 2 and 3 but the expression was weak. The load and 
flowthrough analysed on the SDS-PAGE also showed the presence of protein. 
Presence of protein in flow through indicated that all protein did not efficiently bind to 
the column. The CFP-TG2-YFP plasmid was then transformed into Rosetta 2 cells 
for efficient mammalian gene expression.  
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Figure 4.2 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Novablue cells and purified using His GraviTrap column (GE Healthcare). 
Prestained protein marker is seen in Lane 1. Lane 2 depicts the cell lysate 
applied to the column (load). The load flowthrough is collected and seen in 
Lane3. A 5mM imidazole wash was performed to get rid of unbound protein 
and is seen in Lane4. Protein elution was performed over 10ml using buffer 
containing 200mM imidazole. Protein of interest (135kDa, red box) was seen in 
fractions 2 and 3.   
4.5 Fractions of protein purified on His GraviTrap column 
Fractions that were eluted using 200mM wash of imidazole using His GraviTrap 
column were analysed by western blotting using Cub7402 (figure 4.3). CFP-TG2-
YFP recombinant protein was seen present in the load, flowthrough, 5mM wash and 
eluted fractions using imidazole.  
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Figure 4.3 Western blot analysis of CFP-TG2-YFP recombinant protein 
purification using His GraviTrap column (GE Healthcare). Western blot 
analysis using anti-translgutaminase 2 antibody Cub7402 revealed presence of 
135kDa recombinant protein.   
 
4.6 Gradient purification using GE AKTA prime FPLC 
To improve protein purification, CFP-TG2-YFP plasmid was transformed into Rosetta 
2 cells. The cells were grown and induced using IPTG. Cells were further lysed and 
applied to Ni-NTA column.  A 20mM imidazole wash was performed to elute 
unbound protein. The 20mM wash samples show non-specifically bound protein 
being eluted (contaminated protein).Gradient elution was performed from 20mM to 
200mM imidazole. Protein of interest of about 135kDa was seen being eluted from 
60mM to 110mM imidazole (figure 4.4).  Specific activity of purified protein was 
found to be 4.5 OD490/min/mg. 
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Figure 4.4 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Prestained protein marker is seen in Lane 1. Lane 2 depicts the cell lysate 
applied to the column (load). The load flowthrough is collected and seen in 
Lane3. A 20mM imidazole wash was performed to get rid of unbound protein 
and is seen in Lane4 and Lane5. Protein elution was performed over 20ml 
using gradient elution from 20mM to 200mM imidazole. Protein of interest 
(135kDa, red box) was seen in fractions 7 and 11.   
4.6.1 Western blot analysis of 20mM-200mM imidazole gradient eluted 
fractions 
CFP-TG2-YFP recombinant protein was expressed in Rosetta 2 cells. The 
purification was performed using GE Ni-NTA column. The purification was performed 
using a 20mM imidazole wash, followed by a gradient elution from 20mM to 200mM 
(40ml/ 20 fractions) Western blotting was performed on peak fractions that were first 
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confirmed using SDS-PAGE stained using coomassie blue. The presence of TG2 
antigen was analysed by western blotting using Cub7402. Protein of interest of about 
135kDa was seen being eluted from 60mM to 110mM imidazole (figure 4.5). 
 
Figure 4.5 Western blot analysis of CFP-TG2-YFP recombinant protein 
purification using Ni-NTA column. Western blot analysis using anti-
transglutaminase 2 antibody Cub7402 revealed presence of 135kDa 
recombinant protein.   
Inspite of successful purification, the above purification showed non-specific 
interactions and unwanted protein was eluted with protein of interest. To get rid of 
the unwanted proteins (around 75kDa and below) an attempt was made to wash with 
higher concentration of imidazole. The figure 4.6depicts CFP-TG2-YFP recombinant 
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protein purification. Prior to elution, a 25mM imidazole wash was performed to get rid 
of non-specific interactions.  CFP-TG2-YFP recombinant protein was eluted in 
fractions 6 and 7. Specific activity was found to be 4.34 OD490/min/mg. Unwanted 
protein seen of size around 75kDa was still purified along with protein of interest.  
 
 
Figure 4.6 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Prestained protein marker is seen in Lane 1. Lane 8 depicts the cell lysate 
applied to the column (load). The load flowthrough is collected and seen in 
Lane9. A 25mM imidazole wash was performed to get rid of unbound protein 
and is seen in Lane6and Lane7. Protein elution was performed over 20ml using 
gradient elution from 25mM to 500mM imidazole. Protein of interest (135kDa, 
red box) was seen in fractions 6 and 7. Fractions 21 and 25 represent elution at 
highest concentration (500mM) imidazole.     
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4.6.2 25mM-500mM imidazole gradient eluted fractions 
The purification was performed using a 25mM imidazole wash, followed by a 
gradient elution from 25mM to 500mM (40ml/ 20 fractions) as seen in figure 4.7. 
Western blotting was performed on peak fractions that were first confirmed using 
SDS-PAGE stained using coomassie blue. The presence of TG2 antigen was 
analysed by western blotting using Cub7402.  
 
Figure 4.7 Western blot analysis of CFP-TG2-YFP recombinant protein 
purification using Ni-NTA column using 25-500mM imidazole gradient elution. 
Western blot analysis using anti-transglutaminase 2 antibody Cub7402 
revealed presence of 135kDa recombinant protein.   
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Further purification was performed applying a 30mM imidazole wash followed by a 
gradient elution from 30mM to 500mM imidazole (figure 4.8). CFP-TG2-YFP 
recombinant protein was purified but the yield (specific activity 1.33 OD490/min/mg).    
 
Figure 4.8 SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed in 
Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Prestained protein marker is seen in Lane 1. Lane 7 and 9 depicts the cell 
lysate applied to the column (load). The load flowthrough is collected and seen 
in Lane 6 and 8. A 30mM imidazole wash was performed to get rid of unbound 
protein and is seen in Lane 5. Protein elution was performed over 20ml using 
gradient elution from 30mM to 500mM imidazole. Protein of interest (135kDa, 
red box) was seen in fractions 7 and 8.     
4.6.3 30mM-500mM imidazole gradient eluted fractions 
The purification was performed using a 30mM imidazole wash, followed by a 
gradient elution from 30mM to 500mM (40ml/ 20 fractions) Western blotting was 
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performed on peak fractions that were first confirmed using SDS-PAGE stained 
using coomassie blue. The presence of TG2 antigen was analysed by western 
blotting using Cub7402. Protein of interest of about 135kDa was seen being eluted 
from 60mM to 110mM imidazole (figure 4.9). 
 
Figure 4.9 Western blot analysis of CFP-TG2-YFP recombinant protein 
purification using Ni-NTA column using 30-500mM imidazole gradient elution. 
Western blot analysis using anti-transglutaminase 2 antibody Cub7402 
revealed presence of 135kDa recombinant protein.   
Purification of CFP-TG2-YFP recombinant protein was repeated by gradient eluting 
protein over 20 ml (shallow gradient) figure 4.10. At the end of gradient elution, 
fractions were collected at 200mM imidazole. The purified fractions were then run 
and analysed using SDS-PAGE. Coomassie staining of SDS-PAGE did not show 
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presence of recombinant protein in eluted fractions. CFP-TG2-YFP recombinant 
protein (135kDa) was seen in load and flowthrough samples.  
 
Figure 4.10 SDS PAGE analysis CFP-TG2-YFP recombinant protein using a 
shallow gradient of 20ml.Prestained protein marker is seen in Lane 1,10,11,20. 
Lane 2 depicts the cell lysate applied to the column (load). The load 
flowthrough is collected and seen in Lane 3. A 20mM imidazole wash was 
performed to get rid of unbound protein and is seen in Lane 4. Protein elution 
was performed over 20ml using gradient elution from 20mM to 200mM 
imidazole. Protein of interest 135kDa was not seen in purification.  
Since the purification of CFP-TG2-YFP recombinant protein using shallow gradient 
(elution over 20mls) did not show presence of protein in eluted fractions , purification 
was repeated by gradient eluting protein over 40 ml (steep gradient).A  wash was 
performed using 25mM imidazole wash. The purified fractions were then analysed 
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using SDS-PAGE revealed the presence of 135kDa in fractions 7, 8, 9, 10, 11 and12 
(figure 4.11).  Specific activity was found to be 3.8 OD490/min/mg. 
 
Figure 4.11SDS PAGE analysis CFP-TG2-YFP recombinant protein expressed 
in Rosetta cells and purified using Ni-NTA column (GE AKTA prime FPLC). 
Prestained protein marker is seen in Lane 1. Lane 3 depicts the cell lysate 
applied to the column (load). The load flowthrough is collected and seen in 
Lane 4 and 5. A 25mM imidazole wash was performed to get rid of unbound 
protein and is seen in Lane 5. Protein elution was performed over 40ml using 
gradient elution from 25mM to 200mM imidazole. Protein of interest (135kDa, 
red box) was seen in fractions 7 to 12.     
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4.6.4 Steep 25mM-200mM imidazole gradient eluted fractions 
The purification was performed using a 25mM imidazole wash, followed by a 
gradient elution from 25mM to 200mM (40ml/ 20 fractions) Western blotting was 
performed on peak fractions that were first confirmed using SDS-PAGE stained 
using coomassie blue. The presence of TG2 antigen was analysed by western 
blotting using Cub7402. Presence of protein of interest of about 135kDa was seen in 
fractions (figure 4.12). 
 
Figure 4.12 Western blot analysis of CFP-TG2-YFP recombinant protein 
purification using Ni-NTA column. Western blot analysis using anti-
transglutaminase 2 antibody Cub7402 revealed presence of 135kDa 
recombinant protein.   
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4.7 Control CFP-TG2 recombinant protein purification 
CFP-TG2 (control) recombinant protein was purified using same protocol as CFP-
TG2-YFP recombinant protein purification using the Ni-NTA column. Protein was 
eluted using a 20-200mM imidazole gradient using 40ml volume. Out of the 20 
fractions collected over the elution, fractions 5 to 20 and fraction 21, 22(200mM 
imidazole elution after gradient) fractions were run on a SDS-PAGE gel and 
analysed by coomassie staining. CFP-TG2 (100KDa) recombinant protein was seen 
(figure 4.13).  
 
Figure 4.13 SDS PAGE analysis CFP-TG2 control recombinant protein 
expressed in Rosetta cells and purified using Ni-NTA column (GE AKTA prime 
FPLC). Prestained protein marker is seen in Lane 2. A 20mM imidazole wash 
was performed to get rid of unbound protein. Protein elution was performed 
over 40ml using gradient elution from 20mM to 200mM imidazole. Protein of 
interest (100kDa, red box) was seen in fractions elution fractions (7 to 12 peak 
fractions) 
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4.7.1 Western blot analysis of control CFP-TG2 purification eluted fractions 
Western blotting was performed on peak fractions that were first confirmed using 
SDS-PAGE stained using coomassie blue. The presence of TG2 antigen was 
analysed by western blotting using Cub7402. Protein of interest of about 100Da was 
seen being eluted from 50mM to 110mM imidazole (peak fractions) 
 
 
 
Figure 4.14 Western blot analysis of CFP-TG2 recombinant protein purification 
using Ni-NTA column over a 20-200mM imidazole gradient elution. Western 
blot analysis using anti-transglutaminase 2 antibody Cub7402 revealed 
presence of 100KDa recombinant protein.   
 
 
4.8 Control wild type TG2-pET30ek/LIC purification (wild type TG2) 
Wild type recombinant TG2 was purified using same protocol as CFP-TG2-YFP 
recombinant protein purification using the Ni-NTA column. Protein was eluted using 
a 20-200mM imidazole gradient using 40ml volume. All fractions of the purification 
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were analysed using SDS-PAGE analysis. Protein of correct size of about 80kDa 
was seen in fractions 5 to 13 (figure 4.15).   
 
Figure 4.15 SDS PAGE analysis Control wild type TG2-pET30ek/LIC 
recombinant protein expressed in Rosetta cells and purified using Ni-NTA 
column (GE AKTA prime FPLC). Prestained protein marker is seen in Lane 1. 
Lane 2 depicts the cell lysate applied to the column (load). The load 
flowthrough is collected and seen in Lane 3. A 20mM imidazole wash was 
performed to get rid of unbound protein and is seen in Lane 4, 5 and6. Protein 
elution was performed over 40ml using gradient elution from 20mM to 200mM 
imidazole. Protein of interest (80kDa, red box) was seen in fractions 5 to 13.     
4.9 Binding of TG2 to Heparin-Sepharose 
400ml of LB broth was inoculated with 20ml overnight culture of E.coli Rosetta2 
CFPTG2YFP, cCFPTG2, pET30Ek/LIC TG2 and grown for 4 hours prior to induction 
with 1mM IPTG at 16°C overnight. Cells were centrifuged at 10000g for 15 min at 
4°C. Cells were resuspended in bufferA (refer Material and methods) and thereafter 
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lysed. The cell lysate was centrifuged at 20000g for 30 min at 4°C. Heparin column 
was equilibrated using buffer A and the clarified lysate was loaded onto the column. 
Purification was performed using protocol by Wang et al, 2012.The column was 
washed with 25ml of buffer A and 1ml fractions were eluted with a linear gradient of 
increasing gradient of NaCl from 0 to 0.5M. Every alternate fraction of the gradient 
was run on a SDS page and analysed by western blotting.  
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4.9.1 Western blot analysis of CFPTG2YFP purification through heparin-
Sepharose column 
Western blot analysis revealed that recombinant CFP-TG2-YFP purified protein 
exhibited heparin binding capacity characteristic of tissue transglutaminase. The 
initial load and subsequent flow through were also collected and analysed on SDS-
PAGE. After loading, wash fractions to get rid of unbound protein were also collected 
and analysed. Protein elution fractions (25 fractions of 1 ml each) were collected 
over a gradient of 0 to 0.5M NaCl. Every alternate fraction was analysed by running 
on SDS-PAGE and western blotting using Cub 7402(figure 4.16). 
 
Figure 4.16 Western blot analysis of CFP-TG2-YFP recombinant protein 
purification over heparin sepharose column. Western blot analysis using 
Cub7402 revealed successfully purification of CFP-TG2-YFP recombinant 
protein as seen by band at about 135kDa. Load and flowthrough was seen in 
Lane 2 and 3 respectively. Subsequently loaded wash samples also showed 
presence protein of interest. CFP-TG2-YFP recombinant protein was seen 
being eluted from 12th fraction of gradient onwards (0.24M NaCl) upto 24th 
fraction (0.48M NaCl) with peak of elution seen at 22nd fraction (0.44M NaCl) 
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4.9.2 Western blot analysis of wild type TG2 purification eluted using heparin-
Sepharose column 
Similar to CFP-TG2-YFP recombinant protein purification, wild type TG2 
(pET30Ek/LIC TG2) was also purified over the same heparin sepharose column. 
Load, flowthrough and subsequent wash samples were loaded and analysed (figure 
4.17). Wild type TG2 showed affinity towards heparin sepharose column and purified 
protein fractions were eluted started from 0.28M NaCl upto 0.48M NaCl.  
 
Figure 4.17 Western blot analysis of wild type recombinant protein purification 
over heparin sepharose column. Western blot analysis using Cubb7402 
revealed successfully purification of TG2 recombinant protein as seen by band 
at about 78kDa. Load and flowthrough was seen in Lane 2 and 3 respectively. 
Subsequently loaded wash samples also showed presence protein of interest. 
Wild type TG2 recombinant protein was seen being eluted from 14th fraction of 
gradient onwards (0.28M NaCl) upto 24th fraction (0.48M NaCl) with peak of 
elution seen at 22nd fraction (0.44M NaCl) 
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4.9.3 Western blot analysis of CFPTG2 purification eluted fractions 
As seen in figure 4.17, control CFP-TG2 recombinant protein was also purified using 
the heparin sepharose column. The eluted fractions were resolved using SDS-PAGE 
and analysed using western blot analysis. It was found that CFP-TG2 recombinant 
protein could also bind to heparin. The figure 4.18 represents load and flow through 
in lane 2 and 3 respectively. As compared to CFP-TG2-YFP recombinant protein 
purification seen above, CFP-TG2 exhibits enhanced binding to sepharose as less 
protein is seen in flowthrough sample. Wash fractions were collected and loaded in 
lane 4, 5 and 6. CFP-TG2 recombinant protein was eluted starting from 0.28M NaCl 
upto 0.48M NaCl of gradient.  
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Figure 4.18 Western blot analysis of control CFP-TG2 recombinant protein 
purification over heparin sepharose column. Western blot analysis using 
Cubb7402 revealed successfully purification of TG2 recombinant protein as 
seen by band just over 100kDa. Load and flowthrough was seen in Lane 2 and 
3 respectively. Subsequently loaded wash samples also showed presence 
protein of interest. Control CFP-TG2 recombinant protein was seen being 
eluted from 14th fraction of gradient onwards (0.28M NaCl) upto 24th fraction 
(0.48M NaCl) with peak of elution seen at 20nd fraction (0.4M NaCl) 
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4.9.4 Downstream cleaning of Ni-affinity purified protein using Heparin column 
As both wildtype TG2 and CFP-TG2-YFP recombinant protein showed affinity toward 
heparin sepharose which is characteristic of tissue transglutaminase, an attempt was 
made to use this heparin column for downstream cleaning of protein that was 
purified using the Ni-column. The non-specific contaminated protein which was found 
in purification could possibly be eliminated and result in cleaner purified protein.  
Control pET30Ek/LIC TG2 was affinity purified over Ni column (figure 4.19). Gradient 
eluted fractions were collected and desalted over PD10 column. Fractions 6 and 
7were pooled together desalted and applied to the Heparan column and elution was 
carried out at gradient between 0 to 0.5M NaCl. The fractions were then run on SDS 
gel and stained with coomassie.   
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4.10 Affinity purification of control pET30Ek/LIC TG2 using GE AKTA prime 
FPLC (Ni column purification) 
 
Figure 4.19 SDS PAGE analysis of wild type TG2 protein purification using Ni 
column. The non-specifically bound protein highlighted by the red box. Protein 
of interest was eluted as seen in fractions 5 to 12. Peak fraction 6 and 7 were 
further selected for downstream processing.  
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4.10.1 Purified wild type TG2 through heparin column  
Wild type TG2 which was purified using the Ni column was then loaded onto the 
heparin sepharose column. In this case, fraction 6 and 7 were used as a load. Using 
the heparin sepharose protocol (refer material and methods) the purification was 
performed using a gradient from 0 to 0.5M NaCl over 12 mls. The wild type protein 
was eluted starting from 8th fraction (0.3M NaCl).This elution was similar to the 
previous wildtype purification performed using lysed cells as load (figure 4.20). The 
proteins were analysed using SDS-PAGE and revealed that the purification using 
heparin sepharose was cleaner and showed lesser non-specific bands. Hence the 
protein purified using Ni column was further processed using heparin sepharose 
column.  
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Figure 4.20 SDS PAGE analysis of purified fractions of wild type TG2 protein 
purification using heparin column. Fractions 6 and 7 of Ni column purification 
were loaded onto the heparin column. A gradient elution was performed from 0 
to 0.5M NaCl. Protein was eluted as seen in fractions 8 to 12 and less non-
specific binding observed as compared to Ni-column purification. 
 
 
 
 
 
 
 
 157 
 
4.11 Affinity purification of CFP-TG2-YFP using GE AKTA prime FPLC 
CFP-TG2-YFP was affinity purified over Ni column. Gradient eluted fractions were 
collected and desalted over PD10 column. Fractions 9 and 10 were desalted and 
applied to the Heparin column and elution was carried out at gradient between 0 to 
0.5M NaCl over 12ml. The fractions were then run on SDS gel and stained with 
coomassie blue (figure 4.21).  
  
 
Figure 4.21 SDS PAGE analysis of CFP-TG2-YFP recombinant protein 
purification using Ni column. The non-specifically bound protein highlighted 
by the red box. Protein of interest was eluted as seen in fractions 7 to 13. Peak 
fraction 9 and 10 were further selected for downstream processing.  
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4.11.2 Purified CFP-TG2-YFP fractions through heparin column  
Wild type TG2 which was purified using the Ni column was then loaded onto the 
heparin sepharose column. In this case, fraction 9 and 10 were used as a load. 
Using the heparin sepharose protocol (refer material and methods) the purification 
was performed using a gradient from 0 to 0.5M NaCl over 12 ml. The wild type 
protein elution from 8th fraction (0.3M NaCl).This elution was similar to the previous 
CFP-TG2-YFP recombinant purification performed using lysed cells as load. The 
proteins were analysed using SDS-PAGE (figure 4.22) and revealed that the 
purification using heparin sepharose was cleaner and showed lesser non-specific 
bands. Hence the protein purified using Ni column was further processed using 
heparin sepharose column.  
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Figure 4.22 SDS PAGE analysis of purified fractions of CFP-TG2-YFP 
recombinant protein purification using heparin column. Fractions 9 and 10 of 
Ni column purification were loaded onto the heparin column. A gradient 
elution was performed from 0 to 0.5M NaCl. Protein was eluted as seen in 
fractions 8 to 12 and less non-specific binding observed as compared to Ni-
column purification. 
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4.12 Conformational changes due to effect of monodansyl cadaverin, biotin 
cadaverin, inhibitors R281 / R283  
The protease sensitivity of wild type TG2 (control pET30Ek/LIC TG2) and CFP-TG2-
YFP recombinant protein was analysed. It has been suggested that when TG2 
adapts a closed conformation it is less susceptible to protease digestion. When the 
structure opens, trypsin susceptibility increases resulting in digestion.  
4.12.1 Effect of Biotin cadaverin (BTC) 
Purified recombinant wild type TG2 (3µg) was treated with increasing concentrations 
of biotin cadaverin and then incubated with 80ng of trypsin on ice. After two hours of 
incubation the reaction was stopped by adding laemmli buffer and the results were 
analysed by resolving the protein using SDS PAGE (figure 4.23). The gels were then 
stained with coomassie blue and it was observed that with increasing concentration 
(0 to 1mM) of biotin cadaverin no difference in trypsin digestion was detected.  
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Figure 4.23 SDS PAGE analysis of BTC treated wild type TG2.  3ug of purified 
TG2 (recombinant wild type) was pre-treated with(+) or without (-) increasing 
concentrations of BTC;0mM, 0.1mM, 0.5mM and 1mM and subjected to trypsin 
digestion for 2 hours. The proteins were then resolved by SDS-PAGE and 
stained with coomassie blue. Lane 2 represents prestained protein ladder 
(245kDa). Lane 1 depicts purified recombinant TG2 (wildtype), Lanes 4, 6, 8 
represent protein pre-treated with BTC without trypsin treatment (control).  
 
Purified recombinant CFP-TG2-YFP protein was (3µg) was initially desalted in buffer 
containing 20mM Tris, 300mM NaCl and 10% glycerol and was similarly treated with 
increasing concentrations of biotin cadaverin for 1 hour at room temperature. It was 
then subjected to 80ng of trypsin on ice. After two hours of incubation the reaction 
was stopped by adding laemmili buffer and the results were analysed by resolving 
the protein using SDS PAGE. The gels were then stained with coomassie blue 
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(Figure 4.24) and it was observed that with increasing concentration (0 to 1mM) of 
biotin cadaverin no difference in trypsin digestion was detected. This result was 
similar to the effect observed on wild type TG2.  
 
 
Figure 4.24 SDS PAGE analysis of BTC treated CFP-TG2-YFP recombinant 
protein. 3ug of purified recombinant CFP-TG2-YFP (construct protein) was pre-
treated with(+) or without (-) increasing concentrations of BTC;0mM, 0.1mM, 
0.5mM and 1mM and subjected to trypsin digestion for 2 hours. The proteins 
were then resolved by SDS-PAGE and stained with coomassie blue. Lane 1 
represents prestained protein ladder (245kDa). Lane 2 depicts purified 
recombinant TG2 (wildtype), Lanes 4, 6, 8 represent protein pre-treated with 
BTC without trypsin treatment (control).  
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4.12.2 Effect of monodansyl cadaverin  
Purified recombinant wild type TG2 (3µg) was treated with increasing concentrations 
of monodansyl cadaverin and then incubated with 80ng of trypsin on ice as 
previously reported by Zhang et al, 2013. (Zhang et al., 2013) After two hours of 
incubation the reaction was stopped by adding laemmili buffer and the results were 
analysed by resolving the protein using SDS PAGE. The gels were then stained with 
coomassie blue (figure 4.25) and it was observed that with increasing concentration 
(0 to 1mM) of monodansyl cadaverin, no difference in trypsin digestion was detected 
similar to biotin cadaverin treatment. With the increasing concentration of 
monodansyl cadaverin there was no increase in trypsin susceptibility as a result of 
conformational change as indicated by Zhang et al (2013).  
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Figure 4.25 SDS PAGE analysis of MDC treated wild type TG2.3ug of purified 
TG2 (recombinant wild type) was pre-treated with(+) or without (-) increasing 
concentrations of MDC;0mM, 0.1mM, 0.5mM and 1mM and subjected to trypsin 
digestion for 2 hours. The proteins were then resolved by SDS-PAGE and 
stained with coomassie blue. Lane 2 represents prestained protein ladder 
(245kDa). Lane 1 depicts purified recombinant TG2 (wildtype), Lanes 4, 6, 8 
represent protein pre-treated with BTC without trypsin treatment (control).  
 
Purified recombinant CFP-TG2-YFP protein was (3µg) was initially desalted in buffer 
containing 20mM Tris, 300mM NaCl and 10% glycerol and was similarly treated with 
increasing concentrations of monodansyl cadaverin (MDC) for 1 hour at room 
temperature. It was then subjected to 80ng of trypsin on ice. After two hours of 
incubation the reaction was stopped by adding laemmli buffer and the results were 
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analysed by resolving the protein using SDS PAGE. The gels were then stained with 
coomassie blue (figure 4.26) and it was observed that with increasing concentration 
(0 to 1mM) of monodansyl cadaverin no difference in trypsin digestion was detected. 
This result was similar to the effect observed on control wild type TG2.  
 
 
Figure 4.26 SDS PAGE analysis of BTC treated CFP-TG2-YFP recombinant 
protein. 3ug of purified recombinant CFP-TG2-YFP (construct protein) was pre-
treated with(+) or without (-) increasing concentrations of MDC;0mM, 0.1mM, 
0.5mM and 1mM and subjected to trypsin digestion for 2 hours. The proteins 
were then resolved by SDS-PAGE and stained with coomassie blue. Lane 1 
represents prestained protein ladder (245kDa). Lane 2 depicts purified 
recombinant TG2 (wildtype), Lanes 4, 6, 8 represent protein pre-treated with 
MDC without trypsin treatment (control). 
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4.12.3 Effect of Inhibitors R281 and R283 
TG2 cell permeable inhibitor R283 and cell impermeable TG2 inhibitor R281 are 
known to interfere with transamidating activity of TG2 by targeting the active 
cysteine. Inhibitor bound TG2 adapts an open conformation. (Griffin et al., 2008) 
R281 and R283 were used to assess the effect of trypsin on both wild type TG2 and 
CFP-TG2-YFP recombinant protein. 
4.12.4 R281 and wild type 
3ug of recombinant protein was pre-treated with 20mM calcium chloride, 1mM DTT 
and 500µM R281 for 1 hour on ice. The inhibitor treated protein was then mixed with 
increasing concentrations of trypsin. Two controls were used, one without addition of 
inhibitor and trypsin (purified protein) and second control without pre-treatment with 
inhibitor (only trypsin digested protein). It was observed that wild type TG2 treated 
with R281 was completely digested with lowest concentration of 80ngs of trypsin. 
Control sample with no R281 treatment and only addition of trypsin showed no 
digestion suggesting that TG2 could be in closed conformation, not susceptible to 
protease digestion (figure 4.27). Once treated with inhibitor TG2 (open 
conformation), trypsin was seen to completely digest protein.  
 
 
 167 
 
 
Figure 4.27 SDS PAGE analysis of R281 treated wild type recombinant TG2 
protein. 3ug of purified recombinant wild type TG2 was pre-treated with (+) or 
without (-) 500µM R281 and subjected to trypsin digestion for 2 hours. The 
proteins were then resolved by SDS-PAGE and stained with coomassie blue. 
Lane 1 represents prestained protein ladder (245kDa). Lane 2 depicts purified 
recombinant TG2 (wildtype), Lanes 3 and 4 shows protein digested with 80ngs 
of trypsin. Lane 5 and 7 shows control without pre-treatment with inhibitor and 
digested with trypsin.  
 
4.12.5 R283 and wild type 
Similar to R281 treatment 3µg of wild type TG2 was treated with R283, followed by 
digestion with increasing concentrations of trypsin. Two controls were used, one 
without addition of inhibitor and trypsin (purified protein) and second control without 
pre-treatment with inhibitor (only trypsin digested protein). It was observed that wild 
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type TG2 treated with R281 was completely digested with lowest concentration of 
80ngs of trypsin. Control sample with no R283 treatment and only addition of trypsin 
showed no digestion suggesting that TG2 could be in closed conformation, not 
susceptible to protease digestion. Once treated with inhibitor TG2 (open 
conformation), trypsin was seen to digest protein but at higher concentrations as 
compared to R281 treatment as seen above. At low concentrations of 80ngs to 0.8µg 
no digestion of R283 treated protein was observed (figure 4.28). Digestion of R283 
treated protein was observed at 3.2µg of trypsin and higher suggesting a probable 
slight difference in conformation and protease digestion. 
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Figure 4.28 A and B SDS PAGE analysis of R283 treated wild type recombinant 
TG2 protein. 3ug of purified recombinant wild type TG2 was pre-treated with 
(+) or without (-) 500µM R283 and subjected to trypsin digestion for 2 hours. 
The proteins were then resolved by SDS-PAGE and stained with coomassie 
blue. Lane 1 represents prestained protein ladder (245kDa) figure A and B. 
Lane 2 depicts purified recombinant TG2 (wildtype), Lanes 3 and 4 shows 
protein digested with 80ngs of trypsin in figure A. Lane 5 and 7 shows control 
without pre-treatment with inhibitor and digested with trypsin in figure A. 
Figure B depicts higher concentrations of trypsin digestion from 1.6µg to 8µg. 
Digestion of R283 treated wild type protein was observed at higher 
concentration than R281 as seen in figure B.   
 
4.12.6 R281 and CFP-TG2-YFP recombinant protein 
3ug of recombinant protein was pre-treated with 20mM calcium chloride, 1mM DTT 
and 500µM R281 for 1 hour on ice. The inhibitor treated protein was then mixed with 
increasing concentrations of trypsin. Two controls were used, one without addition of 
inhibitor and trypsin (purified protein) and second control without pre-treatment with 
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inhibitor (only trypsin digested protein). It was observed that wild type TG2 treated 
with R281 was partially digested with lowest concentration of 80ngs of trypsin and 
complete digestion was seen with R281 pre-treated protein using 0.8µg of trypsin.  
Control sample with no R281 treatment and only addition of trypsin showed no 
digestion suggesting that TG2 could be in closed conformation, not susceptible to 
protease digestion (figure 4.29). Once treated with inhibitor TG2 (open 
conformation), trypsin was seen to completely digest protein. It is observed that 
R281 treated wild type TG2 and CFP-TG2-YFP recombinant protein show difference 
in concentration of trypsin required for complete digestion possibly due the difference 
in size.   
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Figure 4.29 A and B SDS PAGE analysis of R281 treated wild type recombinant 
TG2 protein. 3ug of purified recombinant CFP-TG2-YFP recombinant protein 
was pre-treated with (+) or without (-) 500µM R281 and subjected to trypsin 
digestion for 2 hours. The proteins were then resolved by SDS-PAGE and 
stained with coomassie blue. Lane 1 represents prestained protein ladder 
(245kDa). Lane 2 depicts purified recombinant CFP-TG2-YFP, Lanes 4 shows 
protein partially digested with 80ngs of trypsin in figure A. Lane 5 and 7 shows 
control without pre-treatment with inhibitor and digested with trypsin in figure 
A. Complete digestion of protein was observed at 0.8µg trypsin as seen in 
Lane 8 of figure A. Figure B depicts higher concentrations of trypsin digestion 
from 1.6µg to 8µg.  
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4.13 Presence of TG2 antigen by ELISA 
CFP-TG2-YFP recombinant protein and CFP-TG2 recombinant protein were purified 
and presence of TG2 antigen was detected using enzyme linked immunosorbent 
assay. Cub 7402 anti-TG2 monoclonal antibody was used (refer material and 
methods for protocol) CFP-TG2-YFP recombinant protein exhibits similar 
incorporation of fibronectin as compared to recombinant TG2 (RhTG2). The assay 
was repeated using anti-TG2 1D10 monoclonal antibody. The results were 
compared between Cub7402 and 1D10 and it was found that Cub 7402 has higher 
affinity to TG2 as compared to 1D10.   
 
 
Figure 4.30 Detection of TG2 antigen using ELISA. The results represent TG2 
activity comparison of RhTG2, purified CFP-TG2-YFP recombinant protein and 
CFP-TG2 recombinant protein. The experiment was performed using Cub7402 
and 1D10 monoclonal TG2 antibody. Results show mean ± S.E.M of three 
independent experiments done performed in triplicates. Statistical analysis 
was done using ANOVA applying Bonferroni post-test (*** P<0.001) 
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4.14 Biotin-cadaverine incorporation into N,N’-dimethylcasein  
Purified CFP-TG2-YFP recombinant protein was tested and compared to RhTG2 for 
its ability to incorporate biotin-cadaverin into N, N-dimethylcasein. The reaction was 
performed at three concentration of calcium. The specific activity was seen to be less 
than half of RhTG2 when using casein.  
 
Figure 4.31 Comparison of specific activity of RhTG2 and purified CFP-TG2-
YFP recombinant with respect to biotin cadaverin incorporation into N, N’-
dimethylcasien. The experiment was performed at three different 
concentration of calcium. Results show mean ± S.D of three independent 
experiments done performed 
 
4.15 Biotin-cadaverine incorporation into Fibronectin 
Purified CFP-TG2-YFP recombinant protein was tested and compared to RhTG2 for 
its ability to incorporate biotin-cadaverin into fibronectin. The reaction was performed 
at three concentration of calcium. The specific activity was seen to be more than half 
of RhTG2 when using fibronectin.  
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Figure 4.32 Comparison of specific activity of RhTG2 and purified CFP-TG2-
YFP recombinant with respect to biotin cadaverin incorporation into 
fibronectin. The experiment was performed at three different concentration of 
calcium. Results show mean ± S.D of three independent experiments done 
performed 
 
4.16 Calcium activation assay 
To compare calcium sensitivity biotin-X-cadaverin activity assay was performed 
based on incorporation into immobilised fibronectin (refer material and methods). 
Trangluataminase activity was measured over a range of varying calcium 
concentrations using 5µM, 10µM, 50µM, 0.1mM, 0.25mM, 0.5mM, 0.75mM, 1mM, 
5mM, 10mM of calcium chloride with 1µg TG2 (using RhTG2, CFP-TG2-YFP 
recombinant protein and CFP-TG2 recombinant protein) CFP-TG2-YFP recombinant 
protein and CFP-TG2 recombinant protein was purified using Ni-NTA column and 
desalted using PD-10 column in the presence of 1mM EGTA. Addition calcium was 
added to compensate for EGTA chelation. TG2 activity was measured and analysed 
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using Michelis-Menten equation. The curve was plotted in Graphpad prism and the 
Km value was calculated for RhTG2 Km=59.49µM ± 0.03, CFP-TG2-YFP 
recombinant protein Km=98.19µM ± 0.03 and CFP-TG2 recombinant protein 
Km=87.54µM ± 0.03. The results indicate a difference in calcium sensitivity between 
RhTG2 and fluorescent protein tagged TG2.  
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Figure 4.33 Dose-response curve of transglutaminase activity for calcium with 
values plotted on a logarithmic scale. Transglutaminase activity with calcium 
concentration ranging from 5µM to 10mM was compared for RhTG2, purified 
CFP-TG2-YFP recombinant protein and purified CFP-TG2 recombinant protein. 
Rh TG2 Km= 59.49 µM and CFP-TG2-YFP recombinant protein Km=98.19µM. 
CFP-TG2 recombinant protein Km=87.54µM. The results represent mean ± 
S.E.M of three independent experiments done performed in triplicates.  
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4.17 GTP inhibition curve 
GTP is known to negatively regulated activity of tissue transglutaminase. To 
compare GTP inhibition, biotin-X- cadaverin activity assay was performed based on 
incorporation into immobilised fibronectin (refer material and methods). 
Transglutaminase activity was measure over a range of varying GTP concentrations 
using 5µM, 10µM, 50µM, 0.1mM, 0.25mM, 0.5mM, 0.75mM, 1mM, 5mM, 10mM of 
GTP and 250 µM calcium chloride with 1µg TG2 (using RhTG2, CFP-TG2-YFP 
recombinant protein and CFP-TG2 recombinant protein) CFP-TG2-YFP recombinant 
protein and CFP-TG2 recombinant protein was purified using Ni-NTA column and 
desalted using PD-10. TG2 activity was measured and plotted using Morrison Ki 
equation. The curve was plotted in Graphpad prism and the KI value was calculated 
for RhTG2 Km=1.14µM ± 0.02, CFP-TG2-YFP recombinant protein Km=4.56µM ± 
0.02 and CFP-TG2 recombinant protein Km=11.73µM ± 0.02. The result show 
RhTG2, recombinant CFP-TG2-YFP protein and CFP-TG2 recombinant protein 
show a decrease in transamidating activity with increase in GTP concentration.  
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4.34 Figure Dose-response curve of transglutaminase activity for GTP with 
values plotted on a logarithmic scale. Transglutaminase activity with GTP 
concentration ranging from 5µM to 10mM was compared for RhTG2, purified 
CFP-TG2-YFP recombinant protein and purified CFP-TG2 recombinant protein. 
Rh TG2 KI= 1.146 µM and CFP-TG2-YFP recombinant protein KI= 4.562 µM. 
CFP-TG2 recombinant protein Km=11.73 µM. The results represent mean ± 
S.E.M of three independent experiments done performed in triplicates.  
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4.18 Discussion 
The second part of the project was the characterisation of the TG2 FRET construct. 
In order to achieve this, the expression of the construct was first tested. The 
expression of CFP-pTrcHisB clones revealed a 35kDa protein but no difference was 
observed in the expression based on the time course. Changing the time course 
could be another option to assess the expression over time. For example a shorter 
time course where samples are collected every 30mins or less within the first hour of 
expression. Nevertheless the presence of protein of correct size seen via SDS page 
analysis could mean that CFP was expressed. The western blot analysis using anti-
CFP antibody could be another option to be sure the 35kDa protein seen is CFP. For 
the analysis of CFT-TG2-YFP expression the use of alternate antibodies specific to 
CFP or YFP could also be useful. For expression of this construct the possibility of 
expression in yeast could also be another interesting area of investigation. Yeast 
cells are known to support the expression of protein with the advantages like faster 
growth, low cost and easy genetic manipulations. It would also be interesting to 
investigate the truncated products seen in the expression. The use of alternate 
antibodies specific to CFP or YFP rather than TG2 could indicate what sort of 
truncated proteins are seen in the western blots during protein expression. Also the 
use of silver staining for SDS gels could prove to be more sensitive than coomassie 
blue staining. The use of other size exclusion chromatography would also provide a 
cleaner purification and get rid of smaller products that are seen in the SDS gels 
stained with coomassie and western blot analysis using Cub7402 Another future 
prospective could be introducing point mutations within the construct and check how 
it affects the expression of TG2. The use of Gly spacers between the fluorescent 
proteins and TG2 and if it affects expression and activity of the construct could also 
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broaden the existing research. The conformational changes due to monodanysly 
cadaverin, biotin cadaverin and inhibitors could also be assessed using a different 
protease other than trypsin to check digestion. The difference seen by ELISA 
comparing Cub7402 and 1D10 could also indicate a difference in epitope. The 
epitope of Cub7402 is known but epitope of our laboratory produced ID10 still needs 
investigation. A difference in antibody reactivity is observed. An interesting difference 
in affinities of TG2 binding fibronectin and casein is observed via biotin cadaverin 
incorporation using a saturating calcium concentration. This could be due to steric 
hindrance to substrate accessibility using a solid phase assay.  
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Chapter 5 
FRET analysis 
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5.1 Introduction 
FRET is the non-radiative transfer of energy from the donor to the acceptor. This 
chapter focuses on analysis the fluorescence changes that occur as a result of TG2 
structure opening and closing. TG2 opening structure is assessed by increasing 
concentration of calcium and closed form of TG2 is assessed by binding of GTP. 
This chapter also encompasses the use of FRET controls including the fluorescence 
changes occurring in CFP-TG2 construct only, as a result of calcium and GTP. The 
raw fluorescence reading was then processed for FRET efficiency. The activity curve 
seen previously was compared to the FRET efficiency to determine whether or not 
this system is valid.   
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5.2 FRET data analysis 
5.2.1 Effect of GTP on conformation using FRET analysis 
When GTP binds to TG2, structure adapts a closed conformation and not allowing 
access to its active site. Here we investigate the effect of GTP on the conformation 
of TG2 using FRET. An increasing concentration of GTP ranging from 5µM, 10µM, 
50µM, 0.1mM, 0.25mM, 0.5mM, 0.75mM, 1mM, 5mM, 10mM. 250µM of calcium was 
added to the reaction. CFP-TG2-YFP recombinant protein was purified using Ni-NTA 
column and desalted in 50mM Tris buffer, 1mMDTT, 1mM EGTA. 1µg of protein was 
used in each reaction. The figure 5.1 represents the normalised fluorescence 
measure when CFP is excited at 436nm and emission was measured at 476nm (cut 
off selected 455nm). As the GTP concentration increases there is a decrease in CFP 
emission as the TG2 structure closes. A significant difference was observed between 
mean fluorescence at 5µM (lowest GTP concentration) and 10mM (highest 
concentration) of GTP.  
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Figure 5.1 Effect of increasing concentration of GTP on CFP emission 
analysing CFP-TG2-YFP recombinant protein. The graph was plotted using log 
of GTP concentration from 5µM to 10mM. The decrease in fluorescence is 
represented as normalised mean fluorescence. The results represent mean ± 
S.D of three independent experiments done performed in triplicates. Statistical 
analysis was done using ANOVA applying Bonferroni post-test (*** P<0.001) 
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The figure 5.2 represents the normalised fluorescence measure when YFP is excited 
at 516nm and emission was measured at 538nm (cut off selected 530nm). As the 
GTP concentration increases the YFP emission increases. YFP emission indicated 
in figure below is an indication of the amount of protein. Although there is an 
increase with increase in GTP concentration observed in YFP emission, this 
increase was corrected for during FRET efficiency calculation.  
 
Figure 5.2 Effect of increasing concentration of GTP on YFP emission 
analysing CFP-TG2-YFP recombinant protein. The graph was plotted using log 
of GTP concentration from 5µM to 10mM. The fluorescence is represented as 
normalised mean fluorescence represented on the Y axis. The results 
represent mean ± S.D of three independent experiments done performed in 
triplicates.  
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The figure 5.3 represents the normalised fluorescence measure when CFP is excited 
at 436nm and emission was measured at 538nm (cut off selected 530nm). As the 
GTP concentration increases there is a significant increase in YFP emission as the 
TG2 structure closes. A significant difference was observed between mean 
fluorescence at 5µM (lowest calcium concentration) and 10mM (highest 
concentration) of GTP. This increase in FRET indicates the structure of recombinant 
CFP-TG2-YFP closes as the GTP concentration increases. As the structure closes 
more energy is transferred from the donor to acceptor and hence an increase in 
FRET is observed.  
 
Figure 5.3 Effect of increasing concentration of GTP on CFP excitation YFP 
emission analysing CFP-TG2-YFP recombinant protein. The graph was plotted 
using log of calcium concentration from 5µM to 10mM. The increase in 
fluorescence is represented as normalised mean fluorescence. The results 
represent mean ± S.D of three independent experiments done performed in 
triplicates. Statistical analysis was done using ANOVA applying Bonferroni 
post-test (*** P<0.001) 
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5.3 Control CFP-TG2 recombinant protein FRET analysis 
The figure 5.4 represents the normalised fluorescence measured for CFP-TG2 
recombinant protein when CFP is excited at 436nm and emission was measured at 
476nm (cut off selected 455nm). As the GTP concentration increases no significant 
difference was observed in CFP emission.  
 
 
 
Figure 5.4 Effect of increasing concentration of GTP on CFP emission 
analysing control CFP-TG2 recombinant protein. The graph was plotted using 
log of calcium concentration from 5µM to 10mM. The fluorescence is 
represented as normalised mean fluorescence on Y axis. The results represent 
mean ± S.D of three independent experiments done performed in triplicates.  
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Figure 5.5 Effect of increasing concentration of GTP on CFP excitation YFP 
emission analysing control CFP-TG2 recombinant protein. The graph was 
plotted using log of calcium concentration from 5µM to 10mM. The increase in 
fluorescence is represented as normalised mean fluorescence. The results 
represent mean ± S.D of three independent experiments done performed in 
triplicates.  
 
Calculated FRET 
 
A part of above represented YFP emission seen as CFP excitation YFP emission of 
CFP-TG2-YFP recombinant protein also includes bleedthrough. To correct for 
bleedthrough, we first calculated bleedthrough by  
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where “ex” is excitation and “em” represents emission 
 
The calculated YFP emission corrected for bleedthrough is represented in the figure 
5.6. With increase in GTP concentration there is an increase in FRET indicating the 
closing of the structure.  
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Figure 5.6 Effect of increasing concentration of GTP on FRET. The graph was 
plotted using log of GTP concentration from 5µM to 10mM. The figure shows 
the increase in YFP emission corrected for bleedthrough as represented in 
blue. As represented in red is the fluorescence corrected for the increase in 
YFP emission.  
 
For calculating FRET efficiency,  
 
 
 
where A and B represent concentrations of GTP  
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Figure 5.7 Effect of increasing concentration of GTP on FRET efficiency. The 
graph was plotted using log of GTP concentration from 5µM to 10mM.  
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5.4 Effect of Calcium on conformation using FRET analysis 
TG2 activity is dependent of calcium binding. It is known that when calcium binds 
TG2 structure opens up to adapt an extended conformation allowing access to its 
active site. Here we investigate the calcium induced change in conformation of TG2 
using FRET. An increasing concentration of calcium ranging from 5µM, 10µM, 50µM, 
0.1mM, 0.25mM, 0.5mM, 0.75mM, 1mM, 5mM, 10mM. Additional calcium was 
added to compensate for EGTA chelation. CFP-TG2-YFP recombinant protein was 
purified using Ni-NTA column and desalted in 50mM Tris buffer, 1mMDTT, 1mM 
EGTA. 1µg of protein was used in each reaction. The figure 5.8represents the 
normalised fluorescence measure when CFP is excited at 436nm and emission was 
measured at 476nm (cut off selected 455nm). As the calcium concentration 
increases there is an increase in CFP emission as the TG2 structure opens. A 
significant difference was observed between mean fluorescence at 5µM (lowest 
calcium concentration) and 10mM (highest concentration) of calcium. No significant 
difference was observed between 5mM and 10mM of calcium.  
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Figure 5.8 Effect of increasing concentration of calcium on CFP emission 
analysing CFP-TG2-YFP recombinant protein. The graph was plotted using log 
of calcium concentration from 5µM to 10mM. The increase in fluorescence is 
represented as normalised mean fluorescence. The results represent mean ± 
S.D of three independent experiments done performed in triplicates. Statistical 
analysis was done using ANOVA applying Bonferroni post-test (*** P<0.001) 
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The figure 5.9 represents the normalised fluorescence measure when YFP is excited 
at 516nm and emission was measured at 538nm (cut off selected 530nm). As the 
calcium concentration increases the YFP emission does not show much difference in 
mean fluorescence. YFP emission indicated in figure below is a good indication of 
the amount of protein. Although there is a slight decrease with increase in calcium 
concentration observed in YFP emission, this decrease was corrected for during 
FRET efficiency calculation.  
 
Figure 5.9 Effect of increasing concentration of calcium on YFP emission 
analysing CFP-TG2-YFP recombinant protein. The graph was plotted using log 
of calcium concentration from 5µM to 10mM. The fluorescence is represented 
as normalised mean fluorescence represented on the Y axis. The results 
represent mean ± S.D of three independent experiments done performed in 
triplicates.  
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The figure 5.10 represents the normalised fluorescence measure when CFP is 
excited at 436nm and emission was measured at 538nm (cut off selected 530nm). 
As the calcium concentration increases there is a significant decrease in YFP 
emission as the TG2 structure opens. A significant difference was observed between 
mean fluorescence at 5µM (lowest calcium concentration) and 10mM (highest 
concentration) of calcium. This decrease in FRET indicates the structure of 
recombinant CFP-TG2-YFP opens as the calcium concentration increases. As the 
structure opens less energy is transferred from the donor to acceptor and hence a 
decrease in FRET is observed.  
 
Figure 5.10 Effect of increasing concentration of calcium on CFP excitation 
YFP emission analysing CFP-TG2-YFP recombinant protein. The graph was 
plotted using log of calcium concentration from 5µM to 10mM. The decrease in 
fluorescence is represented as normalised mean fluorescence. The results 
represent mean ± S.D of three independent experiments done performed in 
triplicates. Statistical analysis was done using ANOVA applying Bonferroni 
post-test (*** P<0.001) 
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5.5 Control CFP-TG2 recombinant protein FRET analysis 
The figure 5.11represents the normalised fluorescence measured for CFP-TG2 
recombinant protein when CFP is excited at 436nm and emission was measured at 
476nm (cut off selected 455nm). As the calcium concentration increases no 
significant difference was observed in CFP emission.   
 
Figure 5.11 Effect of increasing concentration of calcium on CFP emission 
analysing control CFP-TG2 recombinant protein. The graph was plotted using 
log of calcium concentration from 5µM to 10mM. The fluorescence is 
represented as normalised mean fluorescence on Y axis. The results represent 
mean ± S.D of three independent experiments done performed in triplicates.  
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The figure 5.12 represents the normalised fluorescence measure for CFP-TG2 
recombinant protein when CFP is excited at 436nm and emission was measured at 
538nm (cut off selected 530nm). As the calcium concentration increases there is a 
significant decrease in YFP emission as the TG2 structure opens. This control CFP-
TG2 recombinant protein is important for the calculation of bleedthrough and FRET 
efficiency.  
 
Figure 5.12 Effect of increasing concentration of calcium on CFP excitation 
YFP emission analysing CFP-TG2 recombinant protein. The graph was plotted 
using log of calcium concentration from 5µM to 10mM. The decrease in 
fluorescence is represented as normalised mean fluorescence. The results 
represent mean ± S.D of three independent experiments done performed in 
triplicates.  
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Calculated FRET 
 
A part of above represented YFP emission seen as CFP excitation YFP emission of 
CFP-TG2-YFP recombinant protein also includes bleedthrough. To correct for 
bleedthrough, we first calculated bleedthrough by  
 
 
 
where “ex” is excitation and “em” represents emission 
 
The calculated YFP emission corrected for bleedthrough is represented in the figure 
5.13. With increase in calcium concentration there is a decrease in FRET indicating 
the opening of the structure.  
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Figure 5.13  Effect of increasing concentration of calcium on FRET. The graph 
was plotted using calcium concentration from 5µM to 10mM against mean 
fluorescence. The figure shows the decrease in YFP emission corrected for 
bleedthrough as represented in blue. As represented in red is the fluorescence 
corrected for the increase in YFP emission.  
 
For calculating FRET efficiency,  
 
 
 
where A and B represent concentrations of calcium  
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Figure 5.14 Effect of increasing concentration of calcium on FRET efficiency. 
The graph was plotted using log of calcium concentration from 5µM to 10mM.  
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5.6 Comparison of Calcium activity curve and FRET efficiency  
The calcium activity curve was plotted on the same graph as the calculated FRET 
efficiency (negative FRET efficiency values) to compare the curve. Both curves 
follow the same trend indicating that we could correlate the effect of calcium on TG2 
activity with the calculated FRET (figure 5.15).  
 
Figure 5.15 Comparison of calcium activity and FRET efficiency.  The X axis 
represents the log of calcium concentration plotted against one Y axis 
represents increase in TG2 activity and second Y axis depicts the negative 
value of FRET efficiency.  
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5.7 Discussion 
 The TG2 FRET construct CFP-TG2-YFP was characterised to have properties 
similar to that of TG2. Although the construct and CFP-TG2 control was successfully 
constructed, the only YPF control TG2-YFP needs further investigation. This control 
would be helpful in FRET efficiency calculations. For the TG2-YFP construction a 
PCR cycle could be set up using TG2 forward primer and YFP reverse primer. This 
TG2-YFP construct would be subjected to nucleotide sequencing, expression and 
characterisation similar to that of CFP-TG2-YFP and CFP-TG2 construct. The only 
CFP-TG2 construct could also be applied to further studies investigating inter-
molecular FRET with TG2 binding partners. The FRET data showed that with 
increasing concentration of GTP the TG2 structure adapts a closed conformation as 
accounted by the increase in the fluorescence. It could also be interesting to check 
the conformation when TG2 interacts with other molecules like integrin, heparin and 
syndecan. With increasing concentration of calcium the FRET data suggests the 
opening of the molecule as indicated by the decrease in fluorescence. The validation 
of the FRET construct is also seen by comparing the activity curve of TG2 and FRET 
efficiency.   
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Chapter 6 
Construction of CFP-TG2-
YFP recombinant protein 
in mammalian system 
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6.1 Introduction  
Since the characterisation of the TG2 sensor was investigated, this FRET sensor 
was attempted to be cloned into mammalian expression vector. In this chapter it was 
attempted to describe the cloning strategy for mammalian expression vector. This 
chapter also focuses on some commonly faced problems with cloning. The CFP-
TG2-YFP recombinant protein was attempted to be cloned into mammalian 
expression vector pcDNA3.1-. The use of new primer to amplify the construct were 
designed such that two proteins can be produced with or without the His tag.  
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6.2 PCR amplification  
For expression of CFP-TG2-YFP recombinant protein in mammalian system, CFP-
TG2-YFP in pTrcHisB construct (refer chapter 3) was attempted to be cloned into 
pcDNA3.1- (Invitrogen). 
6.3 CFP-TG2-YFP amplification 
Using primers NotICFP(for NotICFP-TG2-YFP construct) and HispTrc (for His-tag 
CFP-TG2-YFP construct) as forward primers and YFP reverse primer(YFP Rev2) 
was using to amplify the entire CFP-TG2-YFP construct using CFP-YFP-TG2 
plasmid (chapter 3) Reactions were performed in triplicates in MWG Biotech Aviso 
Thermal cycler to avoid over-representation of polymerase-induced errors. Thermal 
cycling conditions were optimised for maximum amplification yield and specificity. 
Amplification of His-CFP-TG2-YFP was obtained as seen in Lanes 2, 3, 4in figure 
6.1. Amplification of NotICFP-TG2-YFP was obtained as seen in Lanes 5, 6, 7 in 
figure 6.1. Bands of correct size of about 3.5Kb were seen. Conditions for PCR were 
optimised to be initial denaturation at 95°C for 2 min, followed by 35 cycles of 95°C 
for 45 s, 70°C for 1 min, 72°C for 1 min, followed by a final extension step at 72°C for 
10 min using KOD Hot start polymerase using 10X KOD hot start buffer and 1mM 
MgSO4.  
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Figure 6.1 Agarose gel electrophoresis of amplified CFP-TG2-YFP plasmid 
using forward primers NotICFP and HispTrc and YFP Rev2 primer. Lane 1 is 
the 2-log marker DNA. Lane 2, 3, 4 showing amplifiedHis-CFP-TG2-YFP 
plasmid and Lane 5, 6, 7 showing the amplified NotICFP-TG2-YFP which is 3.5 
Kb in size.  
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6.4 Cloning amplified products into pSTBlue-1 
Identification of recombinant pSTBlue-1 plasmids.  
Using the pSTBlue-1 blunt cloning kit the amplified products His-CFP-TG2-YFP and 
NotICFP-TG2-YFP were ligated into pSTBlue-1 and transformed into NovaBlue 
competent cells. Blue/white screening was performed by spreading transformed cells 
onto plates containing 100µg/ml ampicillin, 100µM IPTG and 50µg/ml X-gal. White 
colonies, potentially containing inserted DNA, were screened for increased size 
compared to the empty vector pSTBlue-1 using a simple alkaline lysis procedure 
followed by agarose DNA electrophoresis (cracking). 
6.5 His-CFP-TG2-YFP cracking  
Following Blue/White screening, 13 white colonies were selected for the cracking 
procedure. A blue colony (parent pSTBlue-1) was also selected as a negative control 
for cracking. All samples were then run on an agarose gel for further analysis. All 
plasmids which were of a larger size than the parent pSTBlue-1 (blue colony) were 
selected for further analysis. From the figure6.2, clones His-CFP-TG2-YFP 5, 6, 8, 9, 
10, 11, 14 were found to be larger than parent vector.  
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Figure 6.2 Agarose gel electrophoresis of the cracking procedure performed 
on the selected His CFP-TG2-YFP colonies after Blue White screening. Lane 1 
is the 2-log marker DNA. Lanes 2 to 14 showing His-CFP-TG2-YFP clones 1-13. 
Lane 15 showing the blue colony representing a negative control for selection.  
CFP 5, 6, 8, 9, 10, 11 and 14 were found to be of correct size. 
6.6 NotICFP-TG2-YFP cracking  
Following Blue/White screening, 14 white colonies were selected for the cracking 
procedure. A blue colony (parent pSTBlue-1) was also selected as a negative control 
for cracking. All samples were then run on an agarose gel for further analysis. All 
plasmids which were of a larger size than the parent pSTBlue-1 (blue colony) were 
selected for further analysis. From the figure 6.3, clones NotICFP-TG2-YFP 4, 5, 8, 
10, 12, 13 were found to be larger than parent vector.  
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Figure 6.3   Agarose gel electrophoresis of the cracking procedure performed 
on the selected NotI CFP-TG2-YFP colonies after Blue White screening. Lane 1 
is the 2-log marker DNA. Lanes 2 to 15 showing His-CFP-TG2-YFP clones 1-15. 
Lane 16 showing the blue colony representing a negative control for selection.  
CFP 4, 5, 8, 10, 12 and 13 were found to be of correct size. 
 
On analysing the cracking agarose gel results, plasmids which were larger than the 
parent pSTBlue1 vector were selected. Using the Promega Wizard Plus minipreps 
DNA purification Kit, plasmid purification was performed on the selected clones of 
His-CFP-TG2-YFP and NotCFP-TG2-YFP. These plasmids were then digested 
using EcoRI to test for inserts of the correct size (EcoRI digestion cuts out YFP 
(0.75Kb insert), around 2.75Kb insert of CFP-TG2 insert and 3.8Kb insert of 
pSTBlue1.  
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6.7 Cloning of CFP-TG2-YFP construct into expression vector pcDNA3.1- 
pcDNA3.1- vector was transformed into NovaBlue competent cells. Colonies were 
selected from the plate and then grown individually in 5ml LB broth containing 
ampicillin at 37˚C in orbital shaking incubator overnight. Using the Promega Wizard 
Plus minipreps DNA purification Kit, plasmid purification was performed. The 
pcDNA3.1- purified plasmid was run on an agarose gel as shown in figure 6.4.  
 
Figure 6.4 Agarose gel electrophoresis of the purified plasmid of pcDNA3.1-. 
Lane 1 is the 2-log marker DNA. Lanes 2, 3, 5 showing pcDNA3.1- purified 
plasmid of about 5.5 Kb. 
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6.8 Cloning NotCFP-TG2-YFP and HisCFP-TG2-YFP into pcDNA3.1- 
His-CFP-TG2-YFP/NotCFP-TG2-YFP plasmid was digested from the pSTBlue-1 
plasmid using HindIII and NotI. The HindIII digestion was performed and the reaction 
was set up using buffer 2 (NEB) followed by NotI/PvuI double digestion in buffer 3. 
PvuI was used to cut the 3.8Kb pSTblue1 parent vector into smaller fragments to 
facilitate easy agarose gel purification of His-CFP-TG2-YFP insert of 3.5Kb (figure 
6.5). Similar digestion was performed on NotCFP-TG2-YFP plasmid. pcDNA3.1- was 
digested using NotI and HindIII, with gel electrophoresis (Figure6.6 ) showing double 
digested pcDNA3.1- (5.4 Kb). On digestion the purified undigested plasmid runs 
faster as it is super coiled but when digested a band about 5.5 Kb was seen. 
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Figure 6.5 Agarose gel electrophoresis of the digestion of the His-CFP-TG2-
YFP5 plasmid using NotI and HindIII. Lane 1 is the 2-log marker DNA. Lane 2 
and 3 shows purified plasmid of His-CFP-TG2-YFP5. Lanes 4 shows HindIII 
digestion showing 3.8Kb band of pSTblue1 and 3.5Kb band of His-CFP-TG2-
YFP insert. Lane5 shows NotI/PvuI digestion revealing 3.5Kb band of insert 
and lower bands indicated pSTblue1 vector digested into smaller fragments. 
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Figure 6.6 Agarose gel electrophoresis of the digestion of the purified 
pcDNA3.1- plasmid using NotI and HindIII. Lane 1 is the 2-log marker DNA. 
Lanes 4 shows double digested plasmid of about 5.5 Kb.  
 
The digested pcDNA 3.1-, His-CFP-TG2-YFP plasmid, Not-CFP-TG2-YFP plasmids 
were extracted and purified from a low melting point agarose gel. The purified 
pcDNA3.1- was further treated with Antarctic phosphatase to remove 5’ phosphates 
and prevent religation. Further a ligation reaction was performed using Quick ligase 
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to ligate pTrcHis B and CFP and was then transformed into Novablue competent 
cells. Cracking procedure was repeated on the colonies grown.  
 
 
6.9 Screening of recombinant CFP-TG2-YFP-pcDNA3.1- plasmids 
The screening of recombinant plasmids were performed by analysing transformed 
colonies via cracking procedure. Negative control used was pcDNA3.1- self ligated 
control. Cracking procedure did not reveal colonies of correct size. Analysed 
colonies seen in the figure 6.7, 6.8, 6.9 showed plasmid of size similar to that of 
negative control indicating unsuccessful cloning of insert into pcDNA3.1- vector.  
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Figure 6.7 Agarose gel electrophoresis of the cracking procedure performed 
on the selected NotICFP-TG2-YFP-pcDNA3.1- colonies after transformation. 
Lane 1 and 11 is the 2-log marker DNA. Lanes 2 to 9 showing NotICFP-TG2-
YFP-pcDNA3.1- clones 1-8. Lane 10 representing a negative control (self 
ligated vector) for selection.   
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Figure 6.8 NotICFP-TG2-YFP-pcDNA3.1- colonies after transformation. Lane 1 
and 11 is the 2-log marker DNA. Lanes 2, 4 to 10 showing NotICFP-TG2-YFP-
pcDNA3.1- clones 1-8. Lane 3 representing a negative control (self ligated 
vector) for selection.   
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Figure 6.9 Agarose gel electrophoresis of the cracking procedure performed 
on the selected His-CFP-TG2-YFP-pcDNA3.1- colonies after transformation. 
Lane 1 and 15 is the 2-log marker DNA. Lanes 2 to 13 showing His-CFP-TG2-
YFP-pcDNA3.1- clones 1-12. Lane 14 representing a negative control (self-
ligated vector) for selection.   
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6.10 Discussion 
The cloning of the construct into mammalian expression vector still needs further 
investigation. The use of pcDNA3.1- was the choice of expression vector. The use of 
alternate expression vector like LIC vector could be a better option. These vectors 
are better designed to accommodate larger fragments of DNA for mammalian 
expression. The other option is to clone CFP-TG2-YFP into pcDNA3.1+ but changing 
the restriction sites and cloning strategy. Also it could be worth sequencing the 
pcDNA3.1- expression vector to ensure no mutations have occurred and the 
restriction sites are intact for successful cloning. Such point mutations could have 
been introduced during the freezing-thawing of plasmids. The same nucleotide 
sequencing could be done to ensure NotCFP-TG2-YFP and HisCFP-TG2-YFP 
plasmid to ensure no mutations have been introducing during PCR amplification.  
 
 
 
 
 
 
 
 
 
 
 218 
 
 
Chapter 7 
Discussion 
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Transglutaminase is a commercially important enzyme that catalyses the 
posttranslational modifications of proteins, converting the primary amide group of the 
peptidyl-glutamine substrate into a secondary amide by formation of an isopeptide 
bond. The final products undergo polyamidation or are cross-linked aggregated 
proteins.(Bergamini et al., 2011) Tissue transglutaminase is a calcium dependent 
enzyme and its transamidating activity is regulated by the binding of calcium ions 
and exposure of the active site for interaction with glutamine substrate. GTP acts as 
an inhibitor of this reaction by binding to the protein and bringing the core domain 
and β- barrel 1 together adapting a compact form. This conformational change 
thereby also affects the binding of other molecules like fibronectin, heparan sulphate 
and integrins. To have a better understanding of conformation of TG2, that is brought 
about by the binding of calcium and GTP this study incorporated the construction of 
a novel TG2 FRET biosensor.  The construction of this FRET sensor involved a pair 
of fluorescent proteins fused on the N and C terminii of TG2.For this construct CFP 
and YFP were recruited as the choice of fluorescent proteins. CFP-YFP is the most 
commonly used FRET pair due to their small size. This pair was preferred such that 
the use of small fluorescent protein would not interfere with the conformational 
change that TG2 undergoes.(Pinkas et al., 2007) The use of other FRET pair like 
mcerulean C1 and eYFP for TG2 has also been reported. (Caron et al., 2012)For the 
assembly of this TG2 FRET sensor the cloning strategy was to clone the CFP first 
with TG2 and check expression in the expression vector pTrcHisB. This would not 
only serve as a FRET control CFP-TG2 construct but also assess the effect of 
tagging one fluorescent protein onto TG2. The stepwise cloning strategy would also 
ensure the correct sequence of the construct and if it behaves similar to protein 
without the fluorescent tag. The other alternative to step wise clning would be the 
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PCR amplification of the entire construct. This would require a massive screening of 
recombinant TG2. Also the chances of entire sequence to be correct without point 
mutations would be critical. This alternate strategy of constructing the FRET sensor 
could definitely be quicker provided the screening of recombinant clones is 
performed systematically. This method could also be disadvantageous for orientation 
of fluorescent tags and the screening of constructs with correct orientation could be 
time consuming. The step wise cloning also has the advantage of checking whether 
the expression of TG2 is affected because of fluorescent tags attached. PCR 
amplification of the entire construct has the risk that once constructed the expression 
may not be ideal or construct may not function properly. To avoid this risk the step 
wise cloning and checking of construct after attachment of each tag would reduce 
the risk of the entire construct not working altogether. This method would also 
require another protocol to be established for the generated of FRET controls 
including CFP-TG2 and TG2-YFP constructs. This cloning strategy would also 
determine if there is a difference between single tagged CFP-TG2 and double 
tagged CFP-TG2-YFP recombinant protein. Having only one fluorescent protein 
attached to TG2 either CFP-TG2 or TG2-YFP could be applied to study 
intermolecular FRET by binding the other fluorescent protein on to TG2 binding 
partners like intergrin, syndecan or heparin and investigate ECM interactions. The 
use of other expression vectors including pTrcHisA or pTrcHisC would also be 
another possibility but dependent on the restriction sites for cloning. It could also be 
further investigated whether how the expression is increased or decreased using 
another expression vector. This construct was then characterised on the basis of its 
expression and purification in bacterial system. The synthesised CFP-TG2-YFP 
recombinant protein was also tested for its ability to bind to heparin sepharose. The 
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CFP-TG2-YFP recombinant protein was further examined for its protease sensitivity 
after reacting with monodansyl cadaverin, biotin cadaverin and R281/R283 (TG2 
inhibitors). An increasing concentration of calcium and GTP was applied to analyse 
the activity curve of CFP-TG2-YFP recombinant protein. Its ability to bind to 
fibronectin was also examined using an enzyme linked immunosorbent assay.  Using 
this FRET-based TG2 biosensor the changes in fluorescence are measured with 
respect to the conformational changes of TG2. 
 
For the cloning part of this project, Novablue competent cells were used as they are 
highly efficient for transformation and support blue-white screening. Expression of 
CFP-TG2-YFP recombinant protein was tested in Novablue cells first. The construct 
was then transferred into Rosetta 2 cells as they are designed to express 
mammalian genes as the cells have tRNAs necessary for protein expression. The 
use of Rosetta 2 for expression definitely showed enhanced protein expression as 
compared to Novablue cells. Initial expression and purification was performed using 
GE Healthcare His-GraviTrap column. Although CFP-TG2-YFP was successfully 
purified using the pre-packed column, it was limiting with respect to optimisation of 
the gradient. The purification performed using His-GraviTrap column was performed 
using gravity protocol according to manufacturer’s instruction which often was time 
consuming. The use of GE AKTA prime FPLC was better for purification of the 
recombinant CFP-TG2-YFP protein as a higher volume of initial load could be loaded 
onto the column with less difficulty, a better control over protein elution with respect 
to gradient elution and higher yield of purification was seen. The gradient elution for 
purification of recombinant CFP-TG2-YFP was optimised by altering the elution step 
with respect to volume of the elution step. The initial wash step preceding the elution 
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was altered to reduce non-specifically bound proteins. Different concentrations of 
imidazole were tried to optimise the purification of desired protein. The most 
optimum purification of CFP-TG2-YFP recombinant protein was seen when applying 
a 20mM imidazole wash followed by a 20-200mM imidazole gradient elution where 
the specific activity was found to be 4.5 OD490/min/mg. Using this purification 
protocol it is observed that apart from desired protein seen at 135kDa, a 
simultaneous band of around 75kDa is observed in the SDS-PAGE analysis of the 
purified protein. This band is also seen the western blot plot analysis of purified 
protein using Cub7402 mouse monoclonal antibody. This band could possibly be 
due to presence of start codon in the sequence of the construct or due to proteolytic 
cleavage during purification. Subsequent purifications were performed incorporating 
1mM phenylmethylsulfonyl fluoride (PMSF) just before lysing the bacterial cells via 
sonication. But no change in purity of protein was observed, the 75KDa band was 
still eluted simultaneously with CFP-TG2-YFP recombinant protein. The purification 
of control CFP-TG2-pTrcHisB was performed similarly. SDS PAGE analysis stained 
with coomassie blue staining and western blot analysis both confirmed the 
successful purification of the control CFP-TG2 recombinant protein required as a 
FRET control.  
To characterise the CFP-TG2-YFP construct further, the heparin binding ability of the 
newly synthesised recombinant CFP-TG2-YFP recombinant protein was verified. As 
a control to test the heparin sepharose column, purification of pET30Ek/LIC TG2 
(wild type TG2) using Ni-NTA column was performed. The eluted protein was then 
loaded onto the heparin sepharose column and it was observed that wild type TG2 
successfully binds to the heparin column and its presence in eluted fractions was 
confirmed by western blot analysis. The heparin binding ability of CFP-TG2-YFP and 
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CFP-TG2 recombinant protein was tested using the same heparin sepharose 
column. The results revealed that both CFP-TG2-YFP recombinant protein and CFP-
TG2 recombinant protein successfully bind to heparin sepharose column. CFP-TG2-
YFP recombinant protein was purified over Ni-NTA column was processed further 
using heparin sepharose column to get a cleaner purification. A reduction in non-
specifically bound protein was observed after down streaming processing of CFP-
TG2-YFP purified recombinant protein.  
Analysis of protease sensitivity of biotin cadaverin (BTC) treated wild type TG2 
revealed that no digestion of protein was observed with increasing concentrations of 
BTC. The same was observed with purified CFP-TG2-YFP recombinant protein. The 
use of monodansyl cadaverin (MDC) to pre-treat wild type TG2 and recombinant 
CFP-TG2-YFP protein revealed no digestion of protein on treatment with trypsin. 
This probably suggests that TG2 adapts a closed conformation which is less 
susceptible to trypsin digestion. As a positive control we treated wild-type TG2 with 
R281 inhibitors that locks TG2 into its open conformation. R281 treated wild type 
TG2 was then subjected to trypsin digestion and complete digestion of protein was 
observed with 80ngs of trypsin. This could indicate that the open conformation of 
TG2 is susceptible to trypsin digestion. It was further attempted to test the effect of 
R283 inhibitor on the conformation of TG2. Wild type TG2 was treated with R283 
and subjected to trypsin digestion. The results revealed that when wild-type TG2 was 
treated with R283 no digestion was observed until 3.2µg of trypsin. This indicating 
altered conformation as compared to R281 inhibitor. R281 inhibitor treated CFP-
TG2-YFP recombinant protein shows a partial digestion of protein using trypsin 
treatment. Altered trypsin susceptibility of CFP-TG2-YFP recombinant protein could 
be due to attachment of two fluorescent proteins to TG2. Due to the difference in 
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molecular size of wild-type TG2 and CFP-TG2-YFP recombinant protein probably a 
higher concentration of trypsin is required for complete digestion of CFP-TG2-YFP 
recombinant protein.  
Comparison between fibronectin incorporation using a modified ELISA revealed 
CFP-TG2-YFP and RhTG2 show similar fibronectin binding while using Cub7402. 
Control CFP-TG2 recombinant protein showed higher fibronectin incorporation as 
compared to CFP-TG2-YFP recombinant protein and RhTG2 using both Cub7402 
and 1D10. While comparing Cub7402 and 1D10 a difference was observed in 
fibronectin incorporation between CFP-TG2-YFP recombinant protein and RhTG2. 
This could possibly be due to steric hindrance by attaching two fluorescent protein 
and thereby differential binding to 1D10 to TG2.   
Biotin cadaverin incorporation into N, N’ dimethyl casein and fibronectin showed that 
higher specific activity was observed while using fibronectin. It was observed that 
with casein the specific activity was less than half. Using fibronectin the showed an 
increase in specific activity of recombinant CFP-TG2-YFP. 
Further analysis of activity of TG2 with increasing concentrations of calcium showed 
that with the increase in calcium TG2 activity is also upregulated. Comparing 
RhTG2, CFP-TG2-YFP recombinant protein and CFP-TG2 protein followed the 
same curve. It was observed that the Km value for recombinant CFP-TG2-YFP 
protein was higher as compared to RhTG2. A similar curve was plotted using 
increasing concentration of GTP. It was seen that all three proteins followed the 
same curve. RhTG2 and CFP-TG2-YFP recombinant protein has all most 
overlapping curve. With the increasing concentration of GTP TG2 activity is inhibited. 
This is also true for CFP-TG2-YFP recombinant protein and CFP-TG2.  
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It was observed that CFP-TG2-YFP FRET sensor constructed showed similar 
characteristic properties to TG2. To analyse the FRET changes in-vitro, CFP-TG2-
YFP recombinant protein was purified using the Ni-NTA column. Appropriate FRET 
controls include CFP-TG2 and TG2-YFP only constructs. Since BglII the restriction 
site at the start of TG2 was destroyed during infilling the 3’ends, restriction digestion 
of TG2-YFP construct was not possible. CFP-TG2 construct was similarly expressed 
and purified in bacterial cells for FRET analysis. In order to measure the changes in 
fluorescence using an increasing concentration of calcium and GTP were 
incorporated with CFP-TG2-YFP and CFP-TG2 recombinant proteins. Analysing the 
effect of GTP on fluorescence we excited CFP at 436nm and YFP emission was 
measured at 538nm. It was observed that with increasing concentration of GTP, as 
the structure closes more energy is transferred from CFP to YFP and hence an 
increase in YFP emission was observed. An opposing effect was seen in 
fluorescence while measuring CFP emission by exciting CFP. This again is in 
accordance with the closing of TG2 with GTP. Since more energy is transferred to 
YFP, CFP fluorescence is bound to decrease as observed. Exciting YFP and 
emitting YFP should ideally remain constant if the same amount of protein is excited. 
A slight increase in YFP emission that is observed should be accounted for when 
calculating FRET efficiency. All calculations were performed on raw data and was 
observed that with the increase in GTP concentration, the YFP emission and FRET 
efficiency also increases. This suggests with increasing concentration of GTP the 
structure of TG2 closes, bringing the fluorophores together and increasing the 
fluorescence. The opposite effect was observed when increasing calcium 
concentration in solution. As calcium concentration increases a decrease in YFP 
emission was seen when exciting CFP. This suggests that as TG2 structure opens, 
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less energy is transferred from CFP to YFP which explains the decrease seen. While 
measuring fluorescence by exciting CFP, emission of CFP fluorescence was 
observed to increase correctly. The efficiency of FRET with increasing concentration 
of calcium was noted to decrease. This implies that as the structure of TG2 opens up 
with increasing concentration of calcium the fluorophores move apart from each 
other and hence less energy is transferred. A graphical representation of TG2 
activity curve and negative value of FRET efficiency shows that both activity and 
FRET follow the same curve and thereby validating the constructed FRET sensor. 
This sensor can be suggested to work efficiently even in mammalian cells.  
For the expression of this FRET sensor in mammalian cells, it must be subcloned 
into pcDNA3.1-. New primers were designed to expresses the entire CFP-TG2-YFP 
construct and another construct was aimed to have a polyhistidine tag CFP-TG2-
YFP for purification purposes. PCR amplification using NotICFP and HispTrc 
forwards primers with YFP reverse primers showed successful amplification of 3.5Kb 
construct. For optimisation of PCR various concentrations of magnesium sulphate 
were tried. Concentration of DMSO was varied with different dilutions of template 
DNA. Condition of PCR were optimised as initial denaturation at 95°C for 2 min, 
followed by 35 cycles of 95°C for 45 s, 70°C for 1 min, 72°C for 1 min, followed by a 
final extension step at 72°C for 10 min using KOD Hot start polymerase using 10X 
KOD hot start buffer and 1mM MgSO4. Non-specific bands were still observed on 
agarose gel electrophoresis of PCR products. NotICFP-TG2-YFP and His-CFP-TG2-
YFP were ligated into pSTlue1 and the colonies were screened for plasmid larger 
than parent vector were selected for test digestion with EcoRI. For cloning into 
mammalian expression vector pcDNA3.1-, NotI and HindIII digestion was 
successfully perfomed. In order to help easy gel purification of HisCFP-TG2-YFP 
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insert from pSTlue1 cloning vector another restriction enzyme PvuI was employed. 
Ligation was performed to insert HisCFP-TG2-YFP and NotICFP-TG2-YFP into 
pcDNA3.1-. All resulting colonies were screened but showed self ligated plasmid 
only. This could be due to incomplete digestion of insert or due to improper vector: 
insert ratio. Another problem could be the large size of the insert which needs further 
optimisation for successful cloning into pcDNA3.1-. 
Future work 
Now that the basis of constructing FRET sensors has been laid, it would certainly be 
interesting to monitor the real-time changes in-vivo in mammalian cells. Once the 
cloning of this construct into pcDNA3.1- is successful, it can be transfected into 
H293T/17 cells. The construct can be assessed on its expression, activity, stability 
like performed in the bacterial system. It could also be interesting to analyse the 
difference of TG2 behaviour in vitro and in vivo.  TG2 conformation in HEK293T/17 
cells could be assessed using FRET, its response to calcium and GTP influx. The 
real-time monitoring of TG2 could be interesting and take this this project further. 
Also the introduction of mutations into this FRET construct could open a new area of 
investigation. The validating of existing mutations using this FRET contruct would 
also be possible. The use of inter-molecular FRET could also provide newer insights 
into TG2 interactions. The use of CFP-TG2 only construct could be applied for such 
inter-molecular FRET based studies. It would also be an interesting study to 
specifically direct this construct using signal peptides into different compartments like 
the nucleus, extracellular matrix to check its response and interactions specific to 
that environment. The effect of calcimycin or other ionophores could also be 
assessed using this sensor. The use of other TG2 inhibitors and determine the effect 
of such inhibitors could not only contribute to TG2 investigation but also may provide 
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a quicker method for testing inhibitors. The same FRET construct could also be 
applied to study TG2 in plant cells. The use of other FRET pairs like that of turbo 
sapphire and ds Red could also open up new possibilities of exploring and 
comparing the effect of different FRET pairs.  
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